Inventiva (IVA) 20-F 30 Mar 23 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Document and Entity Information
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-39374
Entity Registrant Name	Inventiva S.A.
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	50 rue de Dijon
Entity Address, Postal Zip Code	21121
Entity Address, City or Town	Daix
Entity Address, Country	FR
Entity Common Stock, Shares Outstanding	42,134,169
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001756594
Auditor Name	KPMG SA
Auditor Firm ID	1253
Auditor Location	Paris La Defense, France
American Depositary Shares, each representing one ordinary share
Document and Entity Information
Title of 12(b) Security	American Depositary Shares, each representing one ordinary share, nominal value €0.01 per share
Trading Symbol	IVA
Security Exchange Name	NASDAQ
Ordinary shares
Document and Entity Information
Title of 12(b) Security	Ordinary shares, nominal value €0.01 per share
Security Exchange Name	NASDAQ
No Trading Symbol Flag	true
Business Contact [Member]
Document and Entity Information
Entity Address, Address Line One	50 rue de Dijon
Entity Address, Postal Zip Code	21121
Entity Address, City or Town	Daix
Entity Address, Country	FR
Contact Personnel Name	Frédéric Cren
City Area Code	33
Local Phone Number	3 80 44 75 00

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - EUR (€)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Noncurrent assets
Intangible assets	€ 568,000	€ 770,000	€ 935,000
Property, plant and equipment	7,385,000	3,196,000	3,282,000
Other noncurrent assets	1,668,000	2,442,000	1,706,000
Total noncurrent assets	9,621,000	6,408,000	5,923,000
Current assets
Inventories	373,000	392,000	320,000
Trade receivables	0	4,000,000	48,000
Tax receivables	6,007,000	4,373,000	9,028,000
Other current assets	13,267,000	20,260,000	17,914,000
Cash and cash equivalents	86,736,000	86,553,000	105,687,000
Total current assets	106,383,000	115,578,000	132,997,000
TOTAL ASSETS	116,004,000	121,985,000	138,920,000
Shareholders' equity
Share capital	421,000	409,000	386,000
Premiums related to share capital	173,886,000	165,072,000	139,668,000
Reserves	(74,286,000)	(26,815,000)	4,777,000
Foreign currency translation reserve	(271,000)	(164,000)
Net loss for the period	(54,274,000)	(49,635,000)	(33,619,000)
Total Shareholders' equity	45,476,000	88,866,000	111,211,000
Noncurrent liabilities
Long-term debt	28,663,000	8,837,000	10,037,000
Long-term debt - derivatives	9,876,000
Longterm provisions	0	0	2,377,000
Provisions for retirement benefit obligations	1,234,000	1,429,000	1,385,000
Long-term contract liabilities	55,000
Total noncurrent liabilities	39,827,000	10,266,000	13,800,000
Current liabilities
Shortterm debt	5,851,000	1,282,000	18,000
Shortterm provisions		180,000	130,000
Trade payables	19,359,000	14,602,000	6,923,000
Short-term contract liabilities	6,000
Other current liabilities	5,485,000	6,789,000	6,838,000
Total current liabilities	30,701,000	22,853,000	13,908,000
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	€ 116,004,000	€ 121,985,000	€ 138,920,000

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues and other income
Revenues	€ 12,179	€ 4,194	€ 372
Other income	6,635	4,307	4,891
Total revenues and other income	18,814	8,501	5,263
Research and development expenses	(60,469)	(48,452)	(23,717)
Marketing - Business development expenses	(2,583)	(364)	(563)
General and administrative expenses	(12,912)	(11,155)	(8,499)
Other operating income (expenses)	40	(644)	(2,202)
Operating loss (profit)	(57,110)	(52,114)	(29,718)
Financial income	4,923	5,478	2,057
Financial expenses	(2,107)	(2,635)	(5,959)
Financial income (loss)	2,816	2,842	(3,902)
Income tax	20	(364)
Net loss for the period	€ (54,274)	€ (49,635)	€ (33,619)
Basic loss per share	€ (1.31)	€ (1.27)	€ (0.99)
Diluted loss per share	€ (1.31)	€ (1.27)	€ (0.99)
Weighted average number of outstanding shares used for computing basic loss per share	41,449,732	39,168,152	33,874,751
Weighted average number of outstanding shares used for computing diluted loss per share	41,449,732	39,168,152	33,874,751

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (INCOME) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (INCOME)
Net loss for the period	€ (54,274)	€ (49,635)	€ (33,619)
Items that will be reclassified subsequently to profit or loss	(107)	(164)
Currency translation differences	(107)	(164)
Items that will not be reclassified subsequently to profit or loss	425	82	(49)
Remeasurement of defined benefit plans	425	82	(49)
Total comprehensive loss	€ (53,955)	€ (49,717)	€ (33,668)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - EUR (€) € in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows used in operating activities
Net loss for the period		€ (54,274)	€ (49,635)	€ (33,619)
Elimination of other noncash, nonoperating income and expenses
Depreciation, amortization and provisions		1,698	(1,288)	1,888
Deferred and current taxes		(84)	32
Tax credits		(5,177)	(3,302)	(7,654)
Cost of net debt		676	87	118
Sharebased compensation expense		2,218	2,089	938
Exchange gains / losses		343	(5,198)	3,039
Fair value variation in the result		407	651	(1,791)
Other				41
Cash flows used in operations before tax, interest and changes in working capital		(54,193)	(56,565)	(37,041)
Decrease / (Increase) in operating and other receivables		3,844	(5,317)	(459)
Increase / (Decrease) in operating and other payables		(3,535)	(7,599)	(1,271)
Decrease / (Increase) in inventories		19	(72)	68
Tax credit received		3,553	7,957	8,424
Other	[1]	(1,685)	(1,231)	(2,853)
Tax, interest and changes in operating working capital		9,266	8,936	6,451
Net cash flows used in operating activities		(44,928)	(47,629)	(30,590)
Cash flows provided by (used in) investing activities
Purchases of property, plant and equipment and intangible assets		(561)	(534)	(292)
Disposals of property, plant and equipment and intangible assets		41	89
Decrease / (Increase) in short-term deposit accounts		9,388	(1,302)	(7,694)
Decrease / (Increase) in other noncurrent financial assets		(1)	(47)	(571)
Net cash flows provided by (used in) investing activities		8,868	(1,793)	(8,557)
Cash flows provided by (used in) financing activities
Capital increase, net of transaction costs	[2]	8,827	25,475	101,782
Subscription of debt		30,209		9,979
Repayment of debt		(1,033)	(13)	(61)
Repayment of lease debt		(735)	(15)	(26)
Net cash flows provided by financing activities		37,268	25,447	111,674
Net (decrease) / increase in cash and cash equivalents		1,208	(23,975)	72,527
Net cash and cash equivalents at beginning of period		86,553	105,687	35,840
Exchange gains / losses		(1,025)	4,841	(2,681)
Net cash and cash equivalents at end of period		€ 86,736	€ 86,553	€ 105,687
[1] Including the decrease / (increase) of prepaid expenses for €( 1.1 ) million, (€ 4.1 ) million, and €( 2.8 ) million for the years ended December 31, 2022, December 31, 2021, and December 31, 2020 respectively (see Note 8.2 - Other current assets and receivables). For the year ended December 31, 2021 the increase in prepaid expenses is mainly offset by the indemnity received from the Abbott group under the Additional Agreement of € 2 million in 2021 (see Note 6 - Other Non-Current Assets). Including subscriptions to BSA share warrants for €539 thousand, € 49 thousand, and € 13 thousand for the period ended December 31, 2022, December 31, 2021, and December 31, 2020 respectively.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF CASH FLOWS
Subscriptions to BSA share warrants	€ 539	€ 49	€ 13
Decrease / (increase) of prepaid expenses	€ (1,100)	(4,100)	€ (2,800)
Indemnification amount received		€ 2,000

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - EUR (€)	Share capital	Premiums related to share capital	Reserves	Net profit (loss)	Currency translation adjustments	Total
Balance at the beginning at Dec. 31, 2019	€ 268,461	€ 86,011,893	€ (14,670,000)	€ (30,218,000)	€ 0	€ 41,392,000
Balance at the beginning (in shares) at Dec. 31, 2019	26,846,112
Net loss for the period				(33,619,000)		(33,619,000)
Other comprehensive income (loss)			(49,000)			(49,000)
Total comprehensive loss			(49,000)	(33,619,000)		(33,668,000)
Appropriation of net loss			(30,218,000)	30,218,000
Issue of ordinary shares	€ 113,000	108,986,000				109,099,000
Issue of ordinary shares (in shares)	11,256,599
Transaction costs		(7,397,000)				(7,397,000)
Exercise of BSAs/BSPCEs and vesting of AGAs	€ 5,000	67,000	(5,000)			67,000
Exercise of BSAs/BSPCEs and vesting of AGAs (in shares)	527,550
BSA share warrants subscription premium			13,000			13,000
Share-based compensation expense			938,000			938,000
Appropriation of the issue premium		(48,000,000)	48,000,000
Treasury shares			768,000			768,000
Balance at the end at Dec. 31, 2020	€ 386,302	139,667,603	4,777,000	(33,619,000)		111,211,000
Balance at the end (in shares) at Dec. 31, 2020	38,630,261
Net loss for the period				(49,635,000)		(49,635,000)
Other comprehensive income (loss)			82,000		(164,000)	(82,000)
Total comprehensive loss			82,000	(49,635,000)	(164,000)	(49,717,000)
Appropriation of net loss			(33,619,000)	33,619,000
Issue of ordinary shares	€ 22,000	25,404,000				25,426,000
Issue of ordinary shares (in shares)	2,214,190
Exercise of BSAs/BSPCEs and vesting of AGAs	€ 0		0			0
Exercise of BSAs/BSPCEs and vesting of AGAs (in shares)	29,100
BSA share warrants subscription premium			49,000			49,000
Share-based compensation expense			2,089,000			2,089,000
Other changes			75,000			75,000
Treasury shares			(267,000)			(267,000)
Balance at the end at Dec. 31, 2021	€ 408,735	165,071,566	(26,815,000)	(49,635,000)	(164,000)	88,866,000
Balance at the end (in shares) at Dec. 31, 2021	40,873,551
Net loss for the period				(54,274,000)		(54,274,000)
Other comprehensive income (loss)			425,000		(107,000)	318,000
Total comprehensive loss			425,000	(54,274,000)	(107,000)	(53,955,000)
Appropriation of net loss			(49,635,000)	49,635,000
Issue of ordinary shares	€ 13,000	9,354,000				9,366,000
Transaction costs		(539,000)				(539,000)
Share-based compensation expense			2,218,000			2,218,000
Treasury shares			(479,000)			(479,000)
Balance at the end at Dec. 31, 2022	€ 421,341	€ 173,885,665	€ (74,286,000)	€ (54,274,000)	€ (271,000)	€ 45,476,000
Balance at the end (in shares) at Dec. 31, 2022	42,134,169					42,134,169

Company Information

Company Information	12 Months Ended
	Dec. 31, 2022
Company Information
Company Information	Note 1. Company Information 1.1. Company information Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated financial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group designated as “Inventiva” or the “Company”). Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing Lanifibranor in the treatment for NASH, as well as a pipeline of earlier stage programs or oncology discovery. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a chronic and progressive liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation. The Company initiated the preparations for the pivotal Phase III clinical trial of lanifibranor in NASH (“NATiV3”) in the second half of 2021 and a combination trial with lanifibranor and empagliflozin in patients with NASH and Type 2 Diabetes (“T2D”). In the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate (Accounting impact only relates to personal costs - See Note 17.1). In addition, the Company had seen slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic during 2021 and the Company continues to be unable to conduct clinical trial activities at sites originally located in Ukraine and Russia. Inventiva has amended the protocol for the NATiV3 trial in part to potentially accelerate enrollment and additional sites have been identified to help compensate for the inability to use sites in Ukraine and Russia. In January 2023, the Company decided to modify the design of NATiV3 and the clinical development plan of lanifibranor. The last patient first visit for NATiV3 is now expected for the second half of 2023, subject to the implementation and effect of the protocol amendments and additional measures being reviewed and designed to accelerate the enrollment rate. As of the date of this filing, 369 clinical sites are activated. The publication of the topline results of the part 1 of NATiV3 is targeted for the second half of 2025. If the results of the trial confirm sufficient clinical benefit, the Company will file an application for accelerated approval in the United States and conditional authorization in the European Union for the marketing of lanifibranor. Additionally, in 2022 the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., LTD (“CTTQ”), a Sino Biopharm group company, to develop and commercialize, subject to regulatory approval, lanifibranor for the treatment of NASH and other metabolic diseases in Greater China. Depending on multiple factors, including Chinese regulatory authorities’ feedback, CTTQ is expected to either join the ongoing NATiV3 Phase III clinical trial of lanifibranor in NASH or run an independent study. CTTQ will bear all costs associated with the trials conducted in Greater China. Inventiva’s pipeline also includes odiparcil for the treatment of patients with mucopolysaccharidosis type VI (“MPS VI”), a group of rare genetic diseases. Based on feedback from the U.S. Food and Drug Administration (“FDA”), Inventiva believes there is potential for an efficient development pathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further development of odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership. Inventiva previously had a strategic collaboration with AbbVie Inc. (“AbbVie”) in the area of autoimmune diseases. On October 28, 2022, AbbVie announced that they decided to stop the development of cedirogant (formerly ABBV-157). Inventiva’s and AbbVie’s joint efforts led to the discovery of cedirogant, which was being evaluated by AbbVie in a Phase II clinical trial for the treatment of moderate to severe psoriasis at the time of AbbVie’s decision to discontinue further clinical development. Inventiva’s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva’s American Depositary Shares (ADSs), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020. 1.2. Significant events of 2022 Business Amendments to contract research organization (“CRO”) Agreement with Pharmaceutical Research Associates B.V. – NATiV3 and LEGEND studies In April 2021, Company entered into an agreement with Pharmaceutical Research Associates Groupe B.V. (“PRA”), as CRO, in connection with the NATiV3 clinical trial in NASH, with retroactive effect in January 2021. The contract aims to support the regulatory approval of the product in adult patients in Europe and in the United States. Effective January 14, 2022, in connection with the LEGEND Phase IIa clinical trial (“LEGEND”), the Company entered into an agreement with Pharmaceutical Research Associates Group B.V. (“PRA”), a CRO. Under the terms of the agreement, PRA is to support a clinical trial to evaluate benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic NASH. The Company will pay a total amount of €7.9 million for the services rendered (directly and indirectly) by the CRO over the two years period following the date of the contract. On February 1, 2022, the Company amended its April 2021 agreement with PRA related to the NATiV3 clinical trial to include a bonus and malus mechanism. Depending on whether PRA reaches four milestones in the NATiV3 clinical trial before or after certain dates, PRA will receive a bonus or pay the Company a malus. The bonus and malus scheme is capped at €3.4 million. On April 12, 2022, and on November 10, 2022, the Company further amended its agreement with PRA related to the NATiV3 clinical trial to extend the timelines, with respect to the milestones, and to revise the country/site distribution of the trial. The Company is obligated to pay PRA up to an aggregate of €223.8 million, over the next seven years, under this NATiV3 PRA agreement. As of December 31, 2022, the total amount still to be paid under the LEGEND and NATiV3 PRA agreements amounts to €198.1 million. See Notes 3.21. Other operating income and expenses and 21. Commitments. Service Agreement with Summit Clinical Research LLC (“Summit”) In February 2022, the Company entered into a service agreement with Summit in connection with the NATiV3 trial. Under the terms of the agreement, Summit is to provide services to support recruitment and commitment of volunteers for the NATiV3 clinical trial. The Company agreed to pay Summit a minimum aggregate amount of $4.4 million for the services rendered by Summit from the effective date of the agreement to March 2029. If the Company requests Summit to extend the services rendered, this amount may increase by approximately $1.6 million. See Note 21. Commitments. License and collaboration agreement with CTTQ On September 21, 2022, the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., LTD (“CTTQ”), a Sino Biopharm group company, to develop, import, manufacture, commercialize and market lanifibranor, subject to regulatory approval, for the treatment of NASH and potentially other metabolic diseases, in China, Hong Kong, Macau and Taiwan (Greater China). The Company invoiced CTTQ for $12.6 million on September 28, 2022 (the total invoice corresponds to the initial payment of $12 million, and an additional billing of $0.6 million). On November 4, 2022, the Company received $11.4 million after deducting the withholding tax of $1.3 million 3 In addition, subject to regulatory approval of lanifibranor, the Company has the right to receive tiered royalties ranging from high single-digit to mid-teen double digits of net sales by CTTQ in Greater China during the first three years of commercialization and from low to mid-teen double digits starting from year four. Depending on multiple factors, including Chinese regulatory authorities’ decisions, CTTQ is expected to either (i) join the ongoing NATiV3 Phase III clinical trial of lanifibranor in NASH or (ii) run an independent local phase III clinical trial of lanifibranor. In either case, CTTQ will bear all costs associated with the trials conducted in Greater China. The accounting treatment and accounting impacts as of December 31, 2022 are described in Notes 3.18 – Revenue, 3.25 – Use of estimates and assumptions and 16 – Revenue and other operating income. AbbVie discontinues development of cedirogant The Company previously had a strategic collaboration with AbbVie in the area of autoimmune diseases. On October 28, 2022, AbbVie announced that they decided to stop the development of cedirogant (formerly ABBV-157). The Company’s and AbbVie’s joint efforts led to the discovery of cedirogant, which was being evaluated by AbbVie in a Phase II clinical trial for the treatment of moderate to severe psoriasis at the time of AbbVie’s decision to discontinue further clinical development and the partnership. New patent extending intellectual property protection for lanifibranor in the US On November 28, 2022, the Company announced that it secured a new patent expanding the intellectual property protection of its lead product candidate lanifibranor in the United States. This new patent further strengthens the Company’s patent portfolio for lanifibranor, which already has patents protecting the use of lanifibranor to treat non-alcoholic steatohepatitis and fibrotic diseases. This patent further expands the intellectual property protection of lanifibranor in the United States for use in patients with cirrhotic NASH. Development of odiparcil In August 2022, the Company received feedback from the FDA indicating that odiparcil can be administered to pediatric patients with MPS VI and that the single Phase II/III study design presented by the Company could potentially support a future marketing application for odiparcil. Although the Company’s position not to pursue the development of odiparcil on its own is maintained, the Company continues to evaluate possible options to pursue the development of odiparcil for the treatment of MPS VI, which could include the entering into a partnership. Investigational New Drug application accepted by the FDA for the Phase II clinical trial combining lanifibranor and empagliflozin in patients with NASH and type 2 diabetes On March 8, 2022, the Company announced that the FDA has completed the safety assessment of the Investigational New Drug (“IND”) application and concluded that the proof-of-concept LEGEND Phase II clinical trial combining its lead drug candidate lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic NASH could continue. ​ 3. The LEGEND Phase IIa clinical trial is a multicenter, randomized, placebo-controlled trial and aims to evaluate the safety and efficacy of lanifibranor in combination with empagliflozin, an SGLT2 inhibitor, for the treatment of patients with non-cirrhotic NASH and T2D. The clinical trial will be conducted double-blind for the “placebo” and “lanifibranor” arms and open label for the arm combining lanifibranor and empagliflozin. A total of 63 patients with non-cirrhotic NASH and T2D are expected to be recruited in the LEGEND clinical trial. The diagnosis of non-cirrhotic NASH will be based on the basis of historic histological evaluation or a combination of non-invasive methods including imaging and serum-based metabolic diagnostic serological tests. On July 7, 2022, Inventiva announced the launch of the LEGEND Phase IIa clinical trial with the screening of the first patient. The primary efficacy endpoint of the clinical trial is the change in hemoglobin A1c (HbA1c) at the end of 24 weeks treatment compared to the start of treatment. Secondary endpoints include changes in liver enzymes, glucose and lipid parameters, markers of inflammation, and body fat composition. The study was designed to provide important information on the evolution of body mass and its composition in patients with NASH and T2D treated with lanifibranor in combination with empagliflozin. The use of magnetic resonance imaging (“MRI”) could additionally provide non-invasive data on liver fat, inflammation and fibrosis. The publication of the results is expected for the second half of 2023. Tax dispute settlement On February 15, 2022, the Company received a global settlement from the French tax authorities regarding the tax audit carried out on payroll taxes for 2016 and 2017, and on French Research Tax Credit ( crédit d’impôt recherche Governance Appointment of Dr Lucy Lu as a director of its Board of Directors Effective November 9, 2022, the Company’s board of directors appointed Dr. Lucy Lu as Director on its Board of Directors in lieu of Sofinnova Partners. The nomination of Dr. Lucy Lu has been ratified by the shareholders during the general shareholders meeting held on January 25, 2023. Equity financing Fundraising of €9.4 million in At-The-Market program On June 15, 2022, the Company raised €9.4 million in gross proceeds (€8.8 million in net proceeds) by issuing and selling 1,260,618 American Depositary Shares (“ADS”) pursuant to its At-The-Market (“ATM”) program, established on August 2, 2021. The capital increase was completed at a price of $7.75 per ADS, representing a discount of 0.92% to the volume-weighted average trading price of the Company’s ADSs during the prior day’s trading session (equivalent to €7.43 at an exchange rate of 1.0431 USD/€). Each ADS represents one ordinary share of the Company. Movements in the Company’s capital are described in Note 3.11 – Share Capital. Bank financing and cash flow Receipt of a €4 million milestone payment from AbbVie following the initiation of the Phase IIb trial for cedirogant On January 31, 2022, the Company announced the receipt of a €4.0 million milestone payment from AbbVie, following the enrollment of the first psoriasis patient in the ongoing Phase IIb clinical trial with cedirogant (formerly ABBV-157), an oral RORy reverse agonist jointly discovered by the Company and AbbVie for the treatment of autoimmune diseases. This milestone payment was recognized as revenue over 2021, as the enrollment of the first patient took place in November 2021 (see Note 8 - Trade Receivables and Other Current Assets and Receivables). AbbVie announced its decision to terminate the cedirogant program, and thereby the partnership with the Company, on October 28, 2022. The termination had no impact on the consolidated financial statements as of December 31, 2022. Payments received from the Research Tax Credit (“CIR”) On April 21, 2022, the Company received French Research tax credits ( crédit d’impôt recherche Inventiva entered into a €50 million credit facility from the European Investment Bank (“EIB”), subject to conditions On May 16, 2022, the Company entered into a finance contract with EIB for up to €50 million (the “Finance Contract”) to support the Company’s preclinical and clinical pipeline, including to fund a portion of its Phase III clinical trial of lanifibranor in patients with non-alcoholic steatohepatitis. The Finance Contract provides for funding in two equal tranches of €25 million. The disbursement of the first tranche was subject to, among other conditions, (i) the Company issuing warrants to EIB in accordance with the terms and conditions of the warrants agreement entered into on July 1, 2022, and (ii) the receipt by the Company of an aggregate amount of at least €18 million, obtained either through the issuance of new shares in the Company or through the receipt of upfront or milestone payments from the business development activities on the Company’s various assets. The disbursement of the second tranche under the Finance Contract is also subject to, among other conditions, (i) the Company issuing warrants to EIB in accordance with the terms and conditions of the warrants agreements entered into July 1, 2022, (ii) the full drawdown of the first tranche, (iii) the receipt by the Company from the date of the Finance Contract of an aggregate amount of at least €70 million (inclusive of the €18 million set forth above), paid either in exchange for Company shares or through upfront or milestone payments, (iv) an out-licensing, partnership or royalty transaction with an upfront payment of at least €10 million; and (v) operational criteria based on patient enrollment and number of sites activated in the Company’s Phase III clinical trial of lanifibranor in patients with NASH. Borrowings under the Finance Contract shall bear an interest rate equal to 8% per annum for the first tranche and 7% per annum for the second tranche. Each tranche shall be repayable in a single instalment on the maturity date of the relevant tranche, which shall be no later than four years after the disbursement of the first tranche and no later than three years after the disbursement of the second tranche. Following (i) the receipt of (a) €9.4 million in gross proceeds (€8.8 million in net proceeds) through a capital increase under the ATM program in June 2022 and (b) the net upfront payment of $11.4 million (€11.5 million) pursuant to the license and collaboration agreement with CTTQ on November 4, 2022, and (ii) the issuance of warrants covering 2,266,023 ordinary shares on November 28, 2022, the conditions precedent for the €25 million of the first tranche (with 8% capitalized interest and a 4-year maturity) were met. On December 8, 2022, this tranche was disbursed for an amount of €25 million in return of the issue of the BSAs and the debt. The accounting treatment and impact on the 2022 financial year appear in notes 3.13 – Borrowings and financial debts and 11 - Financial debts. Inventiva obtains non-dilutive financing of €5.3 million in the form of an additional French state-guaranteed loan (“PGE”) and two equity recovery loans (“PPR”) In June 2022, the Company entered into three loan agreements with a syndicate of French banks for a total amount of €5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility ( Prêt Garanti par l’Etat Prêts Participatifs Relance The PGE loan granted by Bpifrance in 2022 is guaranteed for up to 90% by the French government and has a maturity aligned with the PGE loans the Company entered into in 2020 and for which the Company has opted for a linear repayment extension until May 2026. The PPR loans, obtained as part of a French government initiative to support companies, have been granted by Crédit Agricole Champagne-Bourgogne and Société Générale. They are guaranteed predominantly by the French government and feature an eight-year financing period and a four-year repayment period. The accounting treatment and impact on the 2022 financial year appear in notes 3.13 – Borrowings and financial debts and 11 - Financial debts. Inventiva entered into a warrant agreement with the European Investment Bank and issued 2,266,023 of warrants On July 1, 2022, in connection with the Finance Contract with EIB (see paragraph above “Inventiva entered into a €50 million credit facility from the European Investment Bank (“EIB”), subject to conditions”), the Company agreed to issue warrants, with a subscription price of €0.01 per warrant, to EIB as a condition to the potential funding of each tranche of the credit facility. Each warrant gives the right to subscribe one share. The number of warrants to be issued to EIB is determined based on (i) the aggregate amount raised by the Company through one or more equity offerings, or through upfront or milestone payments, from the date of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the average price per share paid for the Company’s shares in its most recent qualifying equity offering or (b) for the first tranche only, in case of no qualifying equity offering, the volume weighted average price per share of the Company shares over the last 180 calendar days. The warrants shall have a maturity of twelve years and shall be exercisable following the earliest to occur of (i) a change of control event, (ii) the maturity date of the first tranche, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The warrants shall automatically be deemed null and void if they are not exercised within the twelve-year period. Each warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise price (subject to anti-dilutive provisions). EIB shall be entitled to a put option at its intrinsic value to require the Company to buy back the exercisable warrants not yet exercised in certain of these occurrences. On November 28, 2022, the Company issued 2,266,023 warrants to EIB, in accordance of the terms of the 25th resolution of the combined general meeting of shareholders of May 19, 2022 and Article L.225- 138 of the French Commercial Code, as a condition to the financing of the first tranche under the Finance Contract, representing approximately 5.4% of the Company’s share capital outstanding as of November 28, 2022. The exercise price of the warrants is equal to €4.0152 per warrant and corresponds to 95% of the volume-weighted average price of the Company’s shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants. EIB has a put option which may require the Company to repurchase all or part of the unexercised warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn under the Finance Contract) under certain circumstances (for example, in the event of a change of control or on the maturity date of the first tranche or in the event of default). The Company (or a substitute third party) has a call option to require EIB to sell all shares and other securities of the Company, including the warrants, to the Company, subject to certain terms and conditions (for example, in case of a public take-over bid from a third party). In addition, the Company has a right of first refusal to buy back all warrants offered for sale to a third party, subject to certain terms and conditions. On the basis of the 2,266,023 new shares of the Company issuable upon potential exercise of all the warrants at an exercise price of €4.0152 per new share, the Company could potentially receive gross proceeds of up to €9,098,535. ​ The accounting treatment and impact on the 2022 financial year appear in notes 3.13 – Loans and Borrowings and 11 – Financial debt. Share-based payments Granting of a new AGA plan On December 8, 2022, the Board of Directors decided to grant 373,000 free shares (the “2022 AGAs”) to 110 employees. The plan is described in the note 10.4 – Bonus share award plans. Business updates and other significant events At the end of 2021 and beginning of 2022, tensions between the U.S. and Russia escalated when Russia amassed large numbers of military ground forces and support personnel on the Ukraine-Russia border and, in February 2022, Russia invaded Ukraine. In response, the European Union, the United States of America (or the “U.S.”) and certain other countries imposed significant sanctions and export controls against Russia, Belarus and certain individuals and entities connected to Russian or Belarusian political, business, and financial organizations, Russia issued related counter-sanctions, and the European Union, the U.S., Russia, and certain other countries could impose further sanctions, trade restrictions, and other retaliatory actions or counter-actions should the conflict continue or worsen. Due to this ongoing war, the recruitment for NATiV3 has been put on hold in Ukraine and the decision has been taken to remove from the trial, all of the Company’s planned sites in Russia. In addition, while the COVID19 pandemic has eased globally, the strain on health systems continues to affect clinical sites, notably through staffing shortages and higher turnover. The Company saw slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic and the Company continues to be unable to conduct clinical trial activities at sites originally located in Ukraine and Russia. However, the delay in NATiV3 the Company faced in the first half of 2022 was primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate. The Company has implemented and continues to plan further measures designed to accelerate enrollment and reduce screen failures in the NATiV3 trial, and identified and activated additional sites to help compensate for the inability to use sites in Ukraine and Russia. The publication of the topline results of the part 1 of NATiV3 is targeted for the second half of 2025, subject to the continuing implementation of measures to accelerate the enrollment rate. Depending on multiple factors, including Chinese regulatory authorities’ feedback, CTTQ is expected to either join the ongoing NATiV3 Phase III clinical trial of lanifibranor in NASH or run an independent study. The investigator driven Phase II trial of lanifibranor in Non-Alcoholic Fatty Liver Disease (“NAFLD”) patients with type 2 diabetes conducted by Professor Cusi from the University of Florida randomized its last patient in September 2022. However, due to the delayed enrollment of this last patient, which happened in September 2022, the topline results from this trial are expected by the middle of the second quarter of 2023. For the ongoing Phase II LEGEND trial combining lanifibranor with SGLT2 inhibitor empagliflozin, patient screening and randomization commenced in July 2022 and top-line results from this trial are expected in the second half of 2023. 1.3. Significant events of 2021 and 2020 Business On January 5, 2021, Inventiva announced the design of its Phase III clinical trial with lanifibranor for the treatment of NASH - for the first half of 2021 See Note 1.1 - Company information. Initiation of Phase IIb of Cedirogant (ex-ABBV 157) announced by AbbVie On May 5, 2021, following the encouraging results from the Phase Ib clinical study, AbbVie announced the launch of Phase IIb development of the Cedirogant clinical study in the second half of 2021. In accordance with the terms of the collaboration agreement between the Company and AbbVie, the initiation of Phase IIb generated a milestone payment to the Company that was recognized as revenue in the second half of 2021 and received in January 2022. AbbVie announced its decision to terminate the cedirogant program, and thereby the partnership with the Company, on October 28, 2022. See Note 1.2 – Significant events of 2022 - AbbVie discontinues development of cedirogant. Launch of the pivotal Phase III clinical trial evaluating lanifibranor in NASH On September 8, 2021, the Company announced the initiation of its NATiV3 Phase III clinical trial evaluating lanifibranor for the treatment of NASH. The first clinical trial sites were activated in the United States and first patients were screened. The clinical trial was designed to include two parts to evaluate the long-term safety of lanifibranor in adult patients with non-cirrhotic NASH and stage F2/F3 liver fibrosis. The primary composite endpoint of part 1 of the NATiV3 Phase III clinical trial is identical to the composite efficacy endpoint used in the Company’s NATIVE Phase IIb clinical trial. The first visit of the last patient enrolled in part 1 of the NATiV3 Phase III clinical trial is planned for the second half of 2023 with the publication of the topline results of part 1 of the trial was expected for the second half of 2024. If part 1 of the NATiV3 trial is successful, the Company intends to seek accelerated approval in the United States and conditional approval in the EU for lanifibranor. In January 2023, the Company decided to modify the design of NATiV3 and the clinical development plan of lanifibranor. The last patient first visit for NATiV3 is now expected for the second half of 2023 and the publication of the topline results of the part 1 of NATiV3 is targeted for the second half of 2025. See Note 1.1 – Company information. Corporate team recruitments anticipated to support the development of lanifibranor in NASH On September 16, 2021, the Company announced a series of recruitments with a view to the development of its lead drug candidate lanifibranor for the treatment of NASH. The seven recruitments with solid track records and complementary profiles are expected to strengthen the Company’s expertise in clinical operations and drug development while reinforcing its core corporate functions. Following the opening of the Company’s subsidiary in the United States in January 2021, these recruitments are further expanding the Company’s footprint in the United States. Tax disputes Tax audit on payroll tax for years 2016 and 2017 On December 8, 2020, the Company submitted claim with a request for deferral of payment. On January 6, 2021, following the positive response of the tax authorities to the request for deferral of payment concerning the payroll tax for the years 2016 and 2017, the Company provided a guarantee, in the form of a bank guarantee from Crédit Agricole, in the amount of €1.0 million (see Note 12 – Provisions and Note 14 – Trade Payables and Other Current Liabilities). By letter dated November 26, 2021, the French tax authorities rejected the Company’s claim for a total amount of €1.2 million (including surcharge and late payment interest) and discussions for a global settlement with the French tax authorities were ongoing as of December 31, 2021, with no impact on the Company’s accounts as of December 31, 2021. See also Note 1.2 – Significant events of 2022 – Tax dispute settlement. Tax audit on payroll tax for years 2013 to 2015 On January 25, 2021, the administrative court of Dijon rejected the Company’s contest claim against the tax authorities regarding the claim filed in October 2018 and its introductory request of September 2019. Abbott and the Company did not wish to contest this decision. On February 11, 2021, the Company received formal notice to pay the amounts due to the French tax authorities under the notice of assessment issued on August 17, 2018 for an amount of €1.9 million. On March 9, 2021, the Company received the payment from Abbott for an amount of €2.0 million corresponding to the maximum amount covered by compensation under the Additional Agreement (see Note 8.2 - Other current assets and receivables). On June 9, 2021, in accordance with the French tax authorities, the Company paid €1.8 million, corresponding to the amounts due and late payment interest, including €1.3 million by offsetting VAT credit receivables (see Note 14.2 - Other current liabilities) and €0.5 million by bank transfer (see Note 14 - Trade Payables and Other Current Liabilities). Following this payment, the Company obtained the partial release of the bank guarantee set up in 2019 and 2020, for a total amount of €1.6 million corresponding to the portion relating to the payroll tax. Consequently, Credit Agricole agreed to release the pledge on short-term deposit for €1.0 million (see Note 14 - Trade Payables and Other Current Liabilities). Tax audit on research tax credit for years 2013 to 2015 On November 26, 2021, in accordance with the clearance granted by the mediator in January 2021, the tax authorities partially accepted the Company’s claim relating to the research tax credit for the years 2013 to 2015 and granted €0.3 million corresponding to the portion of the dispute relating to subcontracting, given that the subcontracting operations carried out by the Company was compliant with the conditions set out by the decision of French supreme court for administrative law (“ Conse

Basis of preparation and statem

Basis of preparation and statement of compliance	12 Months Ended
	Dec. 31, 2022
Basis of preparation and statement of compliance
Basis of preparation and statement of compliance	Note 2.Basis of preparation and statement of compliance 2.1. Basis of preparation The Company has prepared these consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union and IFRS as issued by the International Accounting Standard Board (“IASB”). These consolidated financial statements as of December 31, 2022 and for the twelve months December 31, 2022, 2021 and 2020 were authorized for issue by the Company’s Board of Directors on March 27, 2023. Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2022. The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2022 in the European Union primarily concern: - Amendment to IFRS 3 related to the conceptual framework; - Amendment to IAS 37 related to onerous contracts; - Amendment to IAS 16 related to proceed before intended use; - Annual improvements to IFRS 2018-2020; and - IFRIC decision of April 2021 on configuration or customization costs in a cloud computing arrangement (IAS 38). Those amendments had no material impact on the Company’s consolidated financial statements. Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory No standards, amendments to existing standards or interpretations had been published but were not yet applicable as of December 31, 2022, that may have a material impact on the Company’s financial statements. ​ 2. 2. Basis of consolidation Accounting policy In accordance with IFRS 10 Consolidated Financial Statements Subsidiaries are all entities over which the group has control. The group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date on which control is transferred to the group. They are deconsolidated from the date the control ceases. All intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of statement of income (loss), statement of comprehensive income (loss), statement of changes in shareholders’ equity and statement of financial position respectively. Consolidated entity As of December 31, 2022, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its fully-owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized. ​ ​ ​ ​ ​ ​ ​ ​ Date of incorporation Percent of Ownership Interest Accounting Method INVENTIVA Inc. 01/05/2021 100 % Fully Consolidated ​ The table below shows the impact of the consolidated entities as of December 31, 2022 in the consolidated financial statements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ Consolidation Inventiva Thousands of euros Inventiva S.A. Inventiva Inc. adjustments consolidated Net income (loss) (54,746) 691 208 (54,274) Total assets 112,289 ​ 8,676 4,962 116,004 Shareholders’ equity 44,797 1,111 (5) 45,476 ​ 2.3. Foreign currency translation Functional and presentation currency The Company’s consolidated financial statements are presented in euros, which is also the functional and presentation currency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S. dollar. All amounts presented in these notes to the financial statements are denominated in euros unless otherwise stated. Translation of financial statements into presentation currency The results and financial position of foreign operations that have functional currency different from the presentation currency are translated into euros, the presentation currency, as follows: ● Assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet Income and expenses for each statement of income (loss) and statement of comprehensive income (loss) are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● All results from currency translation differences are recognized in other comprehensive income. ​ ​ ​ ​ ​ ​ Exchange rate (USD per EUR) As of December 31, 2022 As of December 31, 2021 Average exchange rate for the year 1.0530 ​ 1.1827 Exchange rate at year end 1.0666 ​ 1.1326 ​

Accounting Principles

Accounting Principles	12 Months Ended
	Dec. 31, 2022
Accounting Principles
Accounting Principles	Note 3. Accounting Principles The principal accounting policies applied in the preparation of the financial statements are described below. Unless otherwise stated, the same policies have been consistently applied for all periods presented. 3.1. Intangible assets In accordance with IAS 38 — Intangible Assets An internally generated intangible asset arising from a research program is recognized if, and only if, the Company can demonstrate all of the following: ● The technical feasibility necessary to complete the research program. ● Its intention to complete the intangible asset and use or sell it. ● Its ability to use or sell the intangible asset. ● How the intangible asset will generate probable future economic benefits. ● The availability of adequate technical, financial and other resources to complete the research program. ● The ability to measure reliably the expenditure attributable to the intangible asset during its development. Given the risks and uncertainties involved in regulatory approval and in the process of research and development, the Company considers that the six criteria set out in IAS 38 are met only upon obtaining market authorization for a product candidate. Consequently, all research and development costs are charged directly to expenses. Intangible assets include: ● The cost of acquiring software licenses, which are amortized over a period of between one and five years based on their expected useful life. ● The library of compounds acquired pursuant to the Asset Purchase Agreement together with additional chemical components, which are amortized over a 13 - year period corresponding to their estimated useful lives. 3.2. Property, plant and equipment Property, plant and equipment are recognized at historical cost, less depreciation and impairment losses, if any. Depreciation is calculated based on the estimated useful life of assets using the straight-line method. A complete review of the useful lives of acquired non-current assets is performed on an annual basis. Any material adjustments are reflected prospectively in the depreciation schedule. The principal useful lives applied are as follows: ● Buildings: 20 to 25 years ● Fixtures and fittings: 10 years ● Technical facilities: 6 to 10 years ● Equipment and tooling: 6 to 10 years ● General facilities, miscellaneous fixtures and fittings: 10 years ● Office equipment: 5 years ● IT equipment: 5 years ● Furniture: 10 years 3.3. Lease contracts Lease contracts are recognized in accordance with the standard IFRS 16 - Leases ● an asset, representing its right to use the leased asset during the lease term (right-of-use asset); ● a liability, representing the value of the outstanding lease payments (lease liability). For each asset, the discount rate used to calculate the lease liability is determined based on the incremental borrowing rate at the date the Company obtains control of the use of leased asset. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. Exemptions The Company has not restated its other leases because they are covered by the exemptions permitted under the standard (short-time leases and low-value leases). They include: ● leases that expire within 12 months of the date of first-time adoption (January 1, 2019); ● 12-month leases with automatic renewal, where it is not reasonably certain at the date of first-time application that the leases will be renewed; and ● leases for which the underlying asset is less than €5,000 . Rental expenses for short-term and low-value leases continue to be recognized in operating expenses in the Company’s statement of income (loss). 3.4. Other non-current assets Other non-current assets include: - long-term deposit accounts that do not qualify as cash equivalents within the meaning of IAS 7 — Statement of Cash Flows and whose maturity is more than one year on the present closing date; - Security deposits; and - Accrued income with a maturity greater than one year on the present closing date. 3.5. Impairment of non-financial assets IAS 36 — Impairment of Assets 3.6. Inventories In accordance with IAS 2 — Inventories 3.7. Trade receivables Trade receivables are recognized initially at the amount of consideration that is unconditional, net of allowance for doubtful accounts. The Company recognizes loss allowances for expected credit losses (“ECL”), which, for trade receivables and contract assets, are measured at an amount equal to lifetime ECLs that result from all possible default events over their expected life. Loss allowances are deducted from the gross amounts of the assets. 3.8. Other current assets Currency term accounts are classified as other current assets, their main characteristics don’t meet the definition of “Cash equivalents” within the meaning of IAS 7. 3.9. Derivatives The Company may have to use derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. The derivatives used to hedge exchange rate risks are measured at their fair value in the statement of financial position. All changes in fair value of derivative instruments are recognized in the statement of income (loss) and classified in financial income (loss). The fair values of derivatives are estimated based on commonly used valuation models considering data from active markets. During the year ended December 31, 2022, the Company entered into a credit facility with EIB. This financial instrument includes two instruments (i) a host contract representing a debt component (the loans) and (ii) warrants. The two instruments issued (loans and warrants) on the date of issue are economically and intrinsically linked according to the IFRS 9 criteria, thus the transaction is analyzed as a single hybrid instrument on issue in which there is a host contract representing a debt component (the loans) and a derivative (the warrants). The financial instrument includes different options too: a call option, a prepayment option and a put option. The prepayment option is not a separate derivative instrument. The warrants, put option and call option are each classified as derivatives on own equity instruments, because the “fixed-for-fixed” rule under IAS 32, which provides that derivatives will be classified as equity if they can only be settled by delivering a fixed number of shares in exchange for a fixed amount of cash or another financial asset, is not met (non cash settlement option which may result in exchanging a variable number of shares, for a variable price). The derivatives are recognized at fair value through profit and loss. The fair value is estimated using the Longstaff Schwartz model which takes into account data from active markets and unobservable data (directly and indirectly) see Note 3.25 - Use of estimates and judgment. The put option can only be exercised in the framework and for the purposes of a cashless exercise of the warrants, and thus cannot be exercised on a standalone basis. The put option comes into effect upon the issuance of warrants by the Issuer and remains in effect for the lifetime of the warrants. In addition, the put option is not independently transferable from the warrants. Thus, the put option is not bifurcated and it is to be considered as part of the valuation of the warrants. The call option is exercisable by the Company, under very specific circumstances wherein the value of the warrants increase due to a takeover bid for the Company. The Company believes it is very unlikely that it will take advantage of exercising the call option. Thus, the call option has been valued at zero and does not require bifurcation.The accounting treatment and impact on the 2022 financial year is described in Note 11 - Financial debts. 3.10. Cash and cash equivalents Cash and cash equivalents include cash on hand and demand deposits, as well as other short-term highly liquid investments with maturities of three months or less , convertible at a known amount,and subject to an insignificant risk of change in value. Short-term bank deposits may be recognized as cash equivalents when they: ● have an original maturity of three months or less, or there are exit options from the short-term bank deposits at any time; ● are readily convertible to a known cash amount; and ● are subject to an insignificant risk of decrease in value. Bank overdrafts are recorded in liabilities in the statement of financial position under short-term debt. 3.11. Share capital Share capital Ordinary shares are classified in shareholders’ equity. Transaction costs Costs directly attributable to the issuance of ordinary shares or share options are recognized as a reduction in the share premium. Costs related to multiple operations (initial public offering and capital increase) are distinctly recorded. For the IPO, the cost tied to new shares is recognized in the deduction of the share capital premiums, while the costs tied to existing shares is recognized in expenses as transaction costs. 3.12. Share-based payments plans At the Company’s inception, the Company put in place a compensation plan settled in equity instruments in the form of share warrants awarded to employees ( Bons de souscription de parts de créateur d’entreprise Bons de souscription d’actions Attribution gratuite d’actions In accordance with IFRS 2 — Share-based Payment The values of equity instruments are determined, using option valuation models (in particular, a Black and Scholes model or a Monte-Carlo simulation, depending on whether the plans are subject to market performance condition), on the basis of the value of the underlying equity instrument on the grant date, the volatility,observed on the historical share price of the Company and on a sample of comparable listed companies, and the estimated lifespan associated equity instruments. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market presence and performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet related service and performance conditions. non-market performance conditions at the vesting date. For share-based payment awards where the payment is based on shares with market conditions at market acquisition, the grant date fair value of the share-based payment is measured to reflect these conditions and there is no adjustment for differences between the expected results and the actual result. Movement, details, and measurement of the fair value of options incorporates the vesting conditions of these plans are described in Note 10.3 - Share award plans and Note 10.4 - Bonus share award plans. 3.13. Loans and borrowings Bank loans are initially recognized at fair value, i.e., the issue proceeds (fair value of the consideration received) net of transaction costs incurred and the fair value at inception date of the derivative instruments of the debt concerned. Borrowings are subsequently measured at amortized cost, calculated using the effective interest rate method. Any difference between initial fair value and repayment value is recognized in the statement of income (loss) over the life of the loan using the effective interest rate method. The effective interest rate is the discount rate at which the present value of all future cash flows (including transaction costs) over the expected life of the loan, or where appropriate, over a shorter period of time, is equal to the loan’s initial carrying amount. The accounting treatment applied to the financing contract entered with the EIB is described in Note 11 – Financial debt. 3.14. Trade payables and other current liabilities The carrying amounts of trade and other current liabilities are considered to be the same as their fair values, due to their short-term nature. 3.15. Current and deferred tax Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period. The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other comprehensive income and expense or directly in equity, in which case the tax is also recorded in other comprehensive income and expense or directly in equity. Current taxes The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the end of the year in the countries where the Company’s subsidiaries operate and generate taxable income. Deferred taxes Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company’s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, does not affect either the accounting or the taxable profit (tax loss). Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates and tax laws enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are not discounted. Deferred tax assets and liabilities are offset when a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes concern the same entity and the same tax authority. Deferred tax assets Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can be utilized. The recoverable amount of deferred tax assets is reviewed at the end of each reporting period and their carrying amount is reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of the deferred tax assets to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are recognized when it becomes probable that future taxable profit will be available to offset the temporary differences. Deferred tax liabilities Deferred tax liabilities are recognized for all taxable temporary differences, except when the Company is able to control the timing of the reversal of the difference and it is probable that the reversal will not occur in the foreseeable future. 3.16. Provisions for retirement benefit obligations Retirement benefit obligations The Company operates a defined benefit pension plan. Its obligations in respect of the plan are limited to the lump sum payments upon retirements, which are expensed in the period in which the employees provide the corresponding service. The liability recorded in the statement of financial position in respect of defined benefit pension plans and other post-retirement benefits is the present value of the defined benefit obligation at the statement of financial position date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting estimated future cash outflows, using the interest rate of high-quality corporate bonds of a currency and term consistent with the currency and term of the pension obligation concerned. In determining the present value and the related current service cost and, where applicable, past service cost, the benefit is attributed to periods of service under the plan’s benefit formula. However, if an employee’s service in later years will lead to a materially higher level of benefit than in earlier years, the benefit is attributed on a straight-line basis from: ● the date when service by the employee first leads to benefits under the plan (whether or not the benefits are conditional on further service) until ● the date when further service by the employee will lead to no material amount of further benefits under the plan, other than from further salary increases. Actuarial gains and losses arise from the effect of changes in assumptions and experience adjustments (i.e., differences between the assumptions used and actual data). These actuarial gains and losses are recognized wholly and immediately in other comprehensive income and expense and are not subsequently reclassified to the statement of income (loss). The net expense in respect of defined benefit obligations recognized in the statement of income (loss) for the period corresponds to: ● The service cost for the period (acquisition of additional rights). ● The interest cost. ● The past service cost. ● The impact of any plan settlements, amendments and curtailments. The discounting effect of the obligation is recognized in net financial income and expenses. Termination benefits Termination benefits are payable when a company terminates an employee’s employment contract before the normal retirement age or when an employee accepts compensation as part of a voluntary redundancy. In the case of termination benefits, the event that gives rise to an obligation is the termination of employment. In the case of an offer made to encourage voluntary redundancy, termination benefits are measured based on the number of employees expected to accept the offer. Profit-sharing and bonus plans The Company recognizes a liability and an expense for profit-sharing and bonus plans based on a formula that takes into consideration the Company’s performance. 3.17. Other provisions In accordance with IAS 37 — Provisions, Contingent Liabilities and Contingent Assets Where there are a number of similar obligations, the probability that an outflow will be required in settlement is determined by considering the class of obligations as a whole. Although the likelihood of outflow for any one item may be small, it may well be probable that some outflow of resources will be needed to settle the class of obligations as a whole. If that is the case, a provision is recognized. The provision represents the best estimate of the amount required to settle the present obligation at the end of the reporting period. Where the effect of the time value of money is material, the amount of a provision corresponds to the present value of the expected costs that the Company considers necessary to settle the obligation. The pre-tax discount rate used reflects current market assessments of the time value of money and specific risks related to the liability. The effect of discounting provisions due to the time value of money is recognized in net financial income and expenses. 3.18. Revenue Revenue is recognized in accordance with IFRS 15 — Revenue from Contracts with Customers Under IFRS 15, revenue is recognized when the Company fulfills a performance obligation by providing separate goods or services to a customer, when the customer obtains control of those goods or services. An asset is transferred when the customer obtains control of that asset or service. Under this standard, each contract must be analyzed on a case-by-case basis in order to verify whether it contains performance obligations to customers, and, if applicable, to identify the nature of said obligations in order to appropriately account for the amount that the Company has received or is entitled to receive from customers: - The transfer of the right to use the intellectual property, via a license granted by the Company, as it exists at the time of the transfer, the date of which will determine that of the revenue recognition; - If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime; - The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; - Revenue from variable consideration, such as development or regulatory milestones, and which are recognized when the achievement is highly probable; or - Revenue from sales-based or usage-based royalty promised in exchange for a license of intellectual property would not be recognized until the achievement of the milestone or completion of the sale. The accounting treatment of the contracts with customers are detailed in Note 16.1 – Revenue. 3.19. Other income Research tax credit Its includes the research tax credit granted by the US Government and the research tax credit ( crédit d’impôt recherche Only those companies meeting the EU definition of a small or medium-sized entity (“SME”) are eligible for payment in cash of their CIR (to the extent not used to offset corporate taxes payable) in the year following the request for reimbursement. Inventiva meets the EU definition of an SME and therefore should continue to be eligible for prepayment. Inventiva has been eligible for CIR since inception. The CIR is recognized in “Other income” during the reporting period in which the eligible expenditure is incurred as it meets the definition of government grant as defined in IAS 20 Accounting for Government Grants and Disclosure of Government Assistance Other grants The Company receives subsidies from several public bodies. The subsidies are related to net income and granted to compensate for incurred expenses. They are therefore recognized in net income as other income for the period in which it becomes reasonably certain that they will be received. 3.20. Net financial income Financial income Financial income includes: - The income from cash and cash equivalents, which includes income from short-term investments and cash and cash equivalents; - Changes in the fair value of cash and cash equivalents, remeasured at the end of each reporting period; - Changes in the fair value of derivatives instruments; - Accretion income; - Foreign exchange gains; - Other financial income. Financial expenses Financial expenses primarily include: - Interest cost; - Changes in the fair value of cash and cash equivalents remeasured at the end of each reporting period; - Changes in the fair value of derivatives instruments; - Foreign exchange losses; - Accretion expenses; - Other financial expenses. 3.21. Other operating income and expenses Other operating income and expenses are disclosed separately on the face of the statement of income (loss). This line item is set aside for events that may arise during the period whose presentation within other items (relating to ordinary activities) could be misleading for users of the financial statements in their understanding of the Company’s performance. This item therefore includes income and expenses that are rare that represent material amounts and that the Company discloses separately on the face of the statement of income (loss) to facilitate understanding of operating performance (see Note 18 - Other operating income (expenses)). Disposals of non-current assets Gain or loss from the disposal of non-current assets during the period is recognized in “Other operating income (expenses)”. 3.22. Fair value measurement In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. ● Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. ● Level 3: Unobservable inputs for the asset or liability. The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 (in thousands of euros) Level 1 Level 2 Level 3 Assets ​ ​ ​ ​ ​ Financial assets at fair value through profit or loss ​ ​ ​ ​ ​ Term deposits — — — Total assets — — — Long-term financial debt - derivatives ​ — ​ — ​ 9,876 Total liabilities — — 9,876 ​ The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Term deposits 8,829 — — Total assets 8,829 — — Total liabilities — — — ​ The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Foreign currency forwards (1) — 1,791 — Total assets — 1,791 — Total liabilities — — — (1) The valuation of the instrument is estimated based on observable market parameters. The instrument is not directly listed on a market. 3.23. Foreign currency transactions Translation of foreign currency transactions As of December 31, 2022, foreign currency transactions include bank accounts and term deposits in U.S dollars implemented after the IPO on the Nasdaq Global Market in July 2020. Certain purchasing transactions are carried out in foreign currencies for our studies and clinical trials conducted in the United States and to a lesser degree the United Kingdom, Switzerland, Australia, Canada and Sweden. For the year ended December 31, 2022, these expenses in a foreign currency amounted to approximately €15.9 million, or 21% of the operating expenses, to be compared with €13.5 million, or 21% for the year ended December 31, 2021 and €2.5 million, or 7% for the year ended December 31, 2020. These transactions are translated into euros at the exchange rate prevailing at the date of each transaction. Purchasing transactions in foreign currencies are presented in operating income as they relate to the Company’s ordinary activities. Foreign exchange gains and losses relating to short-term investments and bank accounts in U.S. dollars are presented in financial income (loss). 3.24. Segment information The assessment of the entity’s performance and the decisions about resources to be allocated are made by the chief operating decision maker (the CEO), based on the management reporting system of the entity. Only one operating segment arises from the management reporting system: service delivery and clinical stage research, notably into potential therapies in the areas of fibrosis, lysosomal storage disorders and oncology. Thus, the entity’s performance is assessed at the Company level. For the company’s geographical split please refer to tables below: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 935 770 568 USA — — — China — — — Intangible assets 935 770 568 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 3,282 3,096 6,324 USA — 101 1,062 China — — — Property, plant and equipment 3,282 3,196 7,385 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 1,706 2,442 1,603 USA — — 65 China — — — Other non-current assets 1,706 2,442 1,668 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) (1) 2020 2021 2022 France 372 194 125 USA — 4,000 — China — — 12,054 Revenue 372 4,194 12,179 (1) Allocation is based on customer location. 3.25. Use of estimates and judgment The preparation of financial statements in accordance with IFRS requires: ● Management to make judgments when selecting appropriate assumptions for accounting estimates, which consequently involve a certain degree of uncertainty. ● Management to make estimates and apply assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as information presented for the period. The estimates and judgments, which are updated on an ongoing basis, are based on past experience and other factors, in particular assumptions of future events, deemed reasonable in light of circumstances. The identification, assessment and response to risks, particularly those related to the climate and to the COVID-19 pandemic, are integrated into the risk management process and have not led to the use of any significant new estimates or judgments in fiscal 2022. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates, by definition, often differ from actual reported values. Estimates and assumptions that could lead to a significant risk of a material adjustment in the carrying amount of assets and liabilities in the subsequent period are analyzed below. Revenue ● Determining the distinctiveness of performance obligations — A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services. In the context of Biotech industry R&D services are generally capable of being distinct if: - The entity sells the services on their own – i.e. without a related license. This indicates that customers can benefit from the services on their own and they are therefore capable of being distinct; or - The customer can benefit from the services together with the license that has already been transferred to the customer. Readily available resources include goods or services that have already been transferred. If the license is transferred at the beginning of the contract, the services will typically be capable of being distinct. In making this determination, the key analysis is whether the R&D services significantly modify or customize the drug compound so that the intellectual property is significantly different at the end of the arrangement as a result of the services. This may be more frequent in early stages of development when the formula is being developed or when the services are developing an existing technology for a significantly different use. ● Allocation of transaction price to performance obligations — A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment; some of the Company’s contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. ● Variable consideration — Due to the nature of the work required to be performed on many of the Company’s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific mileston

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Intangible Assets	Note 4. Intangible Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2020 Increases Decreases December 31, 2020 Library of compounds ​ 2,142 — — 2,142 Software ​ 1,532 1 — 1,533 Intangible assets, gross ​ 3,674 1 — 3,674 Amortization of library of compounds ​ (1,157) (165) — (1,322) Amortization of software ​ (1,289) (129) — (1,417) Amortization ​ (2,446) (293) — (2,739) Intangible assets, net ​ 1,228 (293) — 935 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2021 Increases Decreases December 31, 2021 Library of compounds 2,142 — — 2,142 Software 1,533 53 (10) 1,575 Intangible assets, gross 3,674 53 (10) 3,717 Amortization of library of compounds (1,322) (165) — (1,487) Amortization of software (1,417) (53) 10 (1,460) Amortization (2,739) (217) 10 (2,947) Intangible assets, net 935 (165) (1) 770 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2022 Increases Decreases December 31, 2022 Library of compounds 2,142 — ​ — ​ 2,142 Software 1,575 15 ​ — ​ 1,590 Intangible assets, gross 3,717 15 ​ — ​ 3,732 Amortization of library of compounds (1,487) (165) ​ — ​ (1,651) Amortization of software (1,460) (52) ​ — ​ (1,512) Amortization (2,947) (217) ​ — ​ (3,164) Intangible assets, net 770 (202) ​ — ​ 568 ​ Changes in intangible assets mainly correspond to depreciation expenses, for €0.2 million, €0.2 million and €0.2 million for the years ended December 31, 2022, December 31, 2021, and December 31, 2020 respectively. In the absence of any indication of impairment, no impairment tests have been performed on amortizable intangible assets in the years ended December 31, 2022, 2021 and 2020.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment
Property, Plant and Equipment	Note 5. Property, Plant and Equipment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) 2020 Increases Decreases Others (1) 2020 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,748 108 0 — 4,856 Other property, plant and equipment 1,157 46 0 — 1,203 Property, plant and equipment in progress — 137 — — 137 Right of use (1) 252 — — (218) 34 Property, plant and equipment, gross 9,736 292 0 (218) 9,810 Depreciation and impairment of buildings (1,542) (196) — — (1,737) Depreciation and impairment of technical facilities, equipment and tooling (3,396) (386) — — (3,782) Depreciation and impairment of other property, plant and equipment (874) (102) — — (976) Depreciation and impairment of right of use (203) (32) — 202 (33) Depreciation and impairment (6,015) (716) — 202 (6,528) Property, plant and equipment, net 3,721 (424) 0 (16) 3,282 (1) corresponding to early termination of lease contracts. Changes during the period 2020 mainly correspond to depreciation expenses for €0.7 million. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) ​ 2021 ​ Increases ​ Decreases ​ Others ​ 2021 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,856 336 (75) — 5,118 Other property, plant and equipment 1,203 223 (4) — 1,422 Property, plant and equipment in progress 137 59 — (137) 59 Right of use ​ 34 ​ 143 ​ (34) ​ — ​ 143 Property, plant and equipment, gross 9,810 761 (113) (137) 10,321 Depreciation and impairment of buildings (1,737) (194) — — (1,931) Depreciation and impairment of technical facilities, equipment and tooling (3,782) (384) 75 — (4,091) Depreciation and impairment of other property, plant and equipment (976) (116) 4 — (1,087) Depreciation and impairment of right of use (33) (16) 34 — (14) Depreciation and impairment ​ (6,528) ​ (709) ​ 113 ​ (137) ​ (7,124) Property, plant and equipment, net 3,282 52 0 (274) 3,196 ​ ​ Changes during the period 2021 mainly correspond to acquisition of technical facilities, equipment, and tools for €0.3 million and acquisition of other property, plant and equipment for €0.2 million, offset by depreciation expenses for €0.7 million. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) 2022 Increases Decreases Others 2022 Land ​ 172 — — — 172 Buildings ​ 3,407 86 (23) — 3,470 Technical facilities, equipment and tooling ​ 5,118 357 (18) — 5,457 Other property, plant and equipment ​ 1,422 97 — — 1,519 Property, plant and equipment in progress ​ 59 5 — — 65 Right of use ​ 143 5,109 — 7 5,259 Property, plant and equipment, gross ​ 10,321 5,655 (41) 7 15,941 Depreciation and impairment of buildings ​ (1,931) (196) 23 — (2,104) Depreciation and impairment of technical facilities, equipment and tooling ​ (4,091) (355) 1 — (4,446) Depreciation and impairment of other property, plant and equipment ​ (1,087) (128) — — (1,216) Depreciation and impairment of right of use ​ (14) (776) — (0) (790) Depreciation and impairment ​ (7,124) (1,455) 24 (0) (8,555) Property, plant and equipment, net ​ 3,196 4,200 (17) 7 7,386 ​ In 2022, the net book value of property, plant and equipment increased by €4.2 million. Changes during this period mainly correspond to the recognition of rights of use assets, notably the Fibroscans equipment leases for €5.1 million. On September 21, 2021, the Company entered into a Fibroscans lease agreement with Echosens to equip the open clinical trial centers for the Phase III clinical study evaluating lanifibranor in NASH patients. In the absence of any indication of impairment, no impairment tests have been performed on amortizable tangible assets and right of use in the years ended December 31, 2020, 2021 and 2022.

Other Non-Current Assets

Other Non-Current Assets	12 Months Ended
	Dec. 31, 2022
Other Non-Current Assets
Other Non-Current Assets	Note 6. Other Non-Current Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Advances to suppliers – non-current ​ — 689 895 Long‑term deposit accounts ​ 1,698 1,745 700 Accrued income ​ — — 65 Security deposits ​ 8 8 8 Other non ‑ current assets ​ 1,706 2,442 1,668 ​ Advances to suppliers – non-current At December 31, 2022, non-current advances to suppliers amounted to 0.9 million, corresponding to the advance paid under the CRO contract with PRA (see Note 21 - Commitments) At December 31, 2021, non-current advances to suppliers amounted to €0.7 million, corresponding to the advance paid under the CRO contract with PRA (see Note 21 - Commitments). Long-term deposits accounts In the fiscal year 2022, term accounts whose maturity are shorter than one year from December 31, 2022 have been reclassified as current assets (see Note 8.2 – Other current assets and receivables), resulting in a decrease in the “Financial accounts” item. term deposit” of 1.0 million euros. At December 31, 2022, long-term deposit accounts are mainly composed of one account maturing at January 30, 2024 There are no liens attached to the Company’s bank accounts. At December 31, 2021, two pledges over cash, for a total amount of €1.7 million, were in place: ● one pledge over cash of €0.7 million was granted by the Company on February 1, 2019, equivalent to 50% of the sum not covered by the indemnity to be received from the Abbott group under the Additional Agreement; and ● one pledge over cash of € 1.0 million was granted by the Company on January 6, 2021. Following the request for a deferral of payment on the payroll tax for fiscal years 2016 and 2017, the Company carried out a guarantee to the tax authorities, in the form of a bank guarantee from Crédit Agricole. These pledges were granted as part of the surety provided by the Company to the French tax authorities in connection with its tax disputes, in the form of €1.7 million bank guarantees from Crédit Agricole. During April 2022, two pledges over cash of €1.0 million and €0.7 million were released following the settlement on the payroll tax for fiscal years 2016 and 2017 (see Note 1.2 – Significant events during the first quarter of 2022).

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventories
Inventories	Note 7. Inventories ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Laboratory inventories ​ 353 425 406 Inventories write‑down ​ (33) (33) (33) Total inventories ​ 320 392 373 ​

Trade Receivables and Other Cur

Trade Receivables and Other Current Assets and Receivables	12 Months Ended
	Dec. 31, 2022
Trade Receivables and Other Current Assets and Receivables
Trade Receivables and Other Current Assets and Receivables	Note 8. Trade Receivables and Other Current Assets and Receivables 8.1. Trade receivables Trade receivables break down as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 3 months or less 48 4,000 ​ 0 Between 3 and 6 months — — ​ — Between 6 and 12 months — — ​ — More than 12 months — — ​ — Trade receivables 48 4,000 ​ 0 ​ As of December 31, 2021, the trades receivables consisted exclusively of a receivable from AbbVie following the launch of the Phase IIb trial for the Cedirogant program for a total amount of €4.0 million, in accordance with the terms of the collaboration agreement between the Company and AbbVie (see Note 1.2 - Significant events of 2022). This payment was received by the Company in January 2022. The average payment period is 30 days. 8.2. Other current assets and receivables ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 CIR 9,012 ​ 4,357 5,994 Other 16 ​ 16 13 Tax receivables 9,028 ​ 4,373 6,007 Prepaid expenses 3,313 ​ 7,454 8,601 Short-term deposit account ​ 7,336 ​ 8,829 ​ 1,048 Current accrued income ​ 2,000 ​ 92 ​ 117 Foreign currency forwards ​ 1,791 ​ — ​ 0 Liquidity agreement - Cash ​ 1,029 ​ 762 ​ 282 VAT receivables ​ 1,625 ​ 2,828 ​ 3,057 Other receivables 821 ​ 294 162 Other current assets 17,914 ​ 20,260 13,267 Other current assets and receivables 26,942 ​ 24,632 19,274 ​ French Research Tax Credit (“CIR”) As of December 31, 2022, tax receivables are mainly composed of CIR and other research tax credits for an amount of €6.0 million euros, including €0.8 million for the R&D Tax Research Credit of Inventiva Inc. The increase in CIR compared to December 31, 2021, is mainly due to the €12.0 million increase in Research and Development expenses from €48.5 million for the year ended 2021 to €60.5 million for the year ended 2022. This increase mainly relates to the end of phase II and the launch of the phase III clinical trial evaluating lanifibranor in NASH. As of December 31, 2021, tax receivables mainly corresponded to the research tax credits receivables for 2021 for a total amount of €4.4 million, including €0.2 million of research tax credits for Inventiva Inc. The decrease in tax receivables compared to December 31, 2020, was mainly due to the payment of CIR for 2020 for a total amount of €4.2 million and corrective claims for additional reimbursement of CIR with regards to the years 2016 to 2019 for a total amount of €3.8 million (refer to Notes 1.3, “Significant events of 2021 and 2020”), partially offset by the recording of the 2021 CIR receivable for a total amount of €3.8 million, of which €0.2 million euros relates to the CIR claim of the subsidiary Inventiva Inc. Prepaid expenses As of December 31, 2022, the €1.1 million increase in prepaid expenses mainly relates to research costs incurred in the context of CRO contracts with subcontractors, and to a lesser extent, to computer maintenance costs and research equipment, patent annuity costs and insurance contributions. As of December 31, 2021, prepaid expenses mainly related to research costs incurred in connection with CRO contracts with third parties, and to a lesser extent, to computer maintenance research equipment, patent annuity costs and insurance premiums relating to the first quarter of 2022. Short-term deposit accounts As of December 31, 2022, short-term deposit accounts decreased by €7.8 million, mainly due to the maturity of a term deposit subscribed during the year ended 2021 with Société Générale of $10 million (€8.8 million). As of December 31, 2020, short-term deposit accounts corresponded to short-term deposit accounts in U.S. dollars contracted with Société Générale and Crédit Agricole. Following the closing of the short-term deposit in dollars in the first half of 2021, the cash was transferred to the bank accounts presented in cash and cash equivalents. Current accrued income As of December 31, 2020, current accrued income corresponded entirely to an income receivable from the group Abbott following the tax audit of fiscal years 2013, 2014, 2015. The payment from Abbott of the €2.0 million was received in the first semester 2021(see Note 1.3 - Significant events of 2021 and 2020 and Note 12 - Provisions). Foreign currency forwards As of December 31, 2020, foreign currency forwards correspond to the change in fair value of the contracts that have been subscribed by the Company with Société Générale and Crédit Agricole to protect the value of investments in dollars against fluctuations in the exchange rate between the euro and the dollar up to $60 million (refer to Note 1.3 - Significant events of 2021 and 2020).

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents
Cash and Cash Equivalents	Note 9. Cash and Cash Equivalents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 Other cash equivalents (1) 12,001 ​ 42,900 16,798 Cash at bank and at hand 93,686 ​ 43,653 69,939 Cash and cash equivalents 105,687 ​ 86,553 86,736 (1) Other cash equivalents correspond to short-term bank deposits at Société Générale and Crédit Agricole. As of December 31, 2022, cash and cash equivalents amounted to €86.7 million, compared with €86.6 million at December 31, 2021, an increase of €0.1 million. Other cash equivalents decreased and cash at bank increased mainly due to withdrawals in 2022 for a total of $31 million from a short-term deposit account, set up with Société Générale in October 2021 for an amount of €30.9 million or $35 million.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2022
Shareholders' Equity
Shareholders' Equity	Note 10. Shareholders’ Equity 10.1. Share capital The share capital is set at €421 thousand at December 31, 2022 divided into 42,134,169 fully authorized, subscribed and paid-up shares with a nominal value of €0.01.Changes in share capital during the years ended December 31, 2022, 2021 and 2020 are as follows: in euros, except number of shares ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Premiums ​ ​ ​ ​ ​ ​ ​ ​ Share ​ related to ​ Number of ​ Nominal Date Nature of the transactions capital share capital shares value Balance as of January 1 st , 2020 268,461 86,011,893 26,846,112 0.01 01/26/2020 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2018-2) 633 — 63,300 0.01 02/07/2020 ​ Capital increase by issuance of ordinary shares – Company’s private placement 37,783 14,962,218 3,778,338 0.01 02/07/2020 ​ Transaction costs related to the Company’s private placement — (319,564) — — 04/17/2020 ​ Appropriation of the issue premium — (48,000,000) — — 06/28/2020 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2019-2) ​ 2,270 ​ — ​ 227,000 ​ 0.01 07/15/2020 ​ Capital increase by issuance of ordinary shares – Company’s initial public offering ​ 74,783 ​ 94,024,272 ​ 7,478,261 ​ 0.01 07/15/2020 ​ Transaction costs related to the Company’s initial public offering — (7,077,866) — — 11/30/2020 ​ Capital increase by emission of ordinary shares – Emission of 10,000 BSA 100 66,650 10,000 0.01 12/14/2020 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2018-3) 2,273 — 227,250 0.01 Balance as of December 31, 2020 ​ 386,302 ​ 139,667,603 ​ 38,630,261 ​ 0.01 06/28/2021 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2019-1) ​ 291 ​ — ​ 29,100 ​ 0.01 09/27/2021 ​ Capital increase by issuance of ordinary shares – (ATM) ​ 20,833 ​ 25,556,803 ​ 2,083,334 ​ 0.01 10/01/2021 ​ Capital increase by issuance of ordinary shares – (ATM) ​ 1,309 ​ 1,615,584 ​ 130,856 ​ 0.01 10/01/2021 ​ Transaction costs related to ATM ​ — ​ (1,768,424) ​ — ​ — Balance as of December 31, 2021 ​ ​ ​ 408,735 ​ 165,071,566 ​ 40,873,551 ​ 0.01 15/06/2022 ​ Capital increase by issue of ordinary shares - (ATM3) ​ 12,606 ​ 9,353,504 ​ 1,260,618 ​ 0.01 15/06/2022 ​ Transaction costs related to ATM ​ — ​ (539,404) ​ — ​ — Balance as of December 31, 2022 ​ 421,341 ​ 173,885,665 ​ 42,134,169 ​ 0.01 ​ During the year ended December 31, 2022, the main impact on the share capital relates to the capital increase for a gross amount of €9.4 million on June 15, 2022, due to the issuance of 1,260,618 new shares as part of the Company’s At-The-Market program set up on August 2, 2021. For more details on the operation of the fiscal year 2022, please refer to Note 1.2 - Significant events of 2022. During the years ended December 31, 2021 and 2020, the main impacts on the share capital relate to the following events: - Capital increase of €25.4 million of cash, consisting of the net proceeds of the two ATM sales on September 27, 2021 and on October 1, 2021; - Final acquisition of 29,100 AGAs 2019-1 on June 28, 2021 ; - $107.7 million initial public offering on the Nasdaq Global Market in July 2020; - The reclassification of €48.0 million from debit retained earnings to premiums related to share capital following the decision of the General Meeting on April 2020; and - Capital increase of €14.7 million reserved for a category of investors in February 2020. For more details on the operations of the fiscal year 2021 and 2020, please refer to Note 1.3 - Significant events of 2021 and 2020. Movements related to BSA share warrants plans and AGA bonus shares award plans are described in Notes - 10.3 - Share warrants plans and 10.4 - Bonus share award plans. 10.2. Liquidity agreement On January 19, 2018, the Company entered into a new liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF, for a period of 12 months renewable by tacit agreement. Under the terms of the agreement, the investment services provider (“ISP”) is authorized to buy and sell Inventiva treasury shares without interference from the Company in order to ensure the liquidity of the shares on the Euronext market. At the date of approval of these financial statements, the liquidity agreement with Kepler Cheuvreux was extended for a new period of 12 months from January 1, 2022. At December 31, 2020, 2021 and 2022 treasury shares purchased and sold by Inventiva through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation transactions during the periods, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company’s results. 10.3. Share warrants plans Share warrants correspond to: ● BSPCE founder share warrants granted to the Company’s employees in 2013 and 2015; ● BSA share warrants granted to Company directors in 2017, with a subscription price set at €0.53 ; ● BSA share warrants granted to Company service providers in 2018, with a subscription price set at €0.48 ; ● BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at € 0.18 ; and ● BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group LLC and to Jeremy Goldberg, a member of PG Healthcare LLC, service providers of Inventiva, with a subscription price set at €0.29 . ● BSPCE founder share warrants granted in 2021 to Frederic Cren and Pierre Broqua, Company’s Directors; and ● BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at €2.45 . Characteristics of BSPCE share warrant plans At January 1, 2022, two BSPCE share warrant plans were outstanding: BSPCE 2013-1 and BSPCE 2021. The main characteristics of the plans are described in the following table: ​ ​ ​ ​ ​ ​ ​ ​ BSPCE 2013-1 BSPCE 2021 Decision of issuance by the Board of Directors 13/12/2013 ​ 04/16/2021 ​ Grant date 13/12/2013 ​ 04/16/2021 ​ Beneficiary 3 employees ​ Executive Directors (Frederic Cren and Pierre Broqua) ​ Number of BSPCE granted 9 027 ​ 600,000 ​ Expiration date 25/01/2024 ​ 03/31/2034 ​ Number of shares per BSPCE 100 ​ 1 ​ Subscription price (€) ​ 58.50 ​ 0 ​ Exercise price (€) ​ 0.585 ​ 11.74 ​ Performance condition ​ No ​ Partially (1) ​ Valuation method used ​ Black and Scholes ​ Monte Carlo ​ Fair value at grant date (€) ​ 19 ​ [5.4 – 5.7] (1) ​ Expected volatility ​ 35 % 64 % Average life (years) ​ 5 ​ 5 ​ Risk-free rate ​ 1.13 % 0.60 % Expected dividends — ​ — ​ (1) The fair value at grant date is different depending on whether the BSPCEs are subject to market performance conditions. Characteristics of BSA share warrant plans At January 1, 2022, seven BSA share warrant plans were outstanding: BSA 2017, BSA 2018, BSA 2019, BSA 2019 bis, BSA 2019 ter and BSA 2021. ​ The main characteristics of the plans are described in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BSA ​ ​ ​ BSA ​ ​ ​ ​ ​ BSA 2017 2018-1 BSA 2019 2019 bis BSA 2019 ter BSA 2021 Decision of issuance by the Board of Directors ​ 05/29/2017 ​ 12/14/2018 06/28/2019 03/09/2020 03/09/2020 ​ 04/16/2021 ​ Grant date ​ 05/29/2017 ​ 12/14/2018 06/28/2019 03/09/2020 03/09/2020 ​ 04/16/2021 ​ Beneficiary ​ Directors ​ Service providers Service providers Service providers Service providers ​ Service providers ​ Vesting period (year) ​ 3 tranches: 1 year , 2 years and 3 years ​ between 1 and 3 years 1 1 between 1 and 3 years ​ 3 ​ Expiration date ​ 05/29/2027 ​ 12/14/2028 06/28/2029 03/09/2030 03/09/2030 ​ 03/31/2034 ​ Number of BSA granted ​ 195,000 ​ 126,000 10,000 10,000 36,000 ​ 50,000 ​ Number of shares per BSA ​ 1 ​ 1 1 1 1 ​ 1 ​ Subscription premium price per share (€) ​ 0.534 ​ 0.48 0.18 0.29 0.29 ​ 2.45 ​ Exercise price per share (€) ​ 6.675 ​ 6.067 2.20 3.68 3.68 ​ 11.74 ​ Performance condition ​ No ​ No No No No ​ Yes ​ Valuation method ​ Black and Scholes ​ Monte Carlo ​ Fair value per BSA at grant date (€) ​ 2.47 ​ 1.98 ​ 0.48 ​ 0.90 ​ 0.90 ​ [3.0 – 3.2] (1) ​ Expected volatility ​ 40 % 40 % 40 % 40 % 40 % 64 % Average life (years) ​ 6 ​ 6 ​ 5.5 ​ 6 ​ 6 ​ 5 ​ Risk free rate ​ 0.22 % 0.30 % 0.33 % 0.0 % 0.0 % 0.60 % Expected dividends ​ — ​ — — — — ​ — ​ (1) The fair value at grant date is different depending on whether the BSPCEs are subject to market performance conditions. Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2022 Issued Exercised Forfeited 2022 exercisable BSPCE — 2013 plan Dec. 13, 2013 0.59 8,800 — — — 8,800 8,800 BSPCE Plan 2021 ​ April 16, 2021 ​ 11.74 ​ 600,000 ​ — ​ — ​ (120,000) ​ 480,000 ​ — Total BSPCE 608,800 — — (120,000) 488,800 8,800 BSA — 2017 plan May 29, 2017 6.67 130,000 — — — 130,000 130,000 BSA — 2018 plan Dec. 14, 2018 6.07 116,000 — — — 116,000 116,000 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis ​ March 9, 2020 ​ 3.68 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 Ter ​ March 9, 2020 ​ 3.68 ​ 36,000 ​ — ​ — ​ — ​ 36,000 ​ 24,000 BSA - Plan 2021-1 ​ April 16, 2021 ​ 11.74 ​ 20,000 ​ — ​ — ​ (4,000) ​ 16,000 ​ — Total BSA 322,000 — — (4,000) 318,000 290,000 Total ​ ​ ​ ​ 930,800 — — (124,000) 806,800 298,800 ​ The change in BSPCE and BSA share warrants over 2022 can be broken down as follows: ● Cancellation of 120,000 BSPCE following the recruitments conditions that haven’t been reached; and ● Cancellation of 4,000 BSA following an employee departure. At December 31, 2022, a total of 480,088 BSPCEs (or 488,800 shares) and 318,000 BSAs were outstanding, which corresponds to a total of 806,800 shares, the maximum number of shares to be issued when all related conditions are met. Share based payment expense totaled €765 thousand for the year ended December 31, 2022 (compared to €859 thousand for the year ended December 31, 2021 and €18 thousand for the year ended December 31, 2020) and were recognized in personnel costs (see Note 17.1 - Personnel costs and headcount). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type ​ Grant date (in euros) 2021 Issued Exercised Forfeited 2021 exercisable BSPCE — 2013 plan ​ Dec. 13, 2013 0.59 8,800 — — — 8,800 8,800 BSPCE Plan 2021 ​ April 16, 2021 11.74 — 600,000 — — 600,000 — Total BSPCE ​ 8,800 600,000 — — 608,800 8,800 BSA — 2017 plan ​ May 29, 2017 6.67 130,000 — — — 130,000 130,000 BSA — 2018 plan ​ Dec. 14, 2018 6.07 116,000 — — — 116,000 116,000 BSA — 2019 plan ​ June 28, 2019 ​ 2.20 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 Bis ​ March 9, 2020 ​ 3.68 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 Ter ​ March 9, 2020 3.68 36,000 — — — 36,000 12,000 BSA - Plan 2021-1 ​ April 16, 2021 11.74 — 50,000 — (30,000) 20,000 — Total BSA ​ ​ ​ ​ 302,000 ​ 50,000 ​ — ​ (30,000) ​ 322,000 ​ 278,000 Total ​ ​ ​ ​ ​ 310,800 ​ 650,000 ​ — ​ (30,000) ​ 930,800 ​ 286,800 ​ The change in BSPCE and BSA share warrants over 2021 can be broken down as follows: ● the issuance of 50,000 new 2021-1 Bis BSAs allocated to ISLS Consulting and David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of the Company, of which 30,000 BSA 2021-1 allocated to ISLS Consulting have been cancelled due to the non-payment of warrants; and ● the issuance of 600,000 new 2021 BSPCE allocated to the Company’s directors, Frederic Cren and Pierre Broqua. At December 31, 2021, a total of 600,088 BSPCEs (or 608,800 shares) and 322,000 BSAs were outstanding, which corresponds to a total of 930,800 shares, the maximum number of shares to be issued when all related conditions are met. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2020 Issued Exercised Forfeited 2020 exercisable BSPCE — 2013 plan Dec. 13, 2013 0.59 8,800 — — — 8,800 8,800 Total BSPCE ​ ​ 8,800 — — — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.67 140,000 — (10,000) — 130,000 130,000 BSA — 2018 plan Dec. 14, 2018 6.07 116,000 — — — 116,000 77,334 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis ​ March 9, 2020 ​ 3.68 ​ — ​ 10,000 ​ — ​ — ​ 10,000 ​ — BSA 2019 Ter March 9, 2020 3.68 — 36,000 — — 36,000 — Total BSA ​ ​ ​ ​ 266,000 46,000 (10,000) — 302,000 217,334 Total ​ ​ ​ ​ ​ 274,800 ​ 46,000 ​ (10,000) ​ — ​ 310,800 ​ 226,134 ​ The change in BSPCE and BSA share warrants over 2020 can be broken down as follows: ● the issuance of 10,000 new 2019 Bis BSAs allocated to Jeremy Goldberg, a member of JPG Healthcare LLC; ● the issuance of 36,000 new 2019 Ter BSAs allocated to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of the Company; and ● the exercise of 10,000 BSA 2017 by Karen Aïach (former administrator). At December 31, 2020, a total of 88 BSPCEs (or 8,800 shares) and 302,000 BSAs were outstanding, which corresponds to a total of 310,800 shares, the maximum number of shares to be issued when all related conditions are met. 10.4. Bonus share award plans At January 1, 2022, two free share award plans were outstanding: AGA 2021 and AGA 2021-bis. On December 8, 2022, the Company decided to establish a new free share award plan. The main characteristics are described in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ AGA 2021 AGA 2021-bis AGA 2022 Decision of issuance by the Board of Directors 04/16/2021 12/08/2021 ​ 12/08/2022 Grant date 04/16/2021 12/08/2021 ​ 12/08/2022 Beneficiary Employees Employees ​ Employees Vesting period (year) 3 3 ​ 1 Holding period (year) — — ​ 1 Service condition Yes Yes ​ Yes Performance condition Partially (1) Partially (1) ​ No Number of AGA granted 466,000 123,000 ​ 373,000 Number of shares per AGA 1 1 ​ 1 Valuation method used ​ Dual (1) ​ Dual (1) ​ Dual (1) Fair value per AGA at grant date ​ [9.8 – 11.3] (1) ​ [11.4 – 12.2] (1) ​ 4.18 Expected volatility ​ 64 % 64 % N/A Average life (years) ​ 3 ​ 2.3 ​ N/A Risk-free rate ​ 0.60 % 0.60 % N/A Expected dividends ​ — ​ — ​ – Stock price reference ​ N/A ​ N/A ​ N/A Non-transferable discount N/A N/A ​ N/A (1) AGA 2021-1 and AGA 2021-bis plans are partially composed of AGAs subject to a market performance condition. AGAs 2022 aren’t subject to a market performance condition. Accordingly, AGAs not subject to performance conditions are valued on the basis of the share price less future dividends, discounted at the risk-free rate. AGAs subject to performance conditions are valued using the same method, adjusted by a discount applied to reflect the performance condition. This discount is determined using the “Monte Carlo” analysis. The fair value at the grant date is different depending on whether the AGAs are subject to market performance conditions. Bonus share movements (in number of shares issuable upon exercise) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock price ​ Outstanding ​ ​ ​ ​ ​ ​ ​ Outstanding ​ Number of ​ ​ ​ ​ at grant date ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2022 Issued vesting Forfeited 2022 exercisable AGA — 2021‑1 plan 04/16/21 11.30 448,000 — — (107,200) 340,800 — AGA — 2021‑bis plan 12/08/21 12.20 123,000 — — (46,200) 76,800 — AGA —2022 plan ​ 12/08/22 ​ 4.18 ​ — ​ 373,000 ​ — ​ — ​ 373,000 ​ — Total AGA ​ ​ ​ ​ 571,000 373,000 — (153,400) 790,600 — ​ During 2022, the change in AGA bonus shares over the period can be broken down as follows: - New free share award plan AGA 2022 granted 373,000 shares; - The cancellation of 107,200 shares of AGA 2021-1 plan that have forfeited following the departure of employees ( 22,000 shares) and the recruitments conditions that haven’t been reached ( 85,200 shares The accounting impacts of not meeting these conditions are described in Note 17.1 - Payroll costs and workforce; and - The cancellation of 46,200 shares of AGA 2021-bis plan that have forfeited following the departure of employees ( 27,000 shares) and the recruitments conditions that have not been reached ( 19,200 shares). At December 31, 2022, 790,600 AGAs were outstanding. ​ Share based payments expense totaled €1,452 thousand for the year ended December 31, 2022 (compared to €1,231 thousand for the year ended December 31, 2021 and €920 thousand for the year ended December 31, 2020) and were recognized in personnel costs (see Note 17.1 - Personnel costs and headcount). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock price ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding ​ ​ ​ ​ ​ ​ at grant ​ Outstanding ​ ​ ​ ​ ​ ​ ​ at ​ Number of ​ ​ ​ ​ date ​ at January 1, ​ ​ ​ ​ ​ ​ ​ December 31, ​ shares Type Grant date (in euros) 2021 Issued vesting Forfeited 2021 exercisable AGA — 2019‑1 plan 08/28/19 2.00 29,100 — (29,100) — — — AGA — 2021‑1 plan 04/16/21 11.30 — 466,000 — (18,000) 448,000 — AGA —2021‑bis plan 08/12/21 12.20 — 123,000 — — 123,000 — Total AGA 29,100 589,000 (29,100) (18,000) 571,000 — ​ During 2021, the change in AGA bonus shares over the period can be broken down as follows: ● The allocation of two new plans AGA 2021-1 and AGA 2021-bis to employees of the Company for a total of 589,000 potential new shares; ● The definitive vesting of 29,100 AGA 2019-1. As a result, 29,100 new shares were issued; and ● The cancellation of a total of 18,000 AGA 2021-1 that have forfeited following the departure of employees. The 2021-1 and 2021-bis AGAs are exercisable with a condition of presence, combined for half of them with certain performance conditions, at the end of a vesting period expiring on the date of the Board of Directors’ meeting planned to approve the Company’s financial statements for the year ending December 31, 2023 and will be exercisable no later than March 31, 2034. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ price ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ at grant ​ Outstanding ​ ​ ​ ​ ​ ​ ​ Outstanding ​ Number of ​ ​ ​ ​ date ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2020 Issued vesting Forfeited 2020 exercisable AGA — 2018-2 plan ​ January 26, 2018 5.76 63,300 — (63,300) — — — AGA — 2018-3 plan ​ December 14, 2018 6.28 227,250 — (227,250) — — — AGA — 2019-1 plan ​ June 28, 2019 2.00 37,500 — — (8,400) 29,100 — AGA — 2019-2 plan ​ June 28, 2019 2.00 228,000 — (227,000) (1,000) — — Total AGA ​ ​ ​ ​ 556,050 — (517,550) (9,400) 29,100 — ​ During 2020, the change in AGA bonus shares over the period can be broken down as follows: ● The definitive vesting of 63,300 AGA 2018-2, 227,000 AGA 2019-2 and 227,250 AGA 2018-3. As a result, 517,550 new shares were issued; and ● The cancellation of a total of 8,400 AGA 2019-1 AGA and 1,000 AGA 2019-2 that have forfeited following the departure of employees.

Financial debt

Financial debt	12 Months Ended
	Dec. 31, 2022
Financial debt
Financial debt	Note 11. Financial debt ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Bank borrowings 9,992 ​ 9,984 29,689 Derivatives instruments ​ — ​ — ​ 9,876 Other loans and similar borrowings (1) 62 ​ 6 316 Lease liabilities 2 ​ 130 4,510 Total debt 10,055 ​ 10,119 44,390 (1) Consists of bank overdrafts and accrued interest payable on loans Change in the period is mainly due to the subscription of new borrowing, the breakdown as follow: ​ ​ ​ ​ (in thousands of euros) January 1, 2020 114 Subscription of bank borrowings ​ 9,979 Repayment of bank borrowings ​ (61) Repayment of lease liabilities ​ (26) Early termination of lease contracts ​ (9) Capitalized interests ​ 59 Accrued interests ​ (0) December 31, 2020 10,055 Subscription of new leases ​ 143 Repayment of bank borrowings ​ (13) Repayment of lease liabilities ​ (15) Accrued interests ​ (51) December 31, 2021 ​ 10,119 Subscription of state-guaranteed PGE loan ​ 1,780 Subscription of PPR loan ​ 3,560 Subscription of derivatives instruments (2) ​ 9,469 Subscription of bank borrowings (1) (2) ​ 15,400 New lease contracts ​ 5,109 Repayment of bank borrowings ​ (1,033) Repayment of lease liabilities ​ (735) Capitalized interests ​ 308 Change in fair value of derivatives instruments (2) ​ 407 Exchange rate change ​ 6 December 31, 2022 44,390 (1) (2) ​ As of December 31, 2022 French state-guaranteed loan (“PGE”) and equity recovery loans (“PPR”) In May 2020, the Company entered into three credit agreements pursuant to which it received €10.0 million in the form of state-guaranteed loans ( Prêts Garantis par l’Etat “PGE” which are provided by a syndicate of French banks and guaranteed by the French government in the context of the COVID-19 pandemic and were initially set to mature in May 2021. These loans were extended until the third quarter of 2022. The amendments provide for reimbursements to be made over four years, beginning in July 2022 for the loan from Crédit Agricole and in September 2022 for the loans from Bpifrance and Société Générale. In June 2022, the Company entered into three loan agreements with a syndicate of French banks for a total amount of €5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility with Bpifrance and the other two loan agreements were part of a stimulus economic plan ( Prêts Participatifs Relance The PGE loan granted by Bpifrance in 2022 is guaranteed up to 90% by the French government and has a maturity aligned with the 2020 PGE for which the Company has opted for a linear repayment extension until May 2026. The two PPR loans are guaranteed predominantly by the French government and feature an eight-year financing period and a four-year repayment period. The PGE repayments in 2022 amounted to €1.0 million. Credit facility agreement with the European Investment Bank On May 16, 2022, the Company entered into the Finance Contract with EIB for up to €50 million, divided into two tranches of €25 million each. Capitalized interest for the first tranche (“ Tranche A Tranche B The two tranches are subject to the completion of certain condition precedents. The disbursement of the Tranche A was subject to, among other conditions: - The Company has to issue warrants to the EIB, in accordance with the terms and conditions of the warrants agreement entered into July 1, 2022. On November 28, 2022, the company issued warrants as described in Note 1.2- Significant events of 2022; and - the receipt by the Company of an aggregate amount of at least € 18 million, paid either through the issuance of new Company shares, or through upfront or milestone payments (at December 31, 2022, the Company had received €9.4 million in gross proceeds ( €8.8 million in net proceeds) through a capital increase under the At-The-Market program, as described in Note 1.2- Significant events of 2022. On November 4, 2022, the Company received a net upfront payment of $11.4 million (after payment of a withholding taxes of $1.3 million) in connection with the signing of the license and collaboration agreement with CTTQ, as described in Note 1.2 - Significant events in of 2022). Following the receipt of the upfront payment from CTTQ on November 4, 2022, and the issuance of warrants on November 28, 2022, the conditions precedents of the Tranche A of €25 million were met. On December 8, 2022, the Company received the disbursement of Tranche A as described in Note 1.2 - Significant events of 2022. The disbursement of the Tranche B is subject to, among other conditions: - the full drawdown of the first tranche, completed in December 8, 2022; - the issuance of the second tranche of warrants regarding the Warrant agreement; - the receipt by the Company of an aggregate amount of at least € 70 million (inclusive of the € 18 million conditioning the Tranche A), made of either the issuance of new Company shares, or through upfront or milestone payments coming from business development activities on the various assets of the Company; - an out-licensing, partnership or royalty transaction with an upfront payment of at least € 10 million (could be include in the € 70 million above), or the initiation of a Phase III clinical trial of cedirogant by AbbVie Inc (on October 28, 2022, AbbVie announced that they decided to stop the development of cedirogant); and - operational criteria based on patient enrollment and number of sites activated in the Company’s Phase III clinical trial of lanifibranor in patients with NASH. The Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment fee, either at the election of the Company or as a result of EIB’s demand following certain prepayment events, including a change of control or change in senior management of the Company. Subject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including payment default, misrepresentation, cross default), EIB may demand immediate repayment by the Company of all or part of the outstanding loan and/or cancel the undisbursed tranches. As at December 31, 2022 none of the conditions that would result in an immediate demand by EIB for the repayment of the first tranche is met. The first Tranche of €25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (warrants) at inception and the borrowing costs of €0.1 m. The amortized cost of the loan is €15.4 million on December 8, 2022, and remains unchanged at closing, with an effective interest rate of 21.91%. The fair value of the loan, at both dates, is close to the amortized cost. Derivatives On November 28, 2022, the Company issued 2,266,023 warrants to EIB (see Note 1.2 - Significant events of 2022) as a condition to the financing of the first tranche, representing approximately 5.4% of the Company’s current share capital. The exercise price of the warrants will be €4.0152 if and when the warrants will be exercised. The potential gross proceeds of the issue would amount to €9.1 million. The transactions costs amounted to €56 thousands. The BSA attached to the loan do not meet the “fixed for fixed” criteria (non-cash settlement option which may result in exchanging a variable number of shares for a variable price), and are accounted for as standalone derivative instruments. The Issuer put options meet the definition of a derivative that are valued with the warrants. The warrants agreement includes a put option: EIB may request the Company to buy back the warrants in cash. In this context the purchase price will be defined as the difference between the volume weighted average of the trading price of the ordinary shares over the last 90 trading days and the strike price. The amount is capped, and EIB may exercise the warrants for which they did not exercise the put option. At inception, the financial debts are split between i) a debt component accounted for at amortized cost, and ii) a premium corresponding the initial fair value of attached BSA (then remeasured at fair value through profit and loss) including a component corresponding to the put options. Valuation approach The fair value of the BSA has been estimated based on a Longstaff Schwartz approach, including the put option and the attached cap. This approach enables to estimate the value of American options (that may be exercised during a specific period of time) with complex way of exercise (the warrant holder may exercise the warrants on the market based on the Company’s share price or exercise the put option based on the 90 days average share price of the Company). The Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the valuation date, the volatility observed on the historical share price of the Company, and the contractual lifespan associated equity instruments. The hypothesis and results are detailed in the following tables: ​ ​ ​ ​ ​ ​ BSA 2022 Grant date 11/28/2022 ​ Expiration date 11/28/2030 ​ Number of BSA issued 2,266,023 ​ Number of shares per BSA 1 ​ Subscription premium price per share (€) 0.01 ​ Exercise price per share (€) 4.02 ​ Valuation method Longstaff Schwartz ​ ​ ​ ​ ​ ​ ​ ​ ​ As of November 28, 2022 ​ ​ ​ (Grant Date) ​ As of December 31, 2022 Number of BSA outstanding 2,266,023 2,266,023 ​ Stock price (€) [4.13] [4.75] ​ Maturity (years) 12 11.9 ​ Volatility 68 % 68 % Cap of the put option (m€) 25.0 25.0 ​ Risk free rate Euribor 6M Euribor 6M ​ Expected dividends — — ​ Fair Value (k€) 9,469 9,876 ​ Unit fair value (€) 4.18 4.36 ​ ​ Lease liabilities The net increase in lease liabilities to €4.5 million as of December 31, 2022, is related to the increase of €5.1 million in rights of use assets for the Fibroscans leased equipment. The lease liabilities are recognized each time a new Fibroscans is leased, on a period of four years. Lease liabilities are calculated using specific discount rates, in connection with the geographic area, the maturity of the debt, and the commencement date, according to the method described in Note 3.3 – Lease contracts. The rates for contracts in progress as of December 31, 2022 range from 1.89% to 5.18%. As of December 31, 2021 Total debt remained stable in 2021. In 2021, the loans guaranteed by the French government taken out in May 2020 with initial maturity in May 2021 were extended until the third quarter of 2022. The amendments provide for reimbursements to be made over four years, beginning in July 2022 for the loan from Crédit Agricole and in September 2022 for the loans from Bpifrance and Société Générale. As of December 31,2020 The €9.9 million increase in 2020 was primarily attributable to the three loans taken out from a syndicate of French banks, in the form of the loans guaranteed by the French government for a total amount of €10.0 million. These loans were taken out in May 2020 and matured in May 2021. In accordance with the guarantees put in place by the government in the context of the COVID-19 health crisis, the Company had the option to extend the maturity date for up to an additional four years. To a lesser extent, this line item also includes the loan taken out from Société Générale in 2015 for a residual amount of €13 thousand. The breakdown between long-term and short-term debt is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 13 9,979 — — Other loans and similar borrowings 3 59 — — Lease liabilities ​ 2 ​ 0 ​ — ​ — Total long ‑ term debt 18 10,037 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 Less than Between Between More than (in thousands of euros) ​ 1 year ​ 1 and 3 years ​ 3 and 5 years ​ 5 years Bank borrowings ​ 1,244 ​ 7,484 ​ 1,256 ​ — Other loans and similar borrowings — 6 — — Lease liabilities 38 92 — — Total long ‑ term debt 1,282 7,582 1,256 — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 Less than Between Between More than (in thousands of euros) ​ 1 year ​ 1 and 3 years ​ 3 and 5 years ​ 5 years Bank borrowings 4,474 4,999 17,768 2,448 Derivatives ​ — ​ — ​ 9,876 ​ — Other loans and similar borrowings 100 0 216 — Lease liabilities 1,277 3,233 — — Total long ‑ term debt 5,851 8,232 27,860 2,448 ​ The maturity of long-term debt and of short-term borrowings and debt is determined according to repayment estimates as at December 31 2020, 2021 and 2022.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2022
Provisions
Provisions	Note 12. Provisions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2020 Additions Reversals/reclasses December 31, 2020 CIR 2013-2015 358 1,139 — 1,497 CIR 2017 ​ 216 ​ 665 ​ — ​ 880 Long ‑ term provisions 574 1,804 — 2,377 Payroll taxes 2016-2018 1,264 90 (1,224) 130 Short ‑ term provisions 1,264 90 (1,224) 130 Total Provisions 1,837 1,894 (1,224) 2,507 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) 2021 Additions Reversals/reclasses 2021 CIR 2013-2015 ​ 1,497 ​ — ​ (1,497) ​ — CIR 2017 ​ 880 ​ — ​ (880) ​ — Long ‑ term provisions 2,377 — (2,377) ​ — Payroll taxes 2016-2018 ​ 130 ​ 51 ​ — ​ 180 Short ‑ term provisions 130 51 — ​ 180 Total Provisions 2,507 51 (2,377) ​ 180 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2022 Additions Reversals/reclasses December 31, 2022 Long ‑ term provisions — — — — Payroll taxes 2016-2018 180 — (180) — Short ‑ term provisions 180 — (180) — Total Provisions 180 — (180) — ​ Provisions booked at January 1, 2022 relate to the late payment penalties as a result of the tax audit carried out on payroll taxes 2016- 2017. The reversal of provisions for the period is due to the receipt of two formal notices from the tax authorities concerning late payments penalties on the tax audit carried out on the CIR and payroll taxes. The settlements of the CIR and payroll tax disputes is described in note 14.2 - Other current liabilities. Provisions booked at December 31, 2020 and 2021 were related to: - The CIR risk and payroll taxes risk pursuant to the tax audit carried out by the French tax authority in July 2016 for the years ended December 31, 2013, 2014 and 2015 (long term for CIR risk and short term for payroll taxes risk); - In September 2019, a tax adjustment risk regarding payroll taxes for the years ended December 31, 2016, 2017 and 2018; and - The CIR risk for the year ended December 31, 2017 in connection with the partial reimbursement received in December 2019.

Provisions for Retirement Benef

Provisions for Retirement Benefit Obligations	12 Months Ended
	Dec. 31, 2022
Provisions for Retirement Benefit Obligations
Provisions for Retirement Benefit Obligations	Note 13. Provisions for Retirement Benefit Obligations Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in accordance with IAS 19 — Employee Benefits Principal actuarial assumptions The following assumptions were used to measure the obligation: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, Variables 2020 2021 2022 Retirement age ​ 65 years 65 years 65 years Payroll taxes ​ 41.41 % 41.41 % 41.41 % Salary growth rate ​ 2 % 2 % 2 % Discount rate ​ 0.35 % 1.00 % 3.7 % Mortality table ​ TGH/TGF 05 ​ TGH/TGF 05 THG/TGF 05 ​ ​ The discount rate corresponds to the rates of Eurozone AA-rated corporate bonds with maturities of over ten years. Net provision The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Retirement benefit obligations 1,385 ​ 1,429 1,234 Obligation 1,385 ​ 1,429 1,234 ​ Given the absence of plan assets at December 31, 2022, 2021 and 2020, the total amount of the provision corresponds to the estimated obligation at those dates. The decrease of the retirement obligation compared to December 31, 2021, is mainly due to the discount rate increase (+2.7 points) for an amount of €383 thousands. Change in net provision The change in the provision recorded in respect of defined benefit schemes breaks down as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31 (in thousands of euros) 2020 2021 2022 Provision at beginning of period (1,127) ​ (1,385) (1,429) Other changes ​ — ​ 75 ​ — Expense for the period (209) ​ (200) (230) Actuarial gains or losses recognized in other comprehensive income (49) ​ 82 425 Provision at end of period (1,385) ​ (1,429) (1,234) ​ Breakdown of expense recognized for the period The expense recognized in the statement of income (loss) breaks down as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Service cost for the period (202) ​ (224) (237) Interest cost for the period (8) ​ (5) (14) Benefits for the period — ​ 29 21 Plan curtailments and modifications — ​ — — Total (209) ​ (200) (230) ​ For the year ended December 31, 2022, the total expense related to the retirement benefit obligation remains stable in comparison to 2021 and 2020. Breakdown of actuarial gains and losses recognized in comprehensive income The actuarial gains (losses) can be analyzed as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Demographic changes 14 ​ (27) 42 Changes in actuarial assumptions (63) ​ 109 383 Total (49) ​ 82 425 ​ Demographic differences mainly relate to salary adjustments. Changes in actuarial assumptions relate to movements in the discount rate (0.35% in 2020, to 1.00% in 2021 and to 3.70% in 2022). Sensitivity analysis A 0.25% change in the discount rate would have had an impact of approximately 2.3% on the obligation amount in 2022 and 2.8% in 2021 and 3.4% in 2020. ​ ​ ​ ​ ​ In thousands December 31, 2020 ​ of euros Benefit obligation at December 31, 2020 at 0.10% 1,433 Benefit obligation at December 31, 2020 at 0.35% 1,385 Benefit obligation at December 31, 2020 at 0.60% 1,340 ​ ​ ​ ​ ​ In thousands December 31, 2021 ​ of euros Benefit obligation at December 31, 2021 at 0.75% 1,471 Benefit obligation at December 31, 2021 at 1.00% 1,429 Benefit obligation at December 31, 2021 at 1.25% 1,389 ​ ​ ​ ​ ​ In thousands December 31, 2022 ​ of euros Benefit obligation at December 31, 2022 at 3.45% 1,263 Benefit obligation at December 31, 2022 at 3.70% 1,234 Benefit obligation at December 31, 2022 at 3.95% 1,205 ​

Trade Payables and Other Curren

Trade Payables and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Trade Payables and Other Current Liabilities
Trade Payables and Other Current Liabilities	Note 14. Trade Payables and Other Current Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 Trade payables ​ 6,923 ​ 14,602 19,359 Other current liabilities ​ 6,838 ​ 6,789 5,485 Trade payables and other current liabilities ​ 13,761 ​ 21,391 24,844 ​ No calculations have been made to discount trade payables and other current liabilities to present value as payment is due within one year of the end of the reporting period. ​ Trade payables include €11.2 million, €6.8 million and €4.3 million of accrued expenses as of December 31, 2022, 2021 and 2020. ​ 14.1. Trade payables Trade payables break down by payment date as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 Due in 30 days ​ 6,834 ​ 14,445 19,156 Due in 30 - 60 days ​ 89 ​ 158 201 Due in more than 60 days ​ — ​ — 2 Trade payables ​ 6,923 ​ 14,602 19,359 ​ At December 31, 2022, trade accounts payable increased by €4.8 million compared to December 31, 2021. In line with the previous year, the variation in trade payables is mainly related to the increase in research and development expenses in connection with the end of phase II and the launch of the phase III clinical trial evaluating lanifibranor in NASH. The studies fee incurred in lanifibranor increased by €24.2 million to €31.2 million for the 2021 year, they increased by €9.8 million to €41.1 million for the 2022 year. ​ 14.2. Other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Employee‑related payables 1,405 ​ 1,518 1,866 Accrued payroll and other employee‑related taxes 1,375 ​ 1,234 1,340 VAT payable 753 ​ 879 2,128 Other accrued taxes and employee‑related expenses 106 ​ 178 140 Other miscellaneous payables 3,198 ​ 2,979 12 Other current liabilities 6,838 ​ 6,789 5,485 ​ No discounting has been performed on other current liabilities as their maturity is less than 1 year at the end of the period. At December 31 2022, other current liabilities decreased by €1.3 million, mainly due to a decrease in other miscellaneous liabilities of €3.0 million and to the €1.2 million increase in VAT payable. At December 31, 2021, other current liabilities mainly consist of “Other miscellaneous payables”, as well as “Employee-related payables” and “Accrued payroll and other employee-related taxes”. Other miscellaneous payables at December 31, 2021 and 2020 mainly correspond to: - An accrued expense for an amount of € 1.2 million (mark-up and delays interests at December 31, 2019 included) following receipt of the Notice of Recovery (AMR), on October 30, 2020, relating to the payroll tax for the taxable years 2016 and 2017 (see Note 12 - Provisions) making the liability certain and, consequently required its reclassification from provision to current liabilities. - An accrued expense for an amount of 1.6 million (mark-up and delays interests included) following the partial acceptance by the tax authorities of the CIR for the years 2013 to 2015 (see Note 12 - Provisions), making the liability certain and requiring its reclassification from a provision to an accrued liability. At December 31, 2022, VAT payable mainly include self-assessed VAT. Accrued payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the last quarter of the year. Other accrued taxes and employee-related expenses concern provisions for payroll taxes, such as contribution to professional training charges, apprenticeship tax, the employer’s contribution to construction investment in France and the payroll tax.

Financial Assets and Liabilitie

Financial Assets and Liabilities	12 Months Ended
	Dec. 31, 2022
Financial Assets and Liabilities
Financial Assets and Liabilities	Note 15. Financial Assets and Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 ​ ​ ​ ​ ​ ​ Financial ​ ​ ​ ​ ​ ​ Book value ​ ​ ​ assets/liabilities ​ ​ ​ ​ ​ ​ on the ​ Financial ​ carried at ​ Liabilities ​ ​ ​ ​ statement ​ assets carried ​ fair value ​ carried at ​ ​ ​ ​ of financial ​ at amortized ​ through ​ amortized ​ ​ (in thousands of euros) position cost profit or loss cost Fair value Financial assets ​ Long‑term deposit accounts ​ 1,698 1,698 — — 1,698 Long-term security deposits ​ 8 ​ 8 ​ — ​ — ​ 8 Accrued income ​ 2,000 2,000 — — 2,000 Short-term deposit accounts ​ 7,336 ​ 7,336 ​ — ​ — ​ 7,336 Trade receivables ​ 48 48 — — 48 Other receivables ​ 1,849 1,849 — — 1,849 Foreign currency forwards ​ 1,791 ​ — ​ 1,791 ​ — ​ 1,791 Cash and cash equivalents ​ 105,687 105,687 — — 105,687 Total assets ​ 120,417 118,626 1,791 — 120,417 Financial liabilities ​ Long‑term debt ​ 10,037 — — 10,037 10,037 Short‑term debt ​ 18 — — 18 18 Trade payables ​ 6,923 — — 6,923 6,923 Other miscellaneous payables ​ 3,198 — — 3,198 3,198 Total liabilities ​ 20,177 — — 20,177 20,177 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 ​ ​ ​ Financial ​ ​ ​ ​ Book value ​ ​ ​ assets/liabilities ​ ​ ​ ​ ​ ​ on the ​ Financial ​ carried at ​ Liabilities ​ ​ ​ ​ statement ​ assets carried ​ fair value ​ carried at ​ ​ ​ ​ of financial ​ at amortized ​ through ​ amortized ​ ​ (in thousands of euros) position cost profit or loss cost Fair value Financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term deposit accounts ​ 1,745 1,745 — — 1,745 Long-term security deposits ​ 8 8 — — 8 Advances to suppliers – non-current ​ 689 ​ 689 ​ — ​ — ​ 689 Accrued income ​ 92 92 — — 92 Short-term deposit accounts ​ 8,829 ​ — ​ 8,829 ​ — ​ 8,829 Trade receivables ​ 4,000 4,000 — — 4,000 Other receivables ​ 1,055 1,055 — — 1,055 Cash and cash equivalents ​ 86,553 86,553 — — 86,553 Total assets ​ 102,972 94,143 8,829 — 102,972 Financial liabilities ​ ​ ​ ​ ​ ​ Long-term debt ​ 8,837 — — 8,837 8,837 Short-term debt ​ 1,282 — — 1,282 1,282 Trade payables ​ 14,602 ​ — ​ — ​ 14,602 ​ 14,602 Other miscellaneous payables ​ 2,979 ​ — ​ — ​ 2,979 ​ 2,979 Total liabilities ​ 27,701 ​ — ​ — ​ 27,701 ​ 27,701 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 ​ ​ ​ Financial ​ ​ ​ ​ Book value ​ ​ ​ assets/liabilities ​ ​ ​ ​ ​ ​ on the ​ Financial ​ carried at ​ Liabilities ​ ​ ​ ​ statement ​ assets carried ​ fair value ​ carried at ​ ​ ​ ​ of financial ​ at amortized ​ through ​ amortized ​ ​ (in thousands of euros) position cost profit or loss cost Fair value Financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term accrued income ​ 65 ​ 65 ​ — ​ — ​ 65 Long‑term deposit accounts ​ 700 700 — — 700 Long-term security deposits ​ 8 ​ 8 ​ — ​ — ​ 8 Advance payment ​ 895 ​ 895 ​ — ​ — ​ 895 Current accrued income ​ 117 117 — — 117 Short‑term deposit accounts ​ 1,048 ​ 1,048 ​ — ​ — ​ 1,048 Trade receivables ​ 0 0 — — 0 Cash and cash equivalents ​ 86,736 86,736 — — 86,736 Other receivables ​ 444 ​ 444 ​ — ​ — ​ 444 Total assets ​ 90,014 90,014 — — 90,014 Financial liabilities ​ Long‑term debt ​ 28,663 — — 28,663 28,663 Derivative instruments ​ 9,876 ​ — ​ 9,876 ​ — ​ 9,876 Short‑term debt ​ 5,851 — — 5,851 5,851 Trade payables ​ 19,359 — — 19,359 19,359 Long-term contract liabilities ​ 55 ​ — ​ — ​ 55 ​ 55 Short-term contract liabilities ​ 6 ​ — ​ — ​ 6 ​ 6 Other miscellaneous payables ​ 12 — — 12 12 Total liabilities ​ 63,821 — 9,876 53,945 63,821 ​

Revenues and Other Income

Revenues and Other Income	12 Months Ended
	Dec. 31, 2022
Revenues and Other Income
Revenues and Other Income	Note 16. Revenues and Other Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands of euros) 2020 2021 2022 Sales 372 ​ 4,194 12,179 Total revenues 372 ​ 4,194 12,179 CIR 4,791 ​ 4,069 5,863 Subsidies — ​ 8 10 Other 100 ​ 229 762 Total other income 4,891 ​ 4,307 6,635 Total revenues and other income 5,263 ​ 8,501 18,814 ​ 16.1. Revenue ​ In 2022, revenue amounted to €12.2 million and corresponds to the License and collaboration agreement signed with CTTQ on September 21, 2022 (see Note 1.2 - Significant events of 2022). Revenue is recognized under IFRS 15 – Revenue Following the IFRS 15 analysis, three main distinct performance obligations have been identified: ● Transfer of Know-How: all data and information that is useful for the development, manufacture or commercialization of the Licensed Compound or Licensed Products in the Field in the Licensee Territory. The transfer of Know-How corresponds to a right-to-use license and the transfer of this license has been completed as of December 31, 2022. Revenue is recognized point in time accordingly (see below); ● Development Services – Phase I: In the course of the Development Services - Phase I, the Company provides development to the license, which is controlled by CTTQ since its transfer, for a certain period of time that will enhance it in the meantime. Based on the Company’s assessment of the nature of the services the Development Services - Phase I were determined to be a separate performance obligation as the promise is separately identifiable as part of the contract and CTTQ can benefit from the services together with the license that has already been transferred to the it. CTTQ has access to the developments overtime and revenue is recognized accordingly (see below); and ● Transfer of the Manufacturing Technology: this transfer gives CTTQ rights to the intellectual property, as such the Transfer of the Manufacturing Technology is determined to be a license in the context of the agreement, in accordance with IFRS 15. The transfer of the Manufacturing Technology corresponds to a right-to-use license and the transfer of this license has not been completed as of December 31, 2022. Revenue will be recognized point in time the performance obligation will be fulfilled (see below). Under the license, CTTQ is committed to make the following payments: ● Upfront payment : Non-refundable upfront fee: $12.0 million; ● Regulatory milestones : Development and regulatory milestone payments – six milestones, amounting up to $40 million in aggregate; ● Commercial milestones : Sales-based milestone payments (SBMs), divided into six successive targets and amounting up to $250 million in aggregate; and ● Royalties : Sales-based royalties. According to the contract the non-refundable upfront fee is due on the effective date as defined in the contract. The potential Regulatory and Commercial Milestone payments may represent up to $290 million, in addition to the non-refundable upfront fee of $12 million. Revenue related to Regulatory Milestone will be recognized when achieved over the contract term until the obtention of the regulatory approval in Mainland China. Revenue related to Commercial Milestone will be recognized over the term of the contract when achieved, starting upon commercialization of the licensed products. The consideration for the licensing contract consists of fixed and variable parts. The license contract in place provides distinct right-to-use licenses, therefore under IFRS 15 the fixed part of the consideration is recognized at the point in time at which the licensee can direct the use and benefit from the license, at the point in time when the licensee can direct the use and benefit from the license. For any variable consideration revenue is recognized at the point in time when the variable constraint is removed. Sales-based royalties revenue is recognized at the later when (i) the subsequent sale occurs and (ii) the performance obligation has been satisfied. Under IFRS 15, the allocation and recognition of revenue was determined as follows based on the stand alone selling price of each of the performance obligations: ● The $12.0 million upfront payment was allocated to the license, the development services and the transfer of manufacturing technology; The allocation of the transaction price to each performance obligation has been performed by determining the stand alone selling price of the development services and the transfer of manufacturing technology and the allocation to the license was determined on the residual method. In 2022, revenue is recognized for the existing know how transferred to CTTQ and overtime for the % completion (input method) for the Phase I (Development Services) Revenue as of December 31, 2022, amounts to €12.1 million, including €12.0 million related to know how transfer. ● Regulatory and Commercial Milestones Payments whose payment depends on the achievement of certain technical, regulatory or commercial events, as provided in the contract, are variable compensation that will be recognized as revenue if and when the milestones are met. No amounts were recognized in 2022. ● Royalties on commercial sales, if any, by CTTQ will be recognized as revenue when the underlying sales will be made, under the terms and timeframes set out in the agreement. No amounts were recognized in 2022. This contract contains several performance obligations. As a result, the Company has ensured, as required by IFRS 15, that the revenue allocation of the transaction corresponds to the stand-alone selling price of each obligation. In 2021, revenue amounted to €4.2 million and mainly corresponds to a milestone payment of €4.0 million to be received by the Company following the launch of the Phase IIb study on the Cedirogant program, in accordance with the terms of the collaboration agreement between the Company and AbbVie. Since August 2018, the Company completed performance of its obligations with respect to the Cedirogant program and AbbVie is responsible, at its sole cost and discretion, for all further development and commercialization activities. Consequently, in accordance with IFRS 15, this milestone payment was recognized for its entire amount as revenue as soon as it became highly probable that it would be obtained, i.e. as soon as the first patient was enrolled in the clinical trial. The Company received the payment from AbbVie on January 31, 2022 (see Note 1.3 - Significant events of 2021 and 2020). On October 28, 2022, AbbVie announced its decision to stop the development of cedirogant (previously ABBV-157), as described in Note 1.2 - Significant events of 2022. 16.2. Other income CIR In 2020 and 2021, the CIR corresponded to the amount of research tax credit recorded for each period and corrective claim established by the Company following the July 22, 2020 decision of the Conseil d’Etat (see Note 12 - Provisions). Other On September 28, 2022, Inventiva invoiced CTTQ a €0.6 million additional billing non-including in the contract, following an agreement between the parties reached after the signature.

Research and Development, Marke

Research and Development, Marketing - Business Development and General and Administrative Expenses	12 Months Ended
	Dec. 31, 2022
Research and Development, Marketing - Business Development and General and Administrative Expenses
Research and Development, Marketing - Business Development and General and Administrative Expenses	Note 17. Research and Development, Marketing — Business Development and General and Administrative Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2020 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) expenses expenses expenses Total Disposables (1,243) — — (1,243) Energy and liquids (539) — — (539) Patents (343) — — (343) Studies (10,987) — — (10,987) Maintenance (846) — — (846) Fees (201) (341) (2,005) (2,548) IT systems (597) (8) (46) (651) Support costs (including taxes) — — (722) (722) Personnel costs (7,518) (197) (2,964) (10,680) Depreciation, amortization and provisions (832) — (177) (1,009) Other (608) (16) (2,585) (3,209) Total operating expenses (23,717) (563) (8,499) (32,779) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2021 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) ​ expenses ​ expenses ​ expenses ​ Total Disposables (1,472) — — (1,472) Energy and liquids (513) — — (513) Patents (543) — — (543) Studies (33,004) — — (33,004) Maintenance (1,017) — — (1,017) Fees (160) (138) (2,746) (3,044) IT systems (744) (9) (52) (806) Support costs (including taxes) — — (782) (782) Personnel costs (9,645) (213) (3,556) (13,413) Depreciation, amortization and provisions (751) — (176) (927) Other (602) (4) (3,844) (4,450) Total operating expenses (48,452) (364) (11,155) (59,971) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2022 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) ​ expenses ​ expenses ​ expenses ​ Total Disposables (1,681) — — (1,681) Energy and liquids (633) — — (633) Patents (510) — — (510) Studies (42,375) — (2) (42,377) Maintenance (995) — — (995) Fees (175) (570) (3,843) (4,587) IT systems (852) (16) (92) (960) Support costs (including taxes) 1 — (1,280) (692) (1,971) Personnel costs (11,149) (219) (3,964) (15,332) Depreciation, amortization and provisions (1,462) — (220) (1,683) Other (637) (499) (4,099) (5,234) Total operating expenses (60,469) (2,583) (12,912) (75,965) ​ (1) ​ 17.1. Personnel costs and headcount ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2020 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) ​ expenses ​ expenses ​ expenses ​ Total Wages, salaries and similar costs (4,590) (183) (1,669) (6,442) Payroll taxes (2,180) 8 (926) (3,098) Provisions for retirement benefit obligations (141) 0 (60) (202) Share‑based compensation expense (607) (22) (309) (938) Total personnel costs (7,518) (197) (2,964) (10,680) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2021 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (6,031) (199) (1,867) (8,097) Payroll taxes (2,173) 0 (838) (3,010) Provisions for retirement benefit obligations (148) 0 (68) (216) Share‑based compensation expense (1,293) (13) (783) (2,089) Total personnel costs (9,645) (213) (3,556) (13,413) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2022 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (7,382) (190) (2,242) (9,814) Payroll taxes (2,213) (16) (841) (3,069) Provisions for retirement benefit obligations (157) — (73) (231) Share-based compensation expense 1 (1,397) (13) (808) (2,218) Total personnel costs (11,149) (219) (3,964) (15,332) (2) ​ As of December 31, 2022, 105 people were employed by Inventiva SA and 8 people by Inventiva Inc, for a total of 113 people, compared with 105 people as of December 31, 2021, and 94 people as of December 31, 2020.

Other Operating Income (expense

Other Operating Income (expenses)	12 Months Ended
	Dec. 31, 2022
Other Operating Income (expenses)
Other Operating Income (expenses)	Note 18. Other Operating Income (expenses) Other operating income (expenses) break down as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Corrective claims - CIR ​ 2,863 ​ — ​ — Proceeds - Disposals of fixed assets ​ — ​ 9 ​ 0 Reversal of restructuring expenses ​ 43 ​ — ​ — Reversal of provisions - CIR 2013-2015 ​ — ​ 1,497 ​ — Reversal of provisions - CIR 2017 ​ — ​ 880 ​ — Reversal of provisions - tax litigation ​ — ​ — ​ 180 Reversal of provisions - AMR penalties ​ — ​ — ​ 114 Reversal of impairment on the carry back receivable ​ — ​ 333 ​ — Total other operating income 2,905 ​ 2,720 294 Disposals of assets ​ — ​ — ​ (9) Provision for risk on payroll taxes (90) ​ (51) — Accrued expenses to be paid to the tax authorities - CIR 2013 to 2015 ​ — ​ (1,584) ​ (0) Late payment interest on CIR 2013-2015 ​ — ​ — ​ (123) Impairment of tax loss carry back ​ (333) ​ — ​ — Waiver of CIR 2017 claim ​ — ​ (640) ​ — CIR provision (1,804) ​ (137) — Transaction costs (2,881) ​ (952) (121) Total other operating expenses (5,108) ​ (3,364) (254) Other operating income (expenses) (2,202) ​ (644) 40 ​ During 2022, other operating income and expenses decreased respectively by €2.4 million and €3.1 million compared to 2021. During 2021, other operating income were mainly composed of: ​ (i) The progress of discussions with the French tax authorities concerning the tax credit for the years 2013 to 2015 (see Note 12 - Provisions). As a result, a reversal of the provision for tax risks on the CIR for the years 2013 to 2015, for €1.5 million, was recorded against an accrued expense of €1.6 million; (ii) The progress of exchanges with the French tax authorities concerning the CIR for the year 2017 (see Note 12 - Provisions). As a result, a reversal of a provision for tax risk on the CIR for fiscal year 2017, in the amount of €0.9 million, and a waiver of a receivable for €0.6 million have been recorded; (iii) The full allowance of the carry back receivable recorded at December 31, 2020 for €0.3 million has been reversed in full and a tax charge is also recognized for the same amount. Consequently, the net impact on the consolidated income statement is zero; and (iv) Insurance costs relating to the Public Offering of Securities Insurance taken out in connection with the Company’s initial public offering on the Nasdaq Global Market in July 2020 for an amount of €0.8 million over fiscal year 2021. During 2020, other operating income were mainly composed of corrective claims for additional reimbursements of CIR with regard to the years from 2017 to 2019 for a total amount of €2.9 million, requested following the recent decision of the Council of State in July 2020 on the eligibility of subcontracting expenses. These corrective claims are presented in other operating income, as they resulted from a non-recurring event which is independent from the current activity of the Company. The other operating expenses were mainly composed of: (i) additional provisions with regard to tax risk on CIR (see Note 12 - Provisions): - an additional provision in the amount of € 0.7 million related to the reassessment of the risk on the CIR for 2017 corresponding to the amount contested by the tax authorities at the date of these financial statements, i.e. € 0.9 million; - an additional provision in the amount of € 1.1 million related to the reassessment of the risk on the CIR for the periods from 2013 to 2015 from € 0.4 million to € 1.5 million. (ii) transaction costs relating to the Nasdaq Global Market IPO, which cannot be deducted from the premiums related to share capital, for € 2.8 million (refer to Note 1.3 - Significant events of 2019 and 2020 and Note 10.1 - Share capital); and (iii) Full depreciation of tax loss carry back receivable following the reception, on December 15, 2020, of a tax audit adjustment proposal rejecting 2017 deficits carry-back receivable booked by the Company (refer to Note 6 - Other Non-Current Assets and Note 12 - Provisions).

Financial Income and Expenses

Financial Income and Expenses	12 Months Ended
	Dec. 31, 2022
Financial Income and Expenses
Financial Income and Expenses	Note 19. Financial Income and Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Income from cash and cash equivalents 226 ​ 57 390 Foreign exchange gains 40 ​ 5,421 4,532 Fair value variation gains / losses ​ 1,791 ​ — ​ — Total financial income 2,057 ​ 5,478 4,923 Interest cost (66) ​ (138) (584) Foreign exchange losses ​ (5,884) ​ (1,842) ​ (1,068) Allocation to financial provisions ​ — ​ — ​ — Losses on change in fair value — ​ (651) (407) Other financial expenses (8) ​ (5) (47) Total financial expenses (5,959) ​ (2,635) (2,107) Net financial income (loss) (3,902) ​ 2,842 2,816 ​ For the year ended December 31, 2022, financial income is mainly composed of foreign exchange gains related to bank accounts denominated in U.S and the appreciation of dollar against euro during the period. Foreign exchange gains include €2.4 million related to short term deposit unwinding in the first quarter for €8 million, in the third quarter for €15 million and €8 million on the fourth quarter. Financial expenses mainly include foreign exchange losses, and also interest related to the PGE loans, the PPR loans and the EIB agreement, change in fair value of the EIB warrants, and financial interest on lease liabilities. For the year ended December 31, 2021, financial income mainly came from foreign exchange gains related to bank accounts denominated in U.S. Financial expenses mainly included foreign exchange losses related to the foreign currency short-term deposits and the change in fair value resulting from the settlement of three foreign currency forward sales contracts. For the year ended December 31, 2020, financial income mainly related to the change in the fair value of foreign currency forwards. Foreign exchange losses were mainly due to bank accounts denominated in U.S. dollars for an amount of €2.7 million and short-term deposit accounts in U.S. dollars for an amount of €2.8 million, and were explained by the depreciation of the dollar against the euro since the IPO on the Nasdaq Global Market.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2022
Income Tax
Income Tax	Note 20. Income Tax The income tax rate applicable to the Company is the French corporate income tax rate, i.e. 25%, 26.5% and 28% for the years ending December 31, 2022, 2021 and 2020, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Loss before tax (33,619) ​ (49,271) (54,294) ​ Theoretical tax rate 28 % 26.5 % 25 % Tax benefit at theoretical rate 9,413 ​ 13,057 13,574 ​ Tax credits 2,143 ​ 1,078 1,432 ​ Permanent differences 1,641 ​ 85 (305) ​ Other differences (471) ​ (582) (428) ​ Tax rate differences ​ — ​ (80) ​ 55 ​ Non recognition of deferred tax assets related to tax losses and temporary differences (12,726) ​ (13,921) (14,309) ​ Actual income tax benefit — ​ (364) 20 ​ of which ​ ​ ​ ​ ​ Current taxes — ​ (364) ​ (34) ​ Deferred taxes — ​ — ​ 54 ​ Effective tax rate — ​ 0.74 % 0.06 % ​ Tax credits mainly include the CIR, non-taxable income, classified in other operating income (see Note16 - Revenues and other income). Inventiva S.A. faced a tax loss in the years ended December 31, 2022, 2021 and 2020. As the recoverability of these tax losses is not considered probable in subsequent periods due to the uncertainties inherent in the Company’s business, no deferred tax assets were recognized in the consolidated financial statements as of December 31, 2022, December 31, 2021 nor as of December 31, 2020. Current taxes and deferred tax liabilities recognized as of December 31, 2022 are related to Inventiva Inc.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2022
Commitments
Commitments	Note 21. Commitments 21.1 Commitments related to operational activities Commitments given - Contracts CRO and CMO with third parties ● Contract CMO with Fisher Clinical Services In March 2021, the Company entered into an agreement with Fisher Clinical Services to perform product packaging and distribution services for large-scale clinical studies, including Phase III studies in 25 countries around the world ( including 300 clinical centers). The Company undertakes to pay for the services rendered by the CMO over the 7 years following the date of the agreement for a total amount of €11.4 million. This decrease in the total contract amount is mainly explained by the changes to the clinical development of lanifibranor from the fourth quarter 2022 (see note 25 - Events After the Reporting Date). As of December 31, 2022, the amount remaining to be paid is €9.6 million. ● Contract CRO with Pharmaceutical Research Associates B.V. In April 2021, as part of the conduct of the Phase III clinical trial in NASH, the Company entered into an agreement, with retroactive effect to January 2021, with Pharmaceutical Research Associates Groupe B.V (“ PRA The Company has signed a CRO agreement with PRA for the conduct of the LEGEND Phase IIa clinical trial, effective January 14, 2022. Under the terms of the contract, PRA will conduct a clinical trial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic NASH. The commitment to PRA under this agreement amounts to an aggregate €7.9 million. The Company undertakes to pay the services rendered (directly and indirectly) by the CRO over the next 7 years for a total budget of €231.6 million. As of December 31, 2022, the amount remaining to be paid under the contract is €198.1 million. ● Contract CRO signed with United BioSource LLC In September 2021, the Company has entered into an agreement in connection with the NATiV3 clinical trial, with retroactive effect in April 2021, with United BioSource LLC (UBC), acting as a CRO. The contract aims to outsource the management of pharmacovigilance operations for the NATiV3 clinical trial. The Company undertakes to pay the services rendered by the CRO over the period from the effective date to December 2028, for a total amount of €2.9 million. As of December 31, 2022, the amount remaining to be paid is €2.5 million. ● Contract CRO signed with Synexus Clinical Research GmbH (“AES”) In October 2021, the Company entered into an agreement with AES, acting as a CRO, in connection with the NATiV3 clinical trial. The purpose of the contract is to outsource the management a part of pharmacovigilance operations for the NATiV3 clinical trial. The Company is to pay the services rendered by the CRO over the period from the effective date of the contract to December 2028, for a total amount of €7.1 million. As of December 31, 2022, the amount remaining to be paid is €5.5 million. ● Contract CRO signed with Syneos Health Clinical Research Services, LLC In March 2021, the Company entered into an agreement with Syneos Health Clinical Research Services LLC, acting as a CRO, in connection with the NATiV3 clinical trial. The purpose of the contract is to assess certain pharmacokinetic parameters of lanifibranor. The Company is committed to pay the services rendered by the CRO over the period from the effective date of the contract until the end of the trial, which is expected to be in the beginning of the second half of 2023, for a total amount of $7.4 million. As of December 31, 2022, the total amount remaining to be paid under the contract is $3.1 million. ● Contract CRO signed with Clinical Research Services Kiel GmbH Effective on March 23, 2022, as part of the conduct of a Phase I trial, the Company entered into an agreement with Clinical Research Services Kiel GmbH. The purpose of the contract is to assess the effect of renal impairment on the pharmacokinetics of lanifibranor, its active metabolites as well as the tolerability of lanifibranor. The Company is committed to pay the services rendered by the CRO over the period from the effective date of the contract to the last quarter of 2023, for a total amount of €2.3 million. As of December 31, 2022, the amount remaining to be paid is €2.0 million. ● Other CMO and CRO contracts As of December 31, 2022, the total amount still to be paid under the other CMO and CRO contracts is €6.2 million. Commitments given – Service Agreement ● Service agreement with Summit Clinical Services LLC (“Summit”) On February 1, 2022, the Company entered into an agreement with Summit to select clinical sites and negotiate contracts in connection with the NATiV3 trial. The company is to pay a total amount of $4.4 million (€4.1 million based on the exchange rate of €1.00 = $1.067 as of December 31, 2022). As of December 31, 2022, the total amount remaining to be paid under this contract is $3.8 million (€3.6 million based on the exchange rate of €1.00 = $1.067 as of December 31, 2022). Commitments received - Agreements concerning the provision of facilities - Agreement with Novolyze On October 13, 2015, the Company signed a contract to make its premises and facilities available to Novolyze for a 36-month As of December 31, 2022, the total commitment received amounted to €103.5 thousand and commitments relating to future payments amounted to €199.1 thousand. - Agreement with Synthecob On March 21, 2016, the Company signed a contract to make its research equipment and services available to the company Synthecob for a two-year Therefore, as of December 31, 2022, the total commitment received amounted to €58.6 thousand and commitments relating to future payments amounted to €69.6 thousand. ​

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2022
Related-Party Transactions
Related-Party Transactions	Note 22. Related-Party Transactions No significant new transactions occurred within the Company’s related parties for the 2022 period. The table below sets out the compensation awarded to the members of the executive team (including the executive and corporate officers) that was recognized in expenses for the years ended December 31, 2020, 2021 and 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Short-term benefits 1,669 ​ 1,517 1,897 Post-employment benefits 77 ​ 92 (14) Other long-term benefits — ​ — — End-of-contract indemnities — ​ — — Share-based payment 259 ​ 907 1,077 Net total 2,005 ​ 2,516 2,960 ​

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	12 Months Ended
	Dec. 31, 2022
Basic and Diluted Loss Per Share
Basic and Diluted Loss Per Share	Note 23. Basic and Diluted Loss Per Share Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the period. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Net loss for the period (33,619) ​ (49,635) (54,274) Weighted average number of outstanding shares used for computing basic/diluted loss per share 33,874,751 ​ 39,168,152 41,449,732 Basic/diluted loss per share (in €) (0.99) ​ (1.27) (1.31) ​ As the Company recorded a loss in 2020, 2021 and 2022, diluted earnings (loss) per share are identical to basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs and AGAs) are not included as their effects would be anti-dilutive.

Financial Risk Management

Financial Risk Management	12 Months Ended
	Dec. 31, 2022
Financial Risk Management
Financial Risk Management	Note 24. Financial Risk Management Through its business activities, the Company is exposed to various types of financial risk: foreign exchange risk, credit risk and liquidity risk. Foreign exchange risk On July 15, 2020, the Company closed its initial public offering on the Nasdaq Global Market for aggregate gross proceeds of $ 107.7 million and, in 2021, raised funds pursuant to its “At-The-Market” program for aggregate gross proceeds of approximately $ 31.9 million (see Note 1.2 - Significant events of 2022 and Note 1.3 - Significant events of 2021 and 2020). The nature of the company exposure to the foreign exchange risk has changed due to the fact that a significant part of its liquidity is denominated in US dollars. The Company decided not to immediately convert the entire cash proceeds obtained through the capital increase into euros, because some of that cash will be used to cover expenses denominated in USD over the coming years. Nevertheless, the Company incurs the majority of its expenses in euros and some of its USD cash resources may therefore have to be converted into euros in order to meet its business needs, thereby exposing the Company to foreign exchange risk. Prior to May 14, 2021, three foreign currency forward contracts were in place for a total amount of $ 60 million to protect the value of the Company’s dollar-denominated investments against exchange rate fluctuations between the euro and the dollar. As these contracts have expired, the Company’s financial position could be further affected by adverse fluctuations in the exchange rate between the euro and the dollar, which are difficult to predict. However, the Company has taken the appropriate steps to ensure that hedging instruments can be put in place at any time to protect its activities against exchange rate fluctuations, whenever it deems necessary and in accordance with its investment policy. The table below shows, at December 31, 2022, the sensitivity analysis of the Company’s assets denominated in USD under the reasonable assumption of a variation of 5% based on the exchange rate at the closing date, to which the Company is exposed: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Impact of a 5% ​ ​ Fair Value as of ​ change in (in thousands of euros) December 31, 2022 fair value Cash and cash equivalents dominated in US Dollar 33,310 (1,586) ​ Credit risk Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as from client exposures. The Company’s exposure to credit risk chiefly stems from to trade receivables. The Company has put in place a system to monitor its receivables and their payment and clearance. Generally, the Company is not exposed to a concentration of credit risk given the outstanding trade receivables balance at each reporting date. Liquidity risk Liquidity risk management aims to ensure that the Company has access to sufficient liquidity and financial resources to be able to meet present and future obligations. The Company prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures. Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market positions. The Company’s operations have consumed substantial amounts of cash since its inception. Developing pharmaceutical product candidates, including conducting clinical trials, is expensive, lengthy and risky, and the Company expects its research and development expenses to increase substantially in connection with its ongoing activities. Accordingly, the Company will continue to require substantial additional capital to continue its clinical development activities and potentially engage in commercialization activities. At the date of these consolidated financial statements, the Company estimates, given its current cost structure and its projected expenditure commitments, to be able to finance its activities until the end of the fourth quarter of 2023 (See Note 3.26 - Going concern for more details). Interest Rate Risk The Company has a very low exposure to interest rate risk. Such exposure primarily involves the money market funds and time deposit accounts. The outstanding bank loans bear interest at a fixed rate, and therefore the Company is not subject to interest rate risk with respect to these loans. Changes in interest rates have a direct impact on the rate of return on these investments and the cash flows generated. The repayment flows of the conditional advances from BPI France are not subject to interest rate risk. Fair Value Measurement - Derivatives Risk The Company is exposed to the fluctuations of the changes in the fair value of the EIB warrants (derivatives), as the changes on the performance of the underlying can have a significant impact on the Statement of Income (Loss) statement. Inflation Risk Inflation will have a general impact on its business in line with overall price increases, increases in the cost of borrowing, and operating in an inflationary economy. A 5-10% price increase in 2022 during negotiations with the vendors, and such higher costs cannot be offset through price increases, as the Company does not have any approved products. It is not possible to predict the timing, strength, or duration of any inflationary period or economic slowdown or its ultimate impact on the Company. If the conditions in the general economy significantly deviate from present levels and continue to deteriorate, it could have a material adverse effect on the business, financial condition, results of operations and growth prospects of the Company.

Events After the Reporting Date

Events After the Reporting Date	12 Months Ended
	Dec. 31, 2022
Events After the Reporting Date
Events After the Reporting Date	Note 25. Events After the Reporting Date Changes in the clinical development of lanifibranor On January 4, 2023, the Company announced changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis. Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to patients with NASH and compensated cirrhosis. Service contract with Avant Santé ​ On February 21, 2023, the Company entered into a study service agreement with Avant Santé, a Mexican CRO, in connection with the NATiV3 clinical trial. Pursuant to the terms of the agreement, the CRO is to randomize 120 subjects on 10 sites in Mexico by December 31, 2023. The Company estimates that it will pay Avant Santé a total amount up to €14.7 million over the entire period from February 22, 2023, the effective date of the contract, until the second half of 2027. ​ ​

Accounting Principles (Policies

Accounting Principles (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Principles
Intangible assets	3.1. Intangible assets In accordance with IAS 38 — Intangible Assets An internally generated intangible asset arising from a research program is recognized if, and only if, the Company can demonstrate all of the following: ● The technical feasibility necessary to complete the research program. ● Its intention to complete the intangible asset and use or sell it. ● Its ability to use or sell the intangible asset. ● How the intangible asset will generate probable future economic benefits. ● The availability of adequate technical, financial and other resources to complete the research program. ● The ability to measure reliably the expenditure attributable to the intangible asset during its development. Given the risks and uncertainties involved in regulatory approval and in the process of research and development, the Company considers that the six criteria set out in IAS 38 are met only upon obtaining market authorization for a product candidate. Consequently, all research and development costs are charged directly to expenses. Intangible assets include: ● The cost of acquiring software licenses, which are amortized over a period of between one and five years based on their expected useful life. ● The library of compounds acquired pursuant to the Asset Purchase Agreement together with additional chemical components, which are amortized over a 13 - year period corresponding to their estimated useful lives.
Property, plant and equipment	3.2. Property, plant and equipment Property, plant and equipment are recognized at historical cost, less depreciation and impairment losses, if any. Depreciation is calculated based on the estimated useful life of assets using the straight-line method. A complete review of the useful lives of acquired non-current assets is performed on an annual basis. Any material adjustments are reflected prospectively in the depreciation schedule. The principal useful lives applied are as follows: ● Buildings: 20 to 25 years ● Fixtures and fittings: 10 years ● Technical facilities: 6 to 10 years ● Equipment and tooling: 6 to 10 years ● General facilities, miscellaneous fixtures and fittings: 10 years ● Office equipment: 5 years ● IT equipment: 5 years ● Furniture: 10 years
Lease contracts	3.3. Lease contracts Lease contracts are recognized in accordance with the standard IFRS 16 - Leases ● an asset, representing its right to use the leased asset during the lease term (right-of-use asset); ● a liability, representing the value of the outstanding lease payments (lease liability). For each asset, the discount rate used to calculate the lease liability is determined based on the incremental borrowing rate at the date the Company obtains control of the use of leased asset. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. Exemptions The Company has not restated its other leases because they are covered by the exemptions permitted under the standard (short-time leases and low-value leases). They include: ● leases that expire within 12 months of the date of first-time adoption (January 1, 2019); ● 12-month leases with automatic renewal, where it is not reasonably certain at the date of first-time application that the leases will be renewed; and ● leases for which the underlying asset is less than €5,000 . Rental expenses for short-term and low-value leases continue to be recognized in operating expenses in the Company’s statement of income (loss).
Other non-current assets	3.4. Other non-current assets Other non-current assets include: - long-term deposit accounts that do not qualify as cash equivalents within the meaning of IAS 7 — Statement of Cash Flows and whose maturity is more than one year on the present closing date; - Security deposits; and - Accrued income with a maturity greater than one year on the present closing date.
Impairment of non-financial assets	3.5. Impairment of non-financial assets IAS 36 — Impairment of Assets
Inventories	3.6. Inventories In accordance with IAS 2 — Inventories
Trade receivables	3.7. Trade receivables Trade receivables are recognized initially at the amount of consideration that is unconditional, net of allowance for doubtful accounts. The Company recognizes loss allowances for expected credit losses (“ECL”), which, for trade receivables and contract assets, are measured at an amount equal to lifetime ECLs that result from all possible default events over their expected life. Loss allowances are deducted from the gross amounts of the assets.
Other current assets	3.8. Other current assets Currency term accounts are classified as other current assets, their main characteristics don’t meet the definition of “Cash equivalents” within the meaning of IAS 7.
Derivatives	3.9. Derivatives The Company may have to use derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. The derivatives used to hedge exchange rate risks are measured at their fair value in the statement of financial position. All changes in fair value of derivative instruments are recognized in the statement of income (loss) and classified in financial income (loss). The fair values of derivatives are estimated based on commonly used valuation models considering data from active markets. During the year ended December 31, 2022, the Company entered into a credit facility with EIB. This financial instrument includes two instruments (i) a host contract representing a debt component (the loans) and (ii) warrants. The two instruments issued (loans and warrants) on the date of issue are economically and intrinsically linked according to the IFRS 9 criteria, thus the transaction is analyzed as a single hybrid instrument on issue in which there is a host contract representing a debt component (the loans) and a derivative (the warrants). The financial instrument includes different options too: a call option, a prepayment option and a put option. The prepayment option is not a separate derivative instrument. The warrants, put option and call option are each classified as derivatives on own equity instruments, because the “fixed-for-fixed” rule under IAS 32, which provides that derivatives will be classified as equity if they can only be settled by delivering a fixed number of shares in exchange for a fixed amount of cash or another financial asset, is not met (non cash settlement option which may result in exchanging a variable number of shares, for a variable price). The derivatives are recognized at fair value through profit and loss. The fair value is estimated using the Longstaff Schwartz model which takes into account data from active markets and unobservable data (directly and indirectly) see Note 3.25 - Use of estimates and judgment. The put option can only be exercised in the framework and for the purposes of a cashless exercise of the warrants, and thus cannot be exercised on a standalone basis. The put option comes into effect upon the issuance of warrants by the Issuer and remains in effect for the lifetime of the warrants. In addition, the put option is not independently transferable from the warrants. Thus, the put option is not bifurcated and it is to be considered as part of the valuation of the warrants. The call option is exercisable by the Company, under very specific circumstances wherein the value of the warrants increase due to a takeover bid for the Company. The Company believes it is very unlikely that it will take advantage of exercising the call option. Thus, the call option has been valued at zero and does not require bifurcation.The accounting treatment and impact on the 2022 financial year is described in Note 11 - Financial debts.
Cash and cash equivalents	3.10. Cash and cash equivalents Cash and cash equivalents include cash on hand and demand deposits, as well as other short-term highly liquid investments with maturities of three months or less , convertible at a known amount,and subject to an insignificant risk of change in value. Short-term bank deposits may be recognized as cash equivalents when they: ● have an original maturity of three months or less, or there are exit options from the short-term bank deposits at any time; ● are readily convertible to a known cash amount; and ● are subject to an insignificant risk of decrease in value. Bank overdrafts are recorded in liabilities in the statement of financial position under short-term debt.
Share capital	3.11. Share capital Share capital Ordinary shares are classified in shareholders’ equity. Transaction costs Costs directly attributable to the issuance of ordinary shares or share options are recognized as a reduction in the share premium. Costs related to multiple operations (initial public offering and capital increase) are distinctly recorded. For the IPO, the cost tied to new shares is recognized in the deduction of the share capital premiums, while the costs tied to existing shares is recognized in expenses as transaction costs.
Share-based payments	3.12. Share-based payments plans At the Company’s inception, the Company put in place a compensation plan settled in equity instruments in the form of share warrants awarded to employees ( Bons de souscription de parts de créateur d’entreprise Bons de souscription d’actions Attribution gratuite d’actions In accordance with IFRS 2 — Share-based Payment The values of equity instruments are determined, using option valuation models (in particular, a Black and Scholes model or a Monte-Carlo simulation, depending on whether the plans are subject to market performance condition), on the basis of the value of the underlying equity instrument on the grant date, the volatility,observed on the historical share price of the Company and on a sample of comparable listed companies, and the estimated lifespan associated equity instruments. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market presence and performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet related service and performance conditions. non-market performance conditions at the vesting date. For share-based payment awards where the payment is based on shares with market conditions at market acquisition, the grant date fair value of the share-based payment is measured to reflect these conditions and there is no adjustment for differences between the expected results and the actual result. Movement, details, and measurement of the fair value of options incorporates the vesting conditions of these plans are described in Note 10.3 - Share award plans and Note 10.4 - Bonus share award plans.
Loans and borrowings	3.13. Loans and borrowings Bank loans are initially recognized at fair value, i.e., the issue proceeds (fair value of the consideration received) net of transaction costs incurred and the fair value at inception date of the derivative instruments of the debt concerned. Borrowings are subsequently measured at amortized cost, calculated using the effective interest rate method. Any difference between initial fair value and repayment value is recognized in the statement of income (loss) over the life of the loan using the effective interest rate method. The effective interest rate is the discount rate at which the present value of all future cash flows (including transaction costs) over the expected life of the loan, or where appropriate, over a shorter period of time, is equal to the loan’s initial carrying amount. The accounting treatment applied to the financing contract entered with the EIB is described in Note 11 – Financial debt.
Trade payables and other current liabilities	3.14. Trade payables and other current liabilities The carrying amounts of trade and other current liabilities are considered to be the same as their fair values, due to their short-term nature.
Current and deferred tax	3.15. Current and deferred tax Tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period. The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the statement of income (loss) unless it relates to items recorded in other comprehensive income and expense or directly in equity, in which case the tax is also recorded in other comprehensive income and expense or directly in equity. Current taxes The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the end of the year in the countries where the Company’s subsidiaries operate and generate taxable income. Deferred taxes Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the Company’s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, does not affect either the accounting or the taxable profit (tax loss). Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates and tax laws enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are not discounted. Deferred tax assets and liabilities are offset when a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes concern the same entity and the same tax authority. Deferred tax assets Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which the deductible temporary difference, unused tax losses or unused tax credits can be utilized. The recoverable amount of deferred tax assets is reviewed at the end of each reporting period and their carrying amount is reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of the deferred tax assets to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are recognized when it becomes probable that future taxable profit will be available to offset the temporary differences. Deferred tax liabilities Deferred tax liabilities are recognized for all taxable temporary differences, except when the Company is able to control the timing of the reversal of the difference and it is probable that the reversal will not occur in the foreseeable future.
Provisions for retirement benefit obligations	3.16. Provisions for retirement benefit obligations Retirement benefit obligations The Company operates a defined benefit pension plan. Its obligations in respect of the plan are limited to the lump sum payments upon retirements, which are expensed in the period in which the employees provide the corresponding service. The liability recorded in the statement of financial position in respect of defined benefit pension plans and other post-retirement benefits is the present value of the defined benefit obligation at the statement of financial position date. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting estimated future cash outflows, using the interest rate of high-quality corporate bonds of a currency and term consistent with the currency and term of the pension obligation concerned. In determining the present value and the related current service cost and, where applicable, past service cost, the benefit is attributed to periods of service under the plan’s benefit formula. However, if an employee’s service in later years will lead to a materially higher level of benefit than in earlier years, the benefit is attributed on a straight-line basis from: ● the date when service by the employee first leads to benefits under the plan (whether or not the benefits are conditional on further service) until ● the date when further service by the employee will lead to no material amount of further benefits under the plan, other than from further salary increases. Actuarial gains and losses arise from the effect of changes in assumptions and experience adjustments (i.e., differences between the assumptions used and actual data). These actuarial gains and losses are recognized wholly and immediately in other comprehensive income and expense and are not subsequently reclassified to the statement of income (loss). The net expense in respect of defined benefit obligations recognized in the statement of income (loss) for the period corresponds to: ● The service cost for the period (acquisition of additional rights). ● The interest cost. ● The past service cost. ● The impact of any plan settlements, amendments and curtailments. The discounting effect of the obligation is recognized in net financial income and expenses. Termination benefits Termination benefits are payable when a company terminates an employee’s employment contract before the normal retirement age or when an employee accepts compensation as part of a voluntary redundancy. In the case of termination benefits, the event that gives rise to an obligation is the termination of employment. In the case of an offer made to encourage voluntary redundancy, termination benefits are measured based on the number of employees expected to accept the offer. Profit-sharing and bonus plans The Company recognizes a liability and an expense for profit-sharing and bonus plans based on a formula that takes into consideration the Company’s performance.
Other provisions	3.17. Other provisions In accordance with IAS 37 — Provisions, Contingent Liabilities and Contingent Assets Where there are a number of similar obligations, the probability that an outflow will be required in settlement is determined by considering the class of obligations as a whole. Although the likelihood of outflow for any one item may be small, it may well be probable that some outflow of resources will be needed to settle the class of obligations as a whole. If that is the case, a provision is recognized. The provision represents the best estimate of the amount required to settle the present obligation at the end of the reporting period. Where the effect of the time value of money is material, the amount of a provision corresponds to the present value of the expected costs that the Company considers necessary to settle the obligation. The pre-tax discount rate used reflects current market assessments of the time value of money and specific risks related to the liability. The effect of discounting provisions due to the time value of money is recognized in net financial income and expenses.
Revenue	3.18. Revenue Revenue is recognized in accordance with IFRS 15 — Revenue from Contracts with Customers Under IFRS 15, revenue is recognized when the Company fulfills a performance obligation by providing separate goods or services to a customer, when the customer obtains control of those goods or services. An asset is transferred when the customer obtains control of that asset or service. Under this standard, each contract must be analyzed on a case-by-case basis in order to verify whether it contains performance obligations to customers, and, if applicable, to identify the nature of said obligations in order to appropriately account for the amount that the Company has received or is entitled to receive from customers: - The transfer of the right to use the intellectual property, via a license granted by the Company, as it exists at the time of the transfer, the date of which will determine that of the revenue recognition; - If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime; - The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products; - Revenue from variable consideration, such as development or regulatory milestones, and which are recognized when the achievement is highly probable; or - Revenue from sales-based or usage-based royalty promised in exchange for a license of intellectual property would not be recognized until the achievement of the milestone or completion of the sale. The accounting treatment of the contracts with customers are detailed in Note 16.1 – Revenue.
Other income	3.19. Other income Research tax credit Its includes the research tax credit granted by the US Government and the research tax credit ( crédit d’impôt recherche Only those companies meeting the EU definition of a small or medium-sized entity (“SME”) are eligible for payment in cash of their CIR (to the extent not used to offset corporate taxes payable) in the year following the request for reimbursement. Inventiva meets the EU definition of an SME and therefore should continue to be eligible for prepayment. Inventiva has been eligible for CIR since inception. The CIR is recognized in “Other income” during the reporting period in which the eligible expenditure is incurred as it meets the definition of government grant as defined in IAS 20 Accounting for Government Grants and Disclosure of Government Assistance Other grants The Company receives subsidies from several public bodies. The subsidies are related to net income and granted to compensate for incurred expenses. They are therefore recognized in net income as other income for the period in which it becomes reasonably certain that they will be received.
Net financial income	3.20. Net financial income Financial income Financial income includes: - The income from cash and cash equivalents, which includes income from short-term investments and cash and cash equivalents; - Changes in the fair value of cash and cash equivalents, remeasured at the end of each reporting period; - Changes in the fair value of derivatives instruments; - Accretion income; - Foreign exchange gains; - Other financial income. Financial expenses Financial expenses primarily include: - Interest cost; - Changes in the fair value of cash and cash equivalents remeasured at the end of each reporting period; - Changes in the fair value of derivatives instruments; - Foreign exchange losses; - Accretion expenses; - Other financial expenses.
Other operating income and expenses	3.21. Other operating income and expenses Other operating income and expenses are disclosed separately on the face of the statement of income (loss). This line item is set aside for events that may arise during the period whose presentation within other items (relating to ordinary activities) could be misleading for users of the financial statements in their understanding of the Company’s performance. This item therefore includes income and expenses that are rare that represent material amounts and that the Company discloses separately on the face of the statement of income (loss) to facilitate understanding of operating performance (see Note 18 - Other operating income (expenses)). Disposals of non-current assets Gain or loss from the disposal of non-current assets during the period is recognized in “Other operating income (expenses)”.
Fair value measurement	3.22. Fair value measurement In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs: ● Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. ● Level 2: Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. ● Level 3: Unobservable inputs for the asset or liability. The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 (in thousands of euros) Level 1 Level 2 Level 3 Assets ​ ​ ​ ​ ​ Financial assets at fair value through profit or loss ​ ​ ​ ​ ​ Term deposits — — — Total assets — — — Long-term financial debt - derivatives ​ — ​ — ​ 9,876 Total liabilities — — 9,876 ​ The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Term deposits 8,829 — — Total assets 8,829 — — Total liabilities — — — ​ The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Foreign currency forwards (1) — 1,791 — Total assets — 1,791 — Total liabilities — — — (1) The valuation of the instrument is estimated based on observable market parameters. The instrument is not directly listed on a market.
Foreign currency transactions	3.23. Foreign currency transactions Translation of foreign currency transactions As of December 31, 2022, foreign currency transactions include bank accounts and term deposits in U.S dollars implemented after the IPO on the Nasdaq Global Market in July 2020. Certain purchasing transactions are carried out in foreign currencies for our studies and clinical trials conducted in the United States and to a lesser degree the United Kingdom, Switzerland, Australia, Canada and Sweden. For the year ended December 31, 2022, these expenses in a foreign currency amounted to approximately €15.9 million, or 21% of the operating expenses, to be compared with €13.5 million, or 21% for the year ended December 31, 2021 and €2.5 million, or 7% for the year ended December 31, 2020. These transactions are translated into euros at the exchange rate prevailing at the date of each transaction. Purchasing transactions in foreign currencies are presented in operating income as they relate to the Company’s ordinary activities. Foreign exchange gains and losses relating to short-term investments and bank accounts in U.S. dollars are presented in financial income (loss).
Segment information	3.24. Segment information The assessment of the entity’s performance and the decisions about resources to be allocated are made by the chief operating decision maker (the CEO), based on the management reporting system of the entity. Only one operating segment arises from the management reporting system: service delivery and clinical stage research, notably into potential therapies in the areas of fibrosis, lysosomal storage disorders and oncology. Thus, the entity’s performance is assessed at the Company level. For the company’s geographical split please refer to tables below: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 935 770 568 USA — — — China — — — Intangible assets 935 770 568 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 3,282 3,096 6,324 USA — 101 1,062 China — — — Property, plant and equipment 3,282 3,196 7,385 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 1,706 2,442 1,603 USA — — 65 China — — — Other non-current assets 1,706 2,442 1,668 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) (1) 2020 2021 2022 France 372 194 125 USA — 4,000 — China — — 12,054 Revenue 372 4,194 12,179 (1) Allocation is based on customer location.
Use of estimates and judgment	3.25. Use of estimates and judgment The preparation of financial statements in accordance with IFRS requires: ● Management to make judgments when selecting appropriate assumptions for accounting estimates, which consequently involve a certain degree of uncertainty. ● Management to make estimates and apply assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as information presented for the period. The estimates and judgments, which are updated on an ongoing basis, are based on past experience and other factors, in particular assumptions of future events, deemed reasonable in light of circumstances. The identification, assessment and response to risks, particularly those related to the climate and to the COVID-19 pandemic, are integrated into the risk management process and have not led to the use of any significant new estimates or judgments in fiscal 2022. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates, by definition, often differ from actual reported values. Estimates and assumptions that could lead to a significant risk of a material adjustment in the carrying amount of assets and liabilities in the subsequent period are analyzed below. Revenue ● Determining the distinctiveness of performance obligations — A promised good or service will need to be recognized separately in revenue if it is distinct as defined in IFRS 15. In determining whether the performance obligation is separate, the Company analyses if (i) the good or service is distinct in absolute terms, i.e. it can be useful to the customer, either on its own or in combination with resources that the customer can obtain separately; and if (ii) the good or service is distinct in the context of the contract, i.e. it can be identified separately from the other goods and services in the contract because there is not a high degree of interdependence or integration between this element and the other goods or services promised in the contract. If either of these two conditions is not met, the good or service is not distinct, and the Company must group it with other promised goods or services until it becomes a distinct group of goods or services. In the context of Biotech industry R&D services are generally capable of being distinct if: - The entity sells the services on their own – i.e. without a related license. This indicates that customers can benefit from the services on their own and they are therefore capable of being distinct; or - The customer can benefit from the services together with the license that has already been transferred to the customer. Readily available resources include goods or services that have already been transferred. If the license is transferred at the beginning of the contract, the services will typically be capable of being distinct. In making this determination, the key analysis is whether the R&D services significantly modify or customize the drug compound so that the intellectual property is significantly different at the end of the arrangement as a result of the services. This may be more frequent in early stages of development when the formula is being developed or when the services are developing an existing technology for a significantly different use. ● Allocation of transaction price to performance obligations — A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. To determine the proper revenue recognition method, the Company evaluates whether the contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment; some of the Company’s contracts have a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. ● Variable consideration — Due to the nature of the work required to be performed on many of the Company’s performance obligations, the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. It is common for the collaboration and license agreements to contain variable consideration that can increase the transaction price. Variability in the transaction price arises primarily due to milestone payments obtained following the achievement of specific milestones (e.g., scientific results or regulatory or commercial approvals). The Company includes the related amounts in the transaction price as soon as their receipt is highly probable. The effect of the increase of the transaction price due to milestones payments is recognized as an adjustment to revenue on a cumulative catch-up basis. ● Revenue recognized over time and input method — Some of the Company’s performance obligations are satisfied over time as work progresses, thus revenue is recognized over time, using an input measure of progress as it best depicts the transfer of control to the customers. The application of the IFRS 15 on the current contracts with customers is detailed in Note 16.1 - Revenue. Provision for tax audit The Company calculated the provision for the tax audits to which the Company has been subject based on an estimate of the related risk. The provision represented the best estimate of the amount required to settle any amounts owed to the French tax authorities at the end of the reporting period (see Note 12 - Provisions). CIR The amount of the CIR is determined based on the Company’s internal and external expenditure in the reporting period. Only eligible research costs may be included when calculating the CIR. Compliance with the eligibility criteria for expenses when calculating the Tax Credit may require some judgment on the part of the Company. Valuation of share warrants and bonus share award plans Fair value measurements of share warrants and bonus share award granted to employees are based on actuarial models which require the Company to factor certain assumptions into its calculations (see Note 10.3 - Share warrants plans and Note 10.4 - Bonus share award plans). Measurement of retirement benefit obligations The Company operates a defined benefit pension plan. Its defined benefit plan obligations are measured in accordance with actuarial calculations based on assumptions such as discount rates, the rate of future salary increases, employee turnover, mortality tables and expected increases in medical costs. The assumptions used are generally reviewed and updated annually. The main assumptions used and the methods chosen to determine them are set out in Note 13 - Provisions for retirement benefit obligations. The Company considers that the actuarial assumptions used are appropriate and justified in light of current circumstances. Nevertheless, retirement benefit obligations are likely to change in the event that actuarial assumptions are revised. Derivatives The Company may have to use derivative financial instruments to hedge its exposure to exchange rate risks (Currency forward sales). The Company has not opted for hedge accounting in accordance with IFRS 9. The fair values of these derivatives are estimated on the basis of commonly used valuation models considering data from active markets. The fair value measurement of the warrants issued to the EIB and the put options related to those EIB warrants is based on the LongStaff Schwartz option valuation model which makes assumptions about complex and subjective variables. These variables include the value of the Company’s shares, the expected volatility of the share price over the lifetime of the instrument, and the present and future behavior of holders of those instruments. There is a high inherent risk of subjectivity when using an option valuation model to measure the fair value of derivative instruments and of the equity instruments in accordance with IAS 32 Financial Instruments – Presentation (“IAS 32”) and IFRS 9. The fair value measurement of the debt component of the warrants was determined by discounting cash flows at market rate (unobservable input). The valuation approach and assumptions utilized are disclosed in Note 11 – Financial debt. Subcontracting Costs Related to Clinical Trials Following the initiation of the Phase III clinical trial evaluating lanifibranor in NASH, Inventiva has signed contracts with contract research organizations. These CRO contracts are intended to conduct clinical trials, to support regulatory approval of the product in Europe and the United States and to manage pharmacovigilance operations (see Note 21.1 - Commitments related to operational activities). In order to reflect the time that may exist between the time when expenses are incurred by subcontractors in clinical trials and the time they are re-invoiced to Inventiva, the Company estimates a liability for accrued expenses or a prepaid expense to be recorded in the consolidated financial statements at each closing date. For each contract, the subcontracting expenses incurred at the consolidated statement of financial position date are estimated on the basis of information provided at each consolidated statement of financial position date by the CRO, in accordance with the contractual terms, and cost analyses carried out by the Company. This estimate is then compared with the amount of invoices received at the period end date. When the estimated incurred expenses are higher than the invoiced expenses, a provision for accrued expenses is recorded in the consolidated financial statements (see Note 14 - Trade payables and other current liabilities). When the expenses incurred are lower than the expenses invoiced, a prepaid expense is recorded in the consolidated financial statements (see Note 8.2 - Other current assets and receivables).
Going concern	3.26. Going concern Since its creation, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates. As of December 31, 2022, the Company had €86.7 million of available cash and cash equivalents. They consist of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 9 – Cash and Cash equivalents). The Company had also €1.0 million of short-term deposits, included in “other current assets” in the consolidated statement of financial position as of December 31, 2022, but are considered by the Company as liquid and easily available. The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. At the date these consolidated financial statements were authorized for issue, the Company estimates, given its current cost structure and its projected expenditure commitments, to be able to finance its activities until the end of the fourth quarter of 2023. This estimate is based on the Company’s current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that may prove to be incorrect and the Company may end up using its resources sooner than anticipated. Accordingly, the Company's current cash position is not expected to be sufficient to cover operating needs for at least the next 12 months. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company expects to extend its financing horizon through: ● sales of ADS under the ATM financing program, for a potential amount of up to $ 58.3 million until August 2, 2024; ● raising additional financing through other public or private equity or debt offerings; ● receipt of the second tranche of the EIB loan for an amount of €25 million if the Company meets the conditions precedent for the availability of this second tranche (refer to Note 1.2 – Significant events of 2022); and ● entering into strategic transactions such as business development partnerships and/or royalty deals. Assuming the conditions precedent for the release of the second tranche of the EIB loan are met, the Company plans to use proceeds from the second tranche under the Finance Contract with the EIB for its preclinical and clinical pipeline, including to help fund part of its Phase III clinical trial of lanifibranor in patients with NASH. It cannot be guaranteed that the milestones provided for by the Company or its partners will be achieved or that the conditions precedent to the receipt of funds under the Finance Contract will be met within the time limits provided, if at all. The Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at acceptable terms and conditions, or at all. If the Company is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any approved product or be unable to expand its operations or otherwise capitalize on its business opportunities, as desired, which could impair the growth prospects. The financial statements as of and for the year ended December 31, 2022, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.

Basis of preparation and stat_2

Basis of preparation and statement of compliance (Tables)	12 Months Ended
	Dec. 31, 2022
Basis of preparation and statement of compliance
Schedule of subsidiaries	As of December 31, 2022, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its fully-owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized. ​ ​ ​ ​ ​ ​ ​ ​ Date of incorporation Percent of Ownership Interest Accounting Method INVENTIVA Inc. 01/05/2021 100 % Fully Consolidated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ Consolidation Inventiva Thousands of euros Inventiva S.A. Inventiva Inc. adjustments consolidated Net income (loss) (54,746) 691 208 (54,274) Total assets 112,289 ​ 8,676 4,962 116,004 Shareholders’ equity 44,797 1,111 (5) 45,476 ​
Schedule of exchange rates	​ ​ ​ ​ ​ ​ Exchange rate (USD per EUR) As of December 31, 2022 As of December 31, 2021 Average exchange rate for the year 1.0530 ​ 1.1827 Exchange rate at year end 1.0666 ​ 1.1326

Accounting Principles (Tables)

Accounting Principles (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Principles
Schedule of financial assets and liabilities measured at fair value	The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 (in thousands of euros) Level 1 Level 2 Level 3 Assets ​ ​ ​ ​ ​ Financial assets at fair value through profit or loss ​ ​ ​ ​ ​ Term deposits — — — Total assets — — — Long-term financial debt - derivatives ​ — ​ — ​ 9,876 Total liabilities — — 9,876 ​ The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Term deposits 8,829 — — Total assets 8,829 — — Total liabilities — — — ​ The tables below present the financial assets and liabilities of the Company measured at fair value at December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 (in thousands of euros) Level 1 Level 2 Level 3 Assets Financial assets at fair value through profit or loss Foreign currency forwards (1) — 1,791 — Total assets — 1,791 — Total liabilities — — — (1) The valuation of the instrument is estimated based on observable market parameters. The instrument is not directly listed on a market.
Summary of entity's geographical split	​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 935 770 568 USA — — — China — — — Intangible assets 935 770 568 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 3,282 3,096 6,324 USA — 101 1,062 China — — — Property, plant and equipment 3,282 3,196 7,385 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 France 1,706 2,442 1,603 USA — — 65 China — — — Other non-current assets 1,706 2,442 1,668 ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) (1) 2020 2021 2022 France 372 194 125 USA — 4,000 — China — — 12,054 Revenue 372 4,194 12,179 (1) Allocation is based on customer location.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Schedule of intangible Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2020 Increases Decreases December 31, 2020 Library of compounds ​ 2,142 — — 2,142 Software ​ 1,532 1 — 1,533 Intangible assets, gross ​ 3,674 1 — 3,674 Amortization of library of compounds ​ (1,157) (165) — (1,322) Amortization of software ​ (1,289) (129) — (1,417) Amortization ​ (2,446) (293) — (2,739) Intangible assets, net ​ 1,228 (293) — 935 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2021 Increases Decreases December 31, 2021 Library of compounds 2,142 — — 2,142 Software 1,533 53 (10) 1,575 Intangible assets, gross 3,674 53 (10) 3,717 Amortization of library of compounds (1,322) (165) — (1,487) Amortization of software (1,417) (53) 10 (1,460) Amortization (2,739) (217) 10 (2,947) Intangible assets, net 935 (165) (1) 770 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2022 Increases Decreases December 31, 2022 Library of compounds 2,142 — ​ — ​ 2,142 Software 1,575 15 ​ — ​ 1,590 Intangible assets, gross 3,717 15 ​ — ​ 3,732 Amortization of library of compounds (1,487) (165) ​ — ​ (1,651) Amortization of software (1,460) (52) ​ — ​ (1,512) Amortization (2,947) (217) ​ — ​ (3,164) Intangible assets, net 770 (202) ​ — ​ 568 ​

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment
Schedule of property, Plant and Equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) 2020 Increases Decreases Others (1) 2020 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,748 108 0 — 4,856 Other property, plant and equipment 1,157 46 0 — 1,203 Property, plant and equipment in progress — 137 — — 137 Right of use (1) 252 — — (218) 34 Property, plant and equipment, gross 9,736 292 0 (218) 9,810 Depreciation and impairment of buildings (1,542) (196) — — (1,737) Depreciation and impairment of technical facilities, equipment and tooling (3,396) (386) — — (3,782) Depreciation and impairment of other property, plant and equipment (874) (102) — — (976) Depreciation and impairment of right of use (203) (32) — 202 (33) Depreciation and impairment (6,015) (716) — 202 (6,528) Property, plant and equipment, net 3,721 (424) 0 (16) 3,282 (1) corresponding to early termination of lease contracts. Changes during the period 2020 mainly correspond to depreciation expenses for €0.7 million. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) ​ 2021 ​ Increases ​ Decreases ​ Others ​ 2021 Land 172 — — — 172 Buildings 3,407 — — — 3,407 Technical facilities, equipment and tooling 4,856 336 (75) — 5,118 Other property, plant and equipment 1,203 223 (4) — 1,422 Property, plant and equipment in progress 137 59 — (137) 59 Right of use ​ 34 ​ 143 ​ (34) ​ — ​ 143 Property, plant and equipment, gross 9,810 761 (113) (137) 10,321 Depreciation and impairment of buildings (1,737) (194) — — (1,931) Depreciation and impairment of technical facilities, equipment and tooling (3,782) (384) 75 — (4,091) Depreciation and impairment of other property, plant and equipment (976) (116) 4 — (1,087) Depreciation and impairment of right of use (33) (16) 34 — (14) Depreciation and impairment ​ (6,528) ​ (709) ​ 113 ​ (137) ​ (7,124) Property, plant and equipment, net 3,282 52 0 (274) 3,196 ​ ​ Changes during the period 2021 mainly correspond to acquisition of technical facilities, equipment, and tools for €0.3 million and acquisition of other property, plant and equipment for €0.2 million, offset by depreciation expenses for €0.7 million. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) 2022 Increases Decreases Others 2022 Land ​ 172 — — — 172 Buildings ​ 3,407 86 (23) — 3,470 Technical facilities, equipment and tooling ​ 5,118 357 (18) — 5,457 Other property, plant and equipment ​ 1,422 97 — — 1,519 Property, plant and equipment in progress ​ 59 5 — — 65 Right of use ​ 143 5,109 — 7 5,259 Property, plant and equipment, gross ​ 10,321 5,655 (41) 7 15,941 Depreciation and impairment of buildings ​ (1,931) (196) 23 — (2,104) Depreciation and impairment of technical facilities, equipment and tooling ​ (4,091) (355) 1 — (4,446) Depreciation and impairment of other property, plant and equipment ​ (1,087) (128) — — (1,216) Depreciation and impairment of right of use ​ (14) (776) — (0) (790) Depreciation and impairment ​ (7,124) (1,455) 24 (0) (8,555) Property, plant and equipment, net ​ 3,196 4,200 (17) 7 7,386 ​

Other Non-Current Assets (Table

Other Non-Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Other Non-Current Assets
Schedule of other non current assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Advances to suppliers – non-current ​ — 689 895 Long‑term deposit accounts ​ 1,698 1,745 700 Accrued income ​ — — 65 Security deposits ​ 8 8 8 Other non ‑ current assets ​ 1,706 2,442 1,668 ​

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventories
Schedule of inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Laboratory inventories ​ 353 425 406 Inventories write‑down ​ (33) (33) (33) Total inventories ​ 320 392 373

Trade Receivables and Other C_2

Trade Receivables and Other Current Assets and Receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Trade Receivables and Other Current Assets and Receivables
Schedule of trade receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 3 months or less 48 4,000 ​ 0 Between 3 and 6 months — — ​ — Between 6 and 12 months — — ​ — More than 12 months — — ​ — Trade receivables 48 4,000 ​ 0 ​
Schedule of other current assets and receivables	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 CIR 9,012 ​ 4,357 5,994 Other 16 ​ 16 13 Tax receivables 9,028 ​ 4,373 6,007 Prepaid expenses 3,313 ​ 7,454 8,601 Short-term deposit account ​ 7,336 ​ 8,829 ​ 1,048 Current accrued income ​ 2,000 ​ 92 ​ 117 Foreign currency forwards ​ 1,791 ​ — ​ 0 Liquidity agreement - Cash ​ 1,029 ​ 762 ​ 282 VAT receivables ​ 1,625 ​ 2,828 ​ 3,057 Other receivables 821 ​ 294 162 Other current assets 17,914 ​ 20,260 13,267 Other current assets and receivables 26,942 ​ 24,632 19,274 ​

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents
Schedule of Cash and Cash Equivalents	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 Other cash equivalents (1) 12,001 ​ 42,900 16,798 Cash at bank and at hand 93,686 ​ 43,653 69,939 Cash and cash equivalents 105,687 ​ 86,553 86,736 (1) Other cash equivalents correspond to short-term bank deposits at Société Générale and Crédit Agricole.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of changes in share capital	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Premiums ​ ​ ​ ​ ​ ​ ​ ​ Share ​ related to ​ Number of ​ Nominal Date Nature of the transactions capital share capital shares value Balance as of January 1 st , 2020 268,461 86,011,893 26,846,112 0.01 01/26/2020 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2018-2) 633 — 63,300 0.01 02/07/2020 ​ Capital increase by issuance of ordinary shares – Company’s private placement 37,783 14,962,218 3,778,338 0.01 02/07/2020 ​ Transaction costs related to the Company’s private placement — (319,564) — — 04/17/2020 ​ Appropriation of the issue premium — (48,000,000) — — 06/28/2020 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2019-2) ​ 2,270 ​ — ​ 227,000 ​ 0.01 07/15/2020 ​ Capital increase by issuance of ordinary shares – Company’s initial public offering ​ 74,783 ​ 94,024,272 ​ 7,478,261 ​ 0.01 07/15/2020 ​ Transaction costs related to the Company’s initial public offering — (7,077,866) — — 11/30/2020 ​ Capital increase by emission of ordinary shares – Emission of 10,000 BSA 100 66,650 10,000 0.01 12/14/2020 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2018-3) 2,273 — 227,250 0.01 Balance as of December 31, 2020 ​ 386,302 ​ 139,667,603 ​ 38,630,261 ​ 0.01 06/28/2021 ​ Capital increase by issuance of ordinary shares – Vesting of AGAs by Company employees (AGA 2019-1) ​ 291 ​ — ​ 29,100 ​ 0.01 09/27/2021 ​ Capital increase by issuance of ordinary shares – (ATM) ​ 20,833 ​ 25,556,803 ​ 2,083,334 ​ 0.01 10/01/2021 ​ Capital increase by issuance of ordinary shares – (ATM) ​ 1,309 ​ 1,615,584 ​ 130,856 ​ 0.01 10/01/2021 ​ Transaction costs related to ATM ​ — ​ (1,768,424) ​ — ​ — Balance as of December 31, 2021 ​ ​ ​ 408,735 ​ 165,071,566 ​ 40,873,551 ​ 0.01 15/06/2022 ​ Capital increase by issue of ordinary shares - (ATM3) ​ 12,606 ​ 9,353,504 ​ 1,260,618 ​ 0.01 15/06/2022 ​ Transaction costs related to ATM ​ — ​ (539,404) ​ — ​ — Balance as of December 31, 2022 ​ 421,341 ​ 173,885,665 ​ 42,134,169 ​ 0.01 ​
BSPCE and BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2022 Issued Exercised Forfeited 2022 exercisable BSPCE — 2013 plan Dec. 13, 2013 0.59 8,800 — — — 8,800 8,800 BSPCE Plan 2021 ​ April 16, 2021 ​ 11.74 ​ 600,000 ​ — ​ — ​ (120,000) ​ 480,000 ​ — Total BSPCE 608,800 — — (120,000) 488,800 8,800 BSA — 2017 plan May 29, 2017 6.67 130,000 — — — 130,000 130,000 BSA — 2018 plan Dec. 14, 2018 6.07 116,000 — — — 116,000 116,000 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis ​ March 9, 2020 ​ 3.68 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 Ter ​ March 9, 2020 ​ 3.68 ​ 36,000 ​ — ​ — ​ — ​ 36,000 ​ 24,000 BSA - Plan 2021-1 ​ April 16, 2021 ​ 11.74 ​ 20,000 ​ — ​ — ​ (4,000) ​ 16,000 ​ — Total BSA 322,000 — — (4,000) 318,000 290,000 Total ​ ​ ​ ​ 930,800 — — (124,000) 806,800 298,800 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type ​ Grant date (in euros) 2021 Issued Exercised Forfeited 2021 exercisable BSPCE — 2013 plan ​ Dec. 13, 2013 0.59 8,800 — — — 8,800 8,800 BSPCE Plan 2021 ​ April 16, 2021 11.74 — 600,000 — — 600,000 — Total BSPCE ​ 8,800 600,000 — — 608,800 8,800 BSA — 2017 plan ​ May 29, 2017 6.67 130,000 — — — 130,000 130,000 BSA — 2018 plan ​ Dec. 14, 2018 6.07 116,000 — — — 116,000 116,000 BSA — 2019 plan ​ June 28, 2019 ​ 2.20 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 Bis ​ March 9, 2020 ​ 3.68 ​ 10,000 ​ — ​ — ​ — ​ 10,000 ​ 10,000 BSA 2019 Ter ​ March 9, 2020 3.68 36,000 — — — 36,000 12,000 BSA - Plan 2021-1 ​ April 16, 2021 11.74 — 50,000 — (30,000) 20,000 — Total BSA ​ ​ ​ ​ 302,000 ​ 50,000 ​ — ​ (30,000) ​ 322,000 ​ 278,000 Total ​ ​ ​ ​ ​ 310,800 ​ 650,000 ​ — ​ (30,000) ​ 930,800 ​ 286,800 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Exercise Outstanding ​ ​ ​ Outstanding Number of ​ ​ ​ ​ price ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2020 Issued Exercised Forfeited 2020 exercisable BSPCE — 2013 plan Dec. 13, 2013 0.59 8,800 — — — 8,800 8,800 Total BSPCE ​ ​ 8,800 — — — 8,800 8,800 BSA — 2017 plan May 29, 2017 6.67 140,000 — (10,000) — 130,000 130,000 BSA — 2018 plan Dec. 14, 2018 6.07 116,000 — — — 116,000 77,334 BSA — 2019 plan June 28, 2019 2.20 10,000 — — — 10,000 10,000 BSA 2019 Bis ​ March 9, 2020 ​ 3.68 ​ — ​ 10,000 ​ — ​ — ​ 10,000 ​ — BSA 2019 Ter March 9, 2020 3.68 — 36,000 — — 36,000 — Total BSA ​ ​ ​ ​ 266,000 46,000 (10,000) — 302,000 217,334 Total ​ ​ ​ ​ ​ 274,800 ​ 46,000 ​ (10,000) ​ — ​ 310,800 ​ 226,134 ​
BSPCE Share Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ BSPCE 2013-1 BSPCE 2021 Decision of issuance by the Board of Directors 13/12/2013 ​ 04/16/2021 ​ Grant date 13/12/2013 ​ 04/16/2021 ​ Beneficiary 3 employees ​ Executive Directors (Frederic Cren and Pierre Broqua) ​ Number of BSPCE granted 9 027 ​ 600,000 ​ Expiration date 25/01/2024 ​ 03/31/2034 ​ Number of shares per BSPCE 100 ​ 1 ​ Subscription price (€) ​ 58.50 ​ 0 ​ Exercise price (€) ​ 0.585 ​ 11.74 ​ Performance condition ​ No ​ Partially (1) ​ Valuation method used ​ Black and Scholes ​ Monte Carlo ​ Fair value at grant date (€) ​ 19 ​ [5.4 – 5.7] (1) ​ Expected volatility ​ 35 % 64 % Average life (years) ​ 5 ​ 5 ​ Risk-free rate ​ 1.13 % 0.60 % Expected dividends — ​ — ​ (1) The fair value at grant date is different depending on whether the BSPCEs are subject to market performance conditions.
BSA Share warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BSA ​ ​ ​ BSA ​ ​ ​ ​ ​ BSA 2017 2018-1 BSA 2019 2019 bis BSA 2019 ter BSA 2021 Decision of issuance by the Board of Directors ​ 05/29/2017 ​ 12/14/2018 06/28/2019 03/09/2020 03/09/2020 ​ 04/16/2021 ​ Grant date ​ 05/29/2017 ​ 12/14/2018 06/28/2019 03/09/2020 03/09/2020 ​ 04/16/2021 ​ Beneficiary ​ Directors ​ Service providers Service providers Service providers Service providers ​ Service providers ​ Vesting period (year) ​ 3 tranches: 1 year , 2 years and 3 years ​ between 1 and 3 years 1 1 between 1 and 3 years ​ 3 ​ Expiration date ​ 05/29/2027 ​ 12/14/2028 06/28/2029 03/09/2030 03/09/2030 ​ 03/31/2034 ​ Number of BSA granted ​ 195,000 ​ 126,000 10,000 10,000 36,000 ​ 50,000 ​ Number of shares per BSA ​ 1 ​ 1 1 1 1 ​ 1 ​ Subscription premium price per share (€) ​ 0.534 ​ 0.48 0.18 0.29 0.29 ​ 2.45 ​ Exercise price per share (€) ​ 6.675 ​ 6.067 2.20 3.68 3.68 ​ 11.74 ​ Performance condition ​ No ​ No No No No ​ Yes ​ Valuation method ​ Black and Scholes ​ Monte Carlo ​ Fair value per BSA at grant date (€) ​ 2.47 ​ 1.98 ​ 0.48 ​ 0.90 ​ 0.90 ​ [3.0 – 3.2] (1) ​ Expected volatility ​ 40 % 40 % 40 % 40 % 40 % 64 % Average life (years) ​ 6 ​ 6 ​ 5.5 ​ 6 ​ 6 ​ 5 ​ Risk free rate ​ 0.22 % 0.30 % 0.33 % 0.0 % 0.0 % 0.60 % Expected dividends ​ — ​ — — — — ​ — ​ (1) The fair value at grant date is different depending on whether the BSPCEs are subject to market performance conditions.
AGA Bonus Share Award Plans Member
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ AGA 2021 AGA 2021-bis AGA 2022 Decision of issuance by the Board of Directors 04/16/2021 12/08/2021 ​ 12/08/2022 Grant date 04/16/2021 12/08/2021 ​ 12/08/2022 Beneficiary Employees Employees ​ Employees Vesting period (year) 3 3 ​ 1 Holding period (year) — — ​ 1 Service condition Yes Yes ​ Yes Performance condition Partially (1) Partially (1) ​ No Number of AGA granted 466,000 123,000 ​ 373,000 Number of shares per AGA 1 1 ​ 1 Valuation method used ​ Dual (1) ​ Dual (1) ​ Dual (1) Fair value per AGA at grant date ​ [9.8 – 11.3] (1) ​ [11.4 – 12.2] (1) ​ 4.18 Expected volatility ​ 64 % 64 % N/A Average life (years) ​ 3 ​ 2.3 ​ N/A Risk-free rate ​ 0.60 % 0.60 % N/A Expected dividends ​ — ​ — ​ – Stock price reference ​ N/A ​ N/A ​ N/A Non-transferable discount N/A N/A ​ N/A (1) AGA 2021-1 and AGA 2021-bis plans are partially composed of AGAs subject to a market performance condition. AGAs 2022 aren’t subject to a market performance condition. Accordingly, AGAs not subject to performance conditions are valued on the basis of the share price less future dividends, discounted at the risk-free rate. AGAs subject to performance conditions are valued using the same method, adjusted by a discount applied to reflect the performance condition. This discount is determined using the “Monte Carlo” analysis. The fair value at the grant date is different depending on whether the AGAs are subject to market performance conditions.
Bonus Share Award Plans [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movements in BSPCE and BSA share warrants and Bonus shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock price ​ Outstanding ​ ​ ​ ​ ​ ​ ​ Outstanding ​ Number of ​ ​ ​ ​ at grant date ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2022 Issued vesting Forfeited 2022 exercisable AGA — 2021‑1 plan 04/16/21 11.30 448,000 — — (107,200) 340,800 — AGA — 2021‑bis plan 12/08/21 12.20 123,000 — — (46,200) 76,800 — AGA —2022 plan ​ 12/08/22 ​ 4.18 ​ — ​ 373,000 ​ — ​ — ​ 373,000 ​ — Total AGA ​ ​ ​ ​ 571,000 373,000 — (153,400) 790,600 — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock price ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding ​ ​ ​ ​ ​ ​ at grant ​ Outstanding ​ ​ ​ ​ ​ ​ ​ at ​ Number of ​ ​ ​ ​ date ​ at January 1, ​ ​ ​ ​ ​ ​ ​ December 31, ​ shares Type Grant date (in euros) 2021 Issued vesting Forfeited 2021 exercisable AGA — 2019‑1 plan 08/28/19 2.00 29,100 — (29,100) — — — AGA — 2021‑1 plan 04/16/21 11.30 — 466,000 — (18,000) 448,000 — AGA —2021‑bis plan 08/12/21 12.20 — 123,000 — — 123,000 — Total AGA 29,100 589,000 (29,100) (18,000) 571,000 — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ price ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ at grant ​ Outstanding ​ ​ ​ ​ ​ ​ ​ Outstanding ​ Number of ​ ​ ​ ​ date ​ at January 1, ​ ​ ​ ​ ​ ​ ​ at December 31, ​ shares Type Grant date (in euros) 2020 Issued vesting Forfeited 2020 exercisable AGA — 2018-2 plan ​ January 26, 2018 5.76 63,300 — (63,300) — — — AGA — 2018-3 plan ​ December 14, 2018 6.28 227,250 — (227,250) — — — AGA — 2019-1 plan ​ June 28, 2019 2.00 37,500 — — (8,400) 29,100 — AGA — 2019-2 plan ​ June 28, 2019 2.00 228,000 — (227,000) (1,000) — — Total AGA ​ ​ ​ ​ 556,050 — (517,550) (9,400) 29,100 — ​

Financial debt (Tables)

Financial debt (Tables)	12 Months Ended
	Dec. 31, 2022
Financial debt
Schedule of debt	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Bank borrowings 9,992 ​ 9,984 29,689 Derivatives instruments ​ — ​ — ​ 9,876 Other loans and similar borrowings (1) 62 ​ 6 316 Lease liabilities 2 ​ 130 4,510 Total debt 10,055 ​ 10,119 44,390 (1) Consists of bank overdrafts and accrued interest payable on loans
Schedule of changes in borrowings	​ ​ ​ ​ (in thousands of euros) January 1, 2020 114 Subscription of bank borrowings ​ 9,979 Repayment of bank borrowings ​ (61) Repayment of lease liabilities ​ (26) Early termination of lease contracts ​ (9) Capitalized interests ​ 59 Accrued interests ​ (0) December 31, 2020 10,055 Subscription of new leases ​ 143 Repayment of bank borrowings ​ (13) Repayment of lease liabilities ​ (15) Accrued interests ​ (51) December 31, 2021 ​ 10,119 Subscription of state-guaranteed PGE loan ​ 1,780 Subscription of PPR loan ​ 3,560 Subscription of derivatives instruments (2) ​ 9,469 Subscription of bank borrowings (1) (2) ​ 15,400 New lease contracts ​ 5,109 Repayment of bank borrowings ​ (1,033) Repayment of lease liabilities ​ (735) Capitalized interests ​ 308 Change in fair value of derivatives instruments (2) ​ 407 Exchange rate change ​ 6 December 31, 2022 44,390 (1) (2) ​
Schedule of valuation approach for BSA arrangement	​ ​ ​ ​ ​ ​ BSA 2022 Grant date 11/28/2022 ​ Expiration date 11/28/2030 ​ Number of BSA issued 2,266,023 ​ Number of shares per BSA 1 ​ Subscription premium price per share (€) 0.01 ​ Exercise price per share (€) 4.02 ​ Valuation method Longstaff Schwartz ​ ​ ​ ​ ​ ​ ​ ​ ​ As of November 28, 2022 ​ ​ ​ (Grant Date) ​ As of December 31, 2022 Number of BSA outstanding 2,266,023 2,266,023 ​ Stock price (€) [4.13] [4.75] ​ Maturity (years) 12 11.9 ​ Volatility 68 % 68 % Cap of the put option (m€) 25.0 25.0 ​ Risk free rate Euribor 6M Euribor 6M ​ Expected dividends — — ​ Fair Value (k€) 9,469 9,876 ​ Unit fair value (€) 4.18 4.36 ​ ​
Schedule of maturity of long-term and short-term debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 Less than Between Between More than (in thousands of euros) 1 year 1 and 3 years 3 and 5 years 5 years Bank borrowings 13 9,979 — — Other loans and similar borrowings 3 59 — — Lease liabilities ​ 2 ​ 0 ​ — ​ — Total long ‑ term debt 18 10,037 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 Less than Between Between More than (in thousands of euros) ​ 1 year ​ 1 and 3 years ​ 3 and 5 years ​ 5 years Bank borrowings ​ 1,244 ​ 7,484 ​ 1,256 ​ — Other loans and similar borrowings — 6 — — Lease liabilities 38 92 — — Total long ‑ term debt 1,282 7,582 1,256 — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 Less than Between Between More than (in thousands of euros) ​ 1 year ​ 1 and 3 years ​ 3 and 5 years ​ 5 years Bank borrowings 4,474 4,999 17,768 2,448 Derivatives ​ — ​ — ​ 9,876 ​ — Other loans and similar borrowings 100 0 216 — Lease liabilities 1,277 3,233 — — Total long ‑ term debt 5,851 8,232 27,860 2,448 ​

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2022
Provisions
Schedule of provisions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2020 Additions Reversals/reclasses December 31, 2020 CIR 2013-2015 358 1,139 — 1,497 CIR 2017 ​ 216 ​ 665 ​ — ​ 880 Long ‑ term provisions 574 1,804 — 2,377 Payroll taxes 2016-2018 1,264 90 (1,224) 130 Short ‑ term provisions 1,264 90 (1,224) 130 Total Provisions 1,837 1,894 (1,224) 2,507 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ ​ December 31, (in thousands of euros) 2021 Additions Reversals/reclasses 2021 CIR 2013-2015 ​ 1,497 ​ — ​ (1,497) ​ — CIR 2017 ​ 880 ​ — ​ (880) ​ — Long ‑ term provisions 2,377 — (2,377) ​ — Payroll taxes 2016-2018 ​ 130 ​ 51 ​ — ​ 180 Short ‑ term provisions 130 51 — ​ 180 Total Provisions 2,507 51 (2,377) ​ 180 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands of euros) January 1, 2022 Additions Reversals/reclasses December 31, 2022 Long ‑ term provisions — — — — Payroll taxes 2016-2018 180 — (180) — Short ‑ term provisions 180 — (180) — Total Provisions 180 — (180) — ​

Provisions for Retirement Ben_2

Provisions for Retirement Benefit Obligations (Tables)	12 Months Ended
	Dec. 31, 2022
Provisions for Retirement Benefit Obligations
Schedule of assumptions used to measure Retirement Benefit Obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, Variables 2020 2021 2022 Retirement age ​ 65 years 65 years 65 years Payroll taxes ​ 41.41 % 41.41 % 41.41 % Salary growth rate ​ 2 % 2 % 2 % Discount rate ​ 0.35 % 1.00 % 3.7 % Mortality table ​ TGH/TGF 05 ​ TGH/TGF 05 THG/TGF 05 ​ ​
Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period	​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Retirement benefit obligations 1,385 ​ 1,429 1,234 Obligation 1,385 ​ 1,429 1,234 ​
Schedule of change in the provision recorded in respect of defined benefit schemes	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31 (in thousands of euros) 2020 2021 2022 Provision at beginning of period (1,127) ​ (1,385) (1,429) Other changes ​ — ​ 75 ​ — Expense for the period (209) ​ (200) (230) Actuarial gains or losses recognized in other comprehensive income (49) ​ 82 425 Provision at end of period (1,385) ​ (1,429) (1,234) ​
Schedule of expense recognized in the statement of income (loss)	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Service cost for the period (202) ​ (224) (237) Interest cost for the period (8) ​ (5) (14) Benefits for the period — ​ 29 21 Plan curtailments and modifications — ​ — — Total (209) ​ (200) (230) ​
Schedule of actuarial gains and losses recognized in comprehensive income	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Demographic changes 14 ​ (27) 42 Changes in actuarial assumptions (63) ​ 109 383 Total (49) ​ 82 425 ​
Schedule of sensitivity analysis	​ ​ ​ ​ ​ In thousands December 31, 2020 ​ of euros Benefit obligation at December 31, 2020 at 0.10% 1,433 Benefit obligation at December 31, 2020 at 0.35% 1,385 Benefit obligation at December 31, 2020 at 0.60% 1,340 ​ ​ ​ ​ ​ In thousands December 31, 2021 ​ of euros Benefit obligation at December 31, 2021 at 0.75% 1,471 Benefit obligation at December 31, 2021 at 1.00% 1,429 Benefit obligation at December 31, 2021 at 1.25% 1,389 ​ ​ ​ ​ ​ In thousands December 31, 2022 ​ of euros Benefit obligation at December 31, 2022 at 3.45% 1,263 Benefit obligation at December 31, 2022 at 3.70% 1,234 Benefit obligation at December 31, 2022 at 3.95% 1,205

Trade Payables and Other Curr_2

Trade Payables and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Trade Payables and Other Current Liabilities
Schedule of trade payables and other current liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 Trade payables ​ 6,923 ​ 14,602 19,359 Other current liabilities ​ 6,838 ​ 6,789 5,485 Trade payables and other current liabilities ​ 13,761 ​ 21,391 24,844 ​
Schedule of trade payables break down by payment	Trade payables break down by payment date as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, (in thousands of euros) 2020 2021 2022 Due in 30 days ​ 6,834 ​ 14,445 19,156 Due in 30 - 60 days ​ 89 ​ 158 201 Due in more than 60 days ​ — ​ — 2 Trade payables ​ 6,923 ​ 14,602 19,359 ​
Schedule of other current liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Employee‑related payables 1,405 ​ 1,518 1,866 Accrued payroll and other employee‑related taxes 1,375 ​ 1,234 1,340 VAT payable 753 ​ 879 2,128 Other accrued taxes and employee‑related expenses 106 ​ 178 140 Other miscellaneous payables 3,198 ​ 2,979 12 Other current liabilities 6,838 ​ 6,789 5,485 ​

Financial Assets and Liabilit_2

Financial Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Assets and Liabilities
Schedule of financial assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 ​ ​ ​ ​ ​ ​ Financial ​ ​ ​ ​ ​ ​ Book value ​ ​ ​ assets/liabilities ​ ​ ​ ​ ​ ​ on the ​ Financial ​ carried at ​ Liabilities ​ ​ ​ ​ statement ​ assets carried ​ fair value ​ carried at ​ ​ ​ ​ of financial ​ at amortized ​ through ​ amortized ​ ​ (in thousands of euros) position cost profit or loss cost Fair value Financial assets ​ Long‑term deposit accounts ​ 1,698 1,698 — — 1,698 Long-term security deposits ​ 8 ​ 8 ​ — ​ — ​ 8 Accrued income ​ 2,000 2,000 — — 2,000 Short-term deposit accounts ​ 7,336 ​ 7,336 ​ — ​ — ​ 7,336 Trade receivables ​ 48 48 — — 48 Other receivables ​ 1,849 1,849 — — 1,849 Foreign currency forwards ​ 1,791 ​ — ​ 1,791 ​ — ​ 1,791 Cash and cash equivalents ​ 105,687 105,687 — — 105,687 Total assets ​ 120,417 118,626 1,791 — 120,417 Financial liabilities ​ Long‑term debt ​ 10,037 — — 10,037 10,037 Short‑term debt ​ 18 — — 18 18 Trade payables ​ 6,923 — — 6,923 6,923 Other miscellaneous payables ​ 3,198 — — 3,198 3,198 Total liabilities ​ 20,177 — — 20,177 20,177 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 ​ ​ ​ Financial ​ ​ ​ ​ Book value ​ ​ ​ assets/liabilities ​ ​ ​ ​ ​ ​ on the ​ Financial ​ carried at ​ Liabilities ​ ​ ​ ​ statement ​ assets carried ​ fair value ​ carried at ​ ​ ​ ​ of financial ​ at amortized ​ through ​ amortized ​ ​ (in thousands of euros) position cost profit or loss cost Fair value Financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term deposit accounts ​ 1,745 1,745 — — 1,745 Long-term security deposits ​ 8 8 — — 8 Advances to suppliers – non-current ​ 689 ​ 689 ​ — ​ — ​ 689 Accrued income ​ 92 92 — — 92 Short-term deposit accounts ​ 8,829 ​ — ​ 8,829 ​ — ​ 8,829 Trade receivables ​ 4,000 4,000 — — 4,000 Other receivables ​ 1,055 1,055 — — 1,055 Cash and cash equivalents ​ 86,553 86,553 — — 86,553 Total assets ​ 102,972 94,143 8,829 — 102,972 Financial liabilities ​ ​ ​ ​ ​ ​ Long-term debt ​ 8,837 — — 8,837 8,837 Short-term debt ​ 1,282 — — 1,282 1,282 Trade payables ​ 14,602 ​ — ​ — ​ 14,602 ​ 14,602 Other miscellaneous payables ​ 2,979 ​ — ​ — ​ 2,979 ​ 2,979 Total liabilities ​ 27,701 ​ — ​ — ​ 27,701 ​ 27,701 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 ​ ​ ​ Financial ​ ​ ​ ​ Book value ​ ​ ​ assets/liabilities ​ ​ ​ ​ ​ ​ on the ​ Financial ​ carried at ​ Liabilities ​ ​ ​ ​ statement ​ assets carried ​ fair value ​ carried at ​ ​ ​ ​ of financial ​ at amortized ​ through ​ amortized ​ ​ (in thousands of euros) position cost profit or loss cost Fair value Financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term accrued income ​ 65 ​ 65 ​ — ​ — ​ 65 Long‑term deposit accounts ​ 700 700 — — 700 Long-term security deposits ​ 8 ​ 8 ​ — ​ — ​ 8 Advance payment ​ 895 ​ 895 ​ — ​ — ​ 895 Current accrued income ​ 117 117 — — 117 Short‑term deposit accounts ​ 1,048 ​ 1,048 ​ — ​ — ​ 1,048 Trade receivables ​ 0 0 — — 0 Cash and cash equivalents ​ 86,736 86,736 — — 86,736 Other receivables ​ 444 ​ 444 ​ — ​ — ​ 444 Total assets ​ 90,014 90,014 — — 90,014 Financial liabilities ​ Long‑term debt ​ 28,663 — — 28,663 28,663 Derivative instruments ​ 9,876 ​ — ​ 9,876 ​ — ​ 9,876 Short‑term debt ​ 5,851 — — 5,851 5,851 Trade payables ​ 19,359 — — 19,359 19,359 Long-term contract liabilities ​ 55 ​ — ​ — ​ 55 ​ 55 Short-term contract liabilities ​ 6 ​ — ​ — ​ 6 ​ 6 Other miscellaneous payables ​ 12 — — 12 12 Total liabilities ​ 63,821 — 9,876 53,945 63,821

Revenues and Other Income (Tabl

Revenues and Other Income (Tables)	12 Months Ended
	Dec. 31, 2022
Revenues and Other Income
Schedule of revenue and other income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, (in thousands of euros) 2020 2021 2022 Sales 372 ​ 4,194 12,179 Total revenues 372 ​ 4,194 12,179 CIR 4,791 ​ 4,069 5,863 Subsidies — ​ 8 10 Other 100 ​ 229 762 Total other income 4,891 ​ 4,307 6,635 Total revenues and other income 5,263 ​ 8,501 18,814 ​

Research and Development, Mar_2

Research and Development, Marketing - Business Development and General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Research and Development, Marketing - Business Development and General and Administrative Expenses
Schedule of research and development, marketing	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2020 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) expenses expenses expenses Total Disposables (1,243) — — (1,243) Energy and liquids (539) — — (539) Patents (343) — — (343) Studies (10,987) — — (10,987) Maintenance (846) — — (846) Fees (201) (341) (2,005) (2,548) IT systems (597) (8) (46) (651) Support costs (including taxes) — — (722) (722) Personnel costs (7,518) (197) (2,964) (10,680) Depreciation, amortization and provisions (832) — (177) (1,009) Other (608) (16) (2,585) (3,209) Total operating expenses (23,717) (563) (8,499) (32,779) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2021 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) ​ expenses ​ expenses ​ expenses ​ Total Disposables (1,472) — — (1,472) Energy and liquids (513) — — (513) Patents (543) — — (543) Studies (33,004) — — (33,004) Maintenance (1,017) — — (1,017) Fees (160) (138) (2,746) (3,044) IT systems (744) (9) (52) (806) Support costs (including taxes) — — (782) (782) Personnel costs (9,645) (213) (3,556) (13,413) Depreciation, amortization and provisions (751) — (176) (927) Other (602) (4) (3,844) (4,450) Total operating expenses (48,452) (364) (11,155) (59,971) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2022 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) ​ expenses ​ expenses ​ expenses ​ Total Disposables (1,681) — — (1,681) Energy and liquids (633) — — (633) Patents (510) — — (510) Studies (42,375) — (2) (42,377) Maintenance (995) — — (995) Fees (175) (570) (3,843) (4,587) IT systems (852) (16) (92) (960) Support costs (including taxes) 1 — (1,280) (692) (1,971) Personnel costs (11,149) (219) (3,964) (15,332) Depreciation, amortization and provisions (1,462) — (220) (1,683) Other (637) (499) (4,099) (5,234) Total operating expenses (60,469) (2,583) (12,912) (75,965) ​ (1)
Schedule of personnel costs and headcount	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2020 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) ​ expenses ​ expenses ​ expenses ​ Total Wages, salaries and similar costs (4,590) (183) (1,669) (6,442) Payroll taxes (2,180) 8 (926) (3,098) Provisions for retirement benefit obligations (141) 0 (60) (202) Share‑based compensation expense (607) (22) (309) (938) Total personnel costs (7,518) (197) (2,964) (10,680) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2021 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (6,031) (199) (1,867) (8,097) Payroll taxes (2,173) 0 (838) (3,010) Provisions for retirement benefit obligations (148) 0 (68) (216) Share‑based compensation expense (1,293) (13) (783) (2,089) Total personnel costs (9,645) (213) (3,556) (13,413) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Marketing — business General and ​ December 31, 2022 ​ development ​ development ​ administrative ​ ​ (in thousands of euros) expenses expenses expenses Total Wages, salaries and similar costs (7,382) (190) (2,242) (9,814) Payroll taxes (2,213) (16) (841) (3,069) Provisions for retirement benefit obligations (157) — (73) (231) Share-based compensation expense 1 (1,397) (13) (808) (2,218) Total personnel costs (11,149) (219) (3,964) (15,332) (2)

Other Operating Income (expen_2

Other Operating Income (expenses) - (Tables)	12 Months Ended
	Dec. 31, 2022
Other Operating Income (expenses)
Schedule of other operating income (expenses)	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Corrective claims - CIR ​ 2,863 ​ — ​ — Proceeds - Disposals of fixed assets ​ — ​ 9 ​ 0 Reversal of restructuring expenses ​ 43 ​ — ​ — Reversal of provisions - CIR 2013-2015 ​ — ​ 1,497 ​ — Reversal of provisions - CIR 2017 ​ — ​ 880 ​ — Reversal of provisions - tax litigation ​ — ​ — ​ 180 Reversal of provisions - AMR penalties ​ — ​ — ​ 114 Reversal of impairment on the carry back receivable ​ — ​ 333 ​ — Total other operating income 2,905 ​ 2,720 294 Disposals of assets ​ — ​ — ​ (9) Provision for risk on payroll taxes (90) ​ (51) — Accrued expenses to be paid to the tax authorities - CIR 2013 to 2015 ​ — ​ (1,584) ​ (0) Late payment interest on CIR 2013-2015 ​ — ​ — ​ (123) Impairment of tax loss carry back ​ (333) ​ — ​ — Waiver of CIR 2017 claim ​ — ​ (640) ​ — CIR provision (1,804) ​ (137) — Transaction costs (2,881) ​ (952) (121) Total other operating expenses (5,108) ​ (3,364) (254) Other operating income (expenses) (2,202) ​ (644) 40 ​

Financial Income and Expenses (

Financial Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Income and Expenses
Schedule of financial income and expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Income from cash and cash equivalents 226 ​ 57 390 Foreign exchange gains 40 ​ 5,421 4,532 Fair value variation gains / losses ​ 1,791 ​ — ​ — Total financial income 2,057 ​ 5,478 4,923 Interest cost (66) ​ (138) (584) Foreign exchange losses ​ (5,884) ​ (1,842) ​ (1,068) Allocation to financial provisions ​ — ​ — ​ — Losses on change in fair value — ​ (651) (407) Other financial expenses (8) ​ (5) (47) Total financial expenses (5,959) ​ (2,635) (2,107) Net financial income (loss) (3,902) ​ 2,842 2,816 ​

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax
Schedule of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Loss before tax (33,619) ​ (49,271) (54,294) ​ Theoretical tax rate 28 % 26.5 % 25 % Tax benefit at theoretical rate 9,413 ​ 13,057 13,574 ​ Tax credits 2,143 ​ 1,078 1,432 ​ Permanent differences 1,641 ​ 85 (305) ​ Other differences (471) ​ (582) (428) ​ Tax rate differences ​ — ​ (80) ​ 55 ​ Non recognition of deferred tax assets related to tax losses and temporary differences (12,726) ​ (13,921) (14,309) ​ Actual income tax benefit — ​ (364) 20 ​ of which ​ ​ ​ ​ ​ Current taxes — ​ (364) ​ (34) ​ Deferred taxes — ​ — ​ 54 ​ Effective tax rate — ​ 0.74 % 0.06 % ​

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Related-Party Transactions
Schedule of transactions with key management personnel	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Short-term benefits 1,669 ​ 1,517 1,897 Post-employment benefits 77 ​ 92 (14) Other long-term benefits — ​ — — End-of-contract indemnities — ​ — — Share-based payment 259 ​ 907 1,077 Net total 2,005 ​ 2,516 2,960

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Basic and Diluted Loss Per Share
Schedule of basic earnings (loss) per share	​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended ​ ​ December 31, (in thousands of euros) 2020 2021 2022 Net loss for the period (33,619) ​ (49,635) (54,274) Weighted average number of outstanding shares used for computing basic/diluted loss per share 33,874,751 ​ 39,168,152 41,449,732 Basic/diluted loss per share (in €) (0.99) ​ (1.27) (1.31) ​

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Risk Management
Schedule of sensitivity analysis of the company's assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Impact of a 5% ​ ​ Fair Value as of ​ change in (in thousands of euros) December 31, 2022 fair value Cash and cash equivalents dominated in US Dollar 33,310 (1,586) ​

Company Information - Amendment

Company Information - Amendments to Contract CRO with Pharmaceutical Research Associates B.V. & Service Agreement with Summit Clinical Research LLC (Details) € in Millions, $ in Millions				12 Months Ended
	Nov. 10, 2022 EUR (€)	Feb. 01, 2022 EUR (€) Milestone	Jan. 14, 2022 EUR (€)	Dec. 31, 2022 EUR (€) shares	Feb. 28, 2022 USD ($)	Feb. 01, 2022 USD ($)
Collaborative Arrangements
Number of active clinical sites in NATiV3 trial				369
Number of ordinary shares represented by one American Depositary Share | shares				1
Contract CRO with Pharmaceutical Research Associates B.V.
Collaborative Arrangements
Amount payable over the two years period following the date of the contract			€ 7.9
Specified period following the date of contract, for payment of commitment amount	7 years		2 years
Number of milestones required to be reached | Milestone		4
Bonus or malus maximum amount		€ 3.4
Outstanding commitments				€ 198.1
Contract CRO with Pharmaceutical Research Associates B.V. | Maximum
Collaborative Arrangements
Amount committed to pay	€ 223.8
Service agreement with Summit Clinical Services LLC
Collaborative Arrangements
Amount committed to pay		€ 4.1				$ 4.4
Incremental amount committed to pay | $					$ 1.6
Service agreement with Summit Clinical Services LLC | Minimum
Collaborative Arrangements
Amount committed to pay | $					$ 4.4

Company Information - License a

Company Information - License and collaboration agreement with CTTQ (Details) - Licensing and collaboration agreement with CTTQ € in Millions, $ in Millions	Nov. 04, 2022 USD ($) € / $	Nov. 04, 2022 EUR (€) € / $	Sep. 28, 2022 USD ($)	Sep. 28, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Sep. 22, 2022 USD ($)
Collaborative Arrangements
Amount invoiced to counterparty			$ 12.6	€ 12.8
Amount invoiced to counterparty for initial payment			12	12.1
Amount invoiced to counterparty for additional payment			$ 0.6	€ 0.6
Amount received on licensing arrangements	$ 11.4	€ 11.5
Amount received attributable to withholding taxes	$ 1.3	€ 1.3
Maximum additional amount receivable upon the achievement of certain development and regulatory milestones					$ 40	$ 40
Maximum additional amount receivable upon the achievement of certain commercial milestones					$ 250	$ 250
Number of years of commercialization during which the company is entitled to receive royalties ranging from high single-digit to mid-teen double digits of net sales			3 years	3 years
Exchange rate on invoice | € / $	1.009	1.009

Company Information - Investiga

Company Information - Investigational New Drug application (Details) - Investigational New Drug application accepted by the FDA for the Phase II clinical trial combining lanifibranor and empagliflozin in patients with NASH and type 2 diabetes	Mar. 08, 2022
Collaborative Arrangements
Number of patients expected to be recruited for trial	63
Patient treatment period, clinical trials	168 days

Company Information - Tax dispu

Company Information - Tax dispute settlement (Details) - EUR (€) € in Millions		12 Months Ended
	Jun. 09, 2021	Dec. 31, 2022
Tax dispute settlement
VAT credit used to offset the accruals	€ 1.3
CIR 2013 - 2015
Tax dispute settlement
Write-off of CIR receivables		€ 0.3
CIR 2017
Tax dispute settlement
Write-off of CIR receivables		0.2
Payroll Tax Audit, 2016 and 2017
Tax dispute settlement
Accruals settled during the period		2.8
Accruals settled through payments		0.4
Accruals settled through offset against VAT credits		€ 1.9

Company Information - Equity fi

Company Information - Equity financing (Details) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions				1 Months Ended	12 Months Ended
	Jun. 15, 2022 EUR (€) $ / € € / shares shares	Jun. 15, 2022 $ / € $ / shares	Jul. 15, 2020 USD ($)	Jun. 30, 2022 EUR (€)	Dec. 31, 2022 $ / € shares	Dec. 31, 2021 USD ($) $ / €	Oct. 01, 2021	Sep. 23, 2021	Aug. 02, 2021
Company Information
Gross proceeds | $			$ 107.7
Exchange rate | $ / €					1.0666	1.1326
ATM
Company Information
Gross proceeds				€ 9.4		$ 31.9
Net proceeds from issuing shares				€ 8.8
Number of shares issued during the period | shares					1,260,618
Number of ordinary shares represented by each ADS									1
ATM | ADS
Company Information
Gross proceeds	€ 9.4
Net proceeds from issuing shares	€ 8.8
Number of shares issued during the period | shares	1,260,618
Price per share | (per share)	€ 7.43	$ 7.75
Percentage of discount to volume weighted average trading price of Company's ADS	0.92%
Exchange rate | $ / €	1.0431	1.0431
Number of ordinary shares represented by each ADS	1	1					1	1

Company Information - Milestone

Company Information - Milestone payment from AbbVie and French Research Tax Credits (CIR) (Details) - EUR (€) € in Millions	Apr. 21, 2022	Jan. 31, 2022	Dec. 31, 2021
Company Information
French Research Tax Credit (CIR), payments received	€ 3.6
AbbVie
Company Information
Milestone payments received		€ 4	€ 4

Company Information - Credit fa

Company Information - Credit facility from the European Investment Bank (Details) € in Thousands, $ in Millions

1 Months Ended

8 Months Ended

12 Months Ended

Dec. 08, 2022 EUR (€)

Nov. 28, 2022 EUR (€) shares

Nov. 04, 2022 EUR (€)

Nov. 04, 2022 USD ($)

Jun. 15, 2022 EUR (€)

May 16, 2022 EUR (€) tranche

Jul. 15, 2020 USD ($) shares

Jun. 30, 2022 EUR (€)

Dec. 31, 2022 EUR (€)

Dec. 31, 2022 EUR (€)

Dec. 31, 2021 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 EUR (€)

Jul. 01, 2022 EUR (€)

Company Information

Gross proceeds | $

$ 107.7

Proceeds from issuance of shares

[1]

€ 8,827

€ 25,475

€ 101,782

Number of shares issued | shares

38,393,011

Loan obtained

30,209

€ 9,979

ATM

Company Information

Gross proceeds

€ 9,400

$ 31.9

Net proceeds from issuing shares

€ 8,800

ATM | ADS

Company Information

Gross proceeds

€ 9,400

Net proceeds from issuing shares

8,800

Licensing and collaboration agreement with CTTQ

Company Information

Net upfront payment

€ 11,500

$ 11.4

Finance contract with EIB

Company Information

Notional amount

€ 50,000

Number of equal tranches | tranche

2

Notional amount per tranche

€ 25,000

Number of warrants issued | shares

2,266,023

Cancellation term for funds not dispersed after execution of finance contract

36 months

Finance contract with EIB | Warrant agreement with the European Investment Bank

Company Information

Notional amount

€ 50,000

Finance contract with EIB, first tranche

Company Information

Notional amount

€ 25,000

Notional amount per tranche

€ 25,000

Aggregate amount to be received either in exchange for new shares of the Company or through the receipt of upfront or milestone payments

€ 18,000

€ 18,000

Interest rate

8%

8%

Maturity term after the disbursement of the tranche

4 years

4 years

Loan obtained

€ 25,000

Finance contract with EIB, first tranche | ATM

Company Information

Proceeds from issuance of shares

€ 9,400

Finance contract with EIB, first tranche | Warrant agreement with the European Investment Bank

Company Information

Number of warrants issued | shares

2,022

Finance contract with EIB, second tranche

Company Information

Notional amount

€ 25,000

€ 25,000

Aggregate amount to be received either in exchange for new shares of the Company or through the receipt of upfront or milestone payments

70,000

€ 70,000

Minimum upfront payments for out-licensing, partnership or royalty transaction

€ 10,000

€ 10,000

Interest rate

7%

Maturity term after the disbursement of the tranche

3 years

[1] Including subscriptions to BSA share warrants for €539 thousand, € 49 thousand, and € 13 thousand for the period ended December 31, 2022, December 31, 2021, and December 31, 2020 respectively.

Company Information - Loan agre

Company Information - Loan agreements with a syndicate of French banks and two equity recovery loans (Details) € in Millions	1 Months Ended	12 Months Ended
	Jun. 30, 2022 EUR (€) loan	Dec. 31, 2022 loan
Loan agreements with a syndicate of French banks
Guarantee Details
Number of loan agreements	3
Total amount of loan | €	€ 5.3
Loan agreements with syndicate of French banks, under stimulus economic plan
Guarantee Details
Number of loan agreements	2
Total amount of loan | €	€ 5.3
Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)
Guarantee Details
Percentage of loan guaranteed by French state	90%
Equity recovery loans
Guarantee Details
Number of loan agreements		2
Financing period of loan	8 years
Repayment period for loan	4 years

Company Information - Warrant a

Company Information - Warrant agreement with the European Investment Bank (Details) - EUR (€)			12 Months Ended
	Nov. 28, 2022	Jul. 01, 2022	Dec. 31, 2022	May 16, 2022
Finance contract with EIB
Company Information
Notional amount				€ 50,000,000
Finance contract with EIB, first tranche
Company Information
Notional amount	€ 25,000,000
Finance contract with EIB, second tranche
Company Information
Notional amount			€ 25,000,000
Warrant agreement with the European Investment Bank
Company Information
Number of warrants issued	2,266,023		2,266,023
Term over which volume weighted average price per share to determine number of warrants to be issued		180 days
Subscription price per warrant		€ 0.01
Maturity term of warrants		12 years
Number of shares per warrant		1
Percentage of Company's share capital outstanding, issued as warrants	5.40%
Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares	95%
Exercise price of warrant	€ 4.0152
Warrant agreement with the European Investment Bank | All warrants are exercised
Company Information
Exercise price of warrant	€ 4.0152
Number of shares issued upon exercise of warrants	2,266,023
Proceeds from exercise of warrants	€ 9,098,535
Warrant agreement with the European Investment Bank | Finance contract with EIB
Company Information
Notional amount		€ 50,000,000

Company Information - Share-bas

Company Information - Share-based payments (Details) - AGA	Dec. 08, 2022 EquityInstruments employee
Company Information
Number of other equity instruments granted in share-based payment arrangement | EquityInstruments	373,000
Number of employees for whom bonus shares were granted | employee	110

Company Information - Tax audit

Company Information - Tax audit on payroll tax (Details) € in Millions						12 Months Ended
	Nov. 26, 2021 EUR (€)	Sep. 16, 2021 employee	Jun. 09, 2021 EUR (€)	Mar. 09, 2021 EUR (€)	Feb. 11, 2021 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2022 EUR (€)	Jan. 06, 2021 EUR (€)
Company Information
Number of key recruitments announced for development of lanifibranor | employee		7
Cash pledged as security						€ 1.7
Indemnification amount received						€ 2
Amount of offsetting against VAT credit receivables			€ 1.3
Provision related to tax audit for the years ended 2013, 2014 and 2015 | Guarantee given to the tax authorities
Company Information
Cash pledged as security							€ 1.6
Provision related to tax audit for the years ended 2013, 2014 and 2015 | Tax audit for payroll taxes
Company Information
Proposed payroll tax adjustment					€ 1.9
Indemnification amount received				€ 2
Total amount paid to French tax authorities			1.8
Net amount paid by bank transfer			€ 0.5
Provision related to tax audit for the years ended december 2016 and 2017 | Guarantee given to the tax authorities
Company Information
Cash pledged as security								€ 1
Provision related to tax audit for the years ended december 2016 and 2017 | Tax audit for payroll taxes
Company Information
Claim for total amount	€ 1.2
Crdit Agricole bank | Provision related to tax audit for the years ended 2013, 2014 and 2015 | Guarantee given to the tax authorities
Company Information
Amount of Release of Term Account Pledge							€ 1

Company Information - Tax aud_2

Company Information - Tax audit on research tax credit (Details) € in Millions, $ in Millions			1 Months Ended	12 Months Ended
	Apr. 21, 2022 EUR (€)	Nov. 06, 2021 EUR (€)	Jan. 31, 2020 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2020 EUR (€)	Nov. 26, 2021 EUR (€)	Feb. 01, 2019 EUR (€)	Jun. 30, 2018 EUR (€)	Jun. 30, 2018 USD ($)
Tax dispute settlement
French Research Tax Credit (CIR), payments received	€ 3.6
Amount of expenses reversed				€ 1.5
Provision for CIR related to tax audit for years 2013 to 2015
Tax dispute settlement
Amount of additional claim | $									$ 0.5
Tax deduction amount for Additional claim								€ 0.3
Amount of bank guarantee related to principal							€ 1.8
Amount of receivable						€ 0.3
Provision for CIR related to tax audit for years 2013 to 2015
Tax dispute settlement
French Research Tax Credit (CIR), payments received			€ 4.3
ProvisionForCirRelatedToTaxAuditForYears2017
Tax dispute settlement
French Research Tax Credit (CIR), payments received					€ 3.6
French Research Tax Credit (CIR), amounts receivable					€ 4.5
Percentage of French Research Tax Credit (CIR) withheld					81%
Amount of expenses reversed				0.9
Amount of receivable				0.2
2017 CIR relating to subcontracting operations
Tax dispute settlement
Maximum expenses to be claimed		€ 0.2
Amount of expenses reversed		€ 0.7
Amount of expenses reversed				€ 0.2

Company Information - Capital i

Company Information - Capital increase (Details)					12 Months Ended
	Dec. 08, 2021 employee	Apr. 16, 2021 shares	Apr. 16, 2021	Apr. 16, 2021 item	Dec. 31, 2021
BSPCE 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of warrants granted | shares		600,000
Number of bonus shares granted			600,000		600,000
AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted	123,000		466,000
Number of employees for whom bonus shares were granted | employee	13
BSA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted			50,000	50,000

Company Information - Vesting o

Company Information - Vesting of bonus shares (Details)			12 Months Ended
	Jun. 28, 2021	Jun. 28, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2020 EquityInstruments
AGA
Tax dispute settlement
Number of bonus shares vested				517,550	517,550
Bonus share award plans
Tax dispute settlement
Number of bonus shares vested			29,100	517,550
AGA 2019-1
Tax dispute settlement
Number of bonus shares vested	29,100	29,100	29,100

Company Information - Bonus sha

Company Information - Bonus share award plans ("AGA") (Details)

12 Months Ended

Dec. 08, 2022 employee

Jun. 28, 2021 EUR (€) € / shares

Dec. 14, 2020 EUR (€) EquityInstruments € / shares

Jun. 28, 2020 EUR (€) EquityInstruments € / shares

Jan. 26, 2020 EUR (€) EquityInstruments € / shares

Jun. 28, 2019

Dec. 14, 2018

Jan. 26, 2018

Dec. 31, 2022 EUR (€) € / shares

Dec. 31, 2021 EUR (€)

Dec. 31, 2020 EUR (€)

Dec. 31, 2020

Dec. 31, 2020 EquityInstruments

Company Information

Capital increase arising from the vesting of bonus share awards | €

€ 2,218,000

€ 2,089,000

€ 938,000

Par value per share | € / shares

€ 0.01

AGA

Company Information

Number of employees for whom bonus shares were granted | employee

110

Number of bonus shares fully vested

517,550

517,550

AGA 2019-1

Company Information

Number of bonus shares fully vested

29,100

29,100

29,100

Capital increase arising from the vesting of bonus share awards | €

€ 291,000

Par value per share | € / shares

€ 0.01

AGA 2018-2

Company Information

Number of bonus shares fully vested

63,300

63,300

63,300

Capital increase arising from the vesting of bonus share awards | €

€ 633,000

Par value per share | € / shares

€ 0.01

AGA 2019-2

Company Information

Number of bonus shares fully vested

227,000

227,000

227,000

Capital increase arising from the vesting of bonus share awards | €

€ 2,270,000

Par value per share | € / shares

€ 0.01

AGA 2018-3

Company Information

Number of bonus shares fully vested

227,250

227,250

227,250

Capital increase arising from the vesting of bonus share awards | €

€ 2,272,500

Par value per share | € / shares

€ 0.01

Company Information - Capital_2

Company Information - Capital increase of 14.7 million (Details) € / shares in Units, € in Thousands, $ in Millions			1 Months Ended		12 Months Ended
		Feb. 07, 2020 EUR (€) € / shares shares	Jul. 31, 2020 USD ($)	Feb. 29, 2020 EUR (€)	Dec. 31, 2022 EUR (€) € / shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)
Disclosure of classes of share capital [line items]
Proceeds from issuance of shares | €	[1]				€ 8,827	€ 25,475	€ 101,782
Par value per share | € / shares					€ 0.01
Issue of ordinary shares			$ 107.7		€ 9,366	€ 25,426	€ 109,099
BVF Partners L.P., Novo A/S, New Enterprise Associates 17, L.P. and Sofinnova Partners
Disclosure of classes of share capital [line items]
Proceeds from issuance of shares | €				€ 14,700
Number of new shares issued | shares		3,778,338
Price per share | € / shares		€ 3.97
Par value per share | € / shares		0.01
Issue premium per share | € / shares		€ 3.96
Gross proceeds from issuance of shares | €		€ 14,700
Issue of ordinary shares | €		€ 15,000
[1] Including subscriptions to BSA share warrants for €539 thousand, € 49 thousand, and € 13 thousand for the period ended December 31, 2022, December 31, 2021, and December 31, 2020 respectively.

Company Information - USD 107.7

Company Information - USD 107.7 million initial public offering (Details) $ / shares in Units, $ in Millions						1 Months Ended	12 Months Ended
	Jun. 15, 2022 EUR (€)	Oct. 01, 2021 $ / shares shares	Sep. 23, 2021 $ / shares shares	Jul. 15, 2020 EUR (€) director contract shares	Jul. 15, 2020 USD ($) director contract $ / shares shares	Jun. 30, 2022 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)
Disclosure of classes of share capital [line items]
Gross proceeds | $					$ 107.7
Share capital				€ 383,930.11			€ 421,000		€ 386,000		€ 409,000
Number of shares issued | shares				38,393,011
Number of new insurances entered | contract				2	2
Insurance amount | $					$ 3.6
Insurance coverage premium for risks related to initial public offering				€ 1,600,000
Number of executive directors under directors' and officers' liability insurance | director				2	2
Insurance coverage premium for directors' and officers' liability				€ 2,000,000
Contracts coverage period				1 year	1 year
Prepaid expenses							8,601,000		3,313,000		€ 7,454,000
Offering expense							€ 539,000		7,397,000
At Market Offering [Member]
Disclosure of classes of share capital [line items]
Gross proceeds						€ 9,400,000		$ 31.9
Amount of Fund Raised | $										$ 1.9
At Market Offering [Member] | Adr [Member]
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding | shares		130,856	2,083,334
Price per share | $ / shares		$ 14.40	$ 14.40
Gross proceeds	€ 9,400,000
Amount of Fund Raised | $										$ 30
Other Operating Income (Expenses)
Disclosure of classes of share capital [line items]
Additional expense including offering expense									1,800,000
Offering expense									800,000
Other Current Assets and Receivables
Disclosure of classes of share capital [line items]
Prepaid expenses									€ 1,800,000
American Depositary Shares
Disclosure of classes of share capital [line items]
Increase (decrease) in number of shares outstanding | shares				7,478,261	7,478,261
Price per share | $ / shares					$ 14.40
Gross proceeds				€ 94,100,000	$ 107.7

Company information - New share

Company information - New share warrant plans ("BSA") (Details)		12 Months Ended
	Mar. 09, 2020 EquityInstruments item	Dec. 31, 2020
BSA 2019 bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted	10,000	10,000
Number of share warrants granted	10,000
BSA 2019 ter
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted	36,000	36,000
Number of share warrants granted	36,000
BSA 2019 ter | David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share warrants granted		36,000
BSA - 2019 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted	46,000

Company Information - Research

Company Information - Research tax credit (Details) - EUR (€) € in Millions		1 Months Ended
	Apr. 21, 2022	Jan. 31, 2020
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received	€ 3.6
Provision for CIR risk related to tax audit for the year ended December 31, 2018
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received		€ 4.2
Provision For CIR Risk Related To Tax Audit For The Year Ended December 31, 2019 [Member]
Disclosure of other provisions [line items]
French Research Tax Credit (CIR), payments received		€ 4.3

Company Information - Non-dilut

Company Information - Non-dilutive financing (Details) € in Thousands	1 Months Ended				12 Months Ended
	May 31, 2020 EUR (€)	May 31, 2020 EUR (€)	May 31, 2020 EUR (€) loan	May 31, 2020 EUR (€) agreement	Dec. 31, 2022 EUR (€)	Dec. 31, 2020 EUR (€)
Disclosure of detailed information about borrowings [line items]
Loan obtained					€ 30,209	€ 9,979
Financing from a syndicate of French banks
Disclosure of detailed information about borrowings [line items]
Loan obtained		€ 10,000
Notional amount	€ 10,000	€ 10,000	€ 10,000	€ 10,000
Number of loans obtained guaranteed by the french state			3	3
Extension of term of debt	4 years					4 years

Company Information - Completio

Company Information - Completion of a future currency contract (Details) - Foreign currency forwards $ in Millions	1 Months Ended		2 Months Ended	10 Months Ended
	Oct. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) contract	Oct. 31, 2020 USD ($)	May 14, 2021 contract
Disclosure of detailed information about financial instruments [line items]
Number of future currency contracts completed | contract		2		3
Amount of future currency contracts completed | $	$ 20	$ 40	$ 60

Company Information - Reinvestm

Company Information - Reinvestment of short-term USD deposits (Details) $ in Millions	1 Months Ended		2 Months Ended
	Feb. 28, 2021	Nov. 30, 2020 item	Oct. 31, 2020 USD ($)
Company Information
Reinvestment of short-term USD deposits | $			$ 9
Number of short-term deposits | item		2
Number of short-term deposits expired	2

Company Information - Payments

Company Information - Payments received from the Research Tax Credit (Details) € in Millions	Jun. 30, 2021 EUR (€)
Company Information
Amount of entire CIR received	€ 4.2
Amount of additional reimbursements of CIR	€ 3.8

Company Information - Unwinding

Company Information - Unwinding of the three forward contracts (Details) - Foreign currency forwards $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($) contract	May 14, 2021 USD ($)	Dec. 31, 2020 USD ($)
Foreign currency forwards contract
Number of contracts expired | contract	3
Total amount of loan | $	$ 60	$ 60	$ 60

Company Information - Equity _2

Company Information - Equity financing - At-The-Market program (Details) $ / shares in Units, $ in Millions				1 Months Ended	12 Months Ended
	Oct. 01, 2021 $ / shares shares	Sep. 23, 2021 $ / shares shares	Aug. 02, 2021 USD ($)	Jul. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Jun. 15, 2022	Jul. 15, 2020 EUR (€)
Tax dispute settlement
Issue of ordinary shares				$ 107.7	€ 9,366,000	€ 25,426,000	€ 109,099,000
Share capital | €					€ 421,000	€ 409,000	€ 386,000		€ 383,930.11
Number of shares outstanding | shares					42,134,169
ADS
Tax dispute settlement
Maximum aggregate sales proceeds | $			$ 100
ATM
Tax dispute settlement
Number of shares represented by one depositary receipt			1
Percentage of dilution subject to regulatory limit			20%
Issue of ordinary shares | €					€ 9,400,000
ATM | ADS
Tax dispute settlement
Number of shares represented by one depositary receipt	1	1						1
Issue of ADSs | shares	130,856	2,083,334
Funds raised, price per share | $ / shares	$ 14.40	$ 14.40

Company Information - Creation

Company Information - Creation of Inventiva U.S. subsidiary (Details)			12 Months Ended
	Mar. 31, 2021	Jan. 05, 2021	Dec. 31, 2022
Inventiva Inc.
Tax dispute settlement
Percent of ownership interest	100%	100%	100%

Basis of preparation and stat_3

Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details) € in Millions			12 Months Ended
	Mar. 31, 2021	Jan. 05, 2021	Dec. 31, 2022 EUR (€) entity
General principles and statement of compliance
Number of entities being consolidated | entity			2
Inventiva Inc.
General principles and statement of compliance
Percent of ownership interest	100%	100%	100%
Non-controlling interests | €			€ 0

Basis of preparation and stat_4

Basis of preparation and statement of compliance - Consolidated financial statements (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
General principles and statement of compliance
Net income (loss)	€ (54,274)	€ (49,635)	€ (33,619)
Total assets	116,004	121,985	138,920
Shareholders' equity	45,476	€ 88,866	€ 111,211	€ 41,392
Adjustments to reconcile separate financial statements to consolidated financial statements
General principles and statement of compliance
Net income (loss)	208
Total assets	4,962
Shareholders' equity	(5)
Separate | Inventiva S.A
General principles and statement of compliance
Net income (loss)	(54,746)
Total assets	112,289
Shareholders' equity	44,797
Separate | Inventiva Inc.
General principles and statement of compliance
Net income (loss)	691
Total assets	8,676
Shareholders' equity	€ 1,111

Basis of preparation and stat_5

Basis of preparation and statement of compliance - Foreign Exchange Rates (Details) - $ / €	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Exchange rate (USD per EUR)
Average exchange rate for the period	1.0530	1.1827
Exchange rate at period end	1.0666	1.1326

Accounting Principles - Intangi

Accounting Principles - Intangible assets (Details)	12 Months Ended
	Dec. 31, 2022
Software licenses | Bottom of range [member]
Accounting Principles
Expected useful life of intangible assets	1 year
Software licenses | Top Of range
Accounting Principles
Expected useful life of intangible assets	5 years
Library of compounds
Accounting Principles
Expected useful life of intangible assets	13 years

Accounting Principles - Propert

Accounting Principles - Property, plant and equipment (Details)	12 Months Ended
	Dec. 31, 2022
Buildings | Bottom of range [member]
Accounting Principles
Useful lives of property, plant and equipment	20 years
Buildings | Top Of range
Accounting Principles
Useful lives of property, plant and equipment	25 years
Fixtures and fittings
Accounting Principles
Useful lives of property, plant and equipment	10 years
Technical facilities | Bottom of range [member]
Accounting Principles
Useful lives of property, plant and equipment	6 years
Technical facilities | Top Of range
Accounting Principles
Useful lives of property, plant and equipment	10 years
Equipment and tooling | Bottom of range [member]
Accounting Principles
Useful lives of property, plant and equipment	6 years
Equipment and tooling | Top Of range
Accounting Principles
Useful lives of property, plant and equipment	10 years
General facilities, miscellaneous fixtures and fittings
Accounting Principles
Useful lives of property, plant and equipment	10 years
Office equipment
Accounting Principles
Useful lives of property, plant and equipment	5 years
IT equipment
Accounting Principles
Useful lives of property, plant and equipment	5 years
Furniture
Accounting Principles
Useful lives of property, plant and equipment	10 years

Accounting Principles - Leases

Accounting Principles - Leases contracts (Details)	Dec. 31, 2022 EUR (€)
IFRS 16
Accounting Principles
Underlying assets of leases not restated	€ 5,000

Accounting Principles - Fair va

Accounting Principles - Fair value measurement (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign currency forwards contract
Financial assets	€ 90,014	€ 102,972	€ 120,417
Financial liabilities	63,821	27,701	20,177
Financial liabilities carried at fair value through profit or loss
Foreign currency forwards contract
Financial liabilities	9,876
Foreign currency forwards
Foreign currency forwards contract
Financial assets			1,791
Financial assets carried at fair value through profit or loss
Foreign currency forwards contract
Financial assets		8,829	1,791
Financial assets carried at fair value through profit or loss | Foreign currency forwards
Foreign currency forwards contract
Financial assets			1,791
Level 1 | Financial assets carried at fair value through profit or loss
Foreign currency forwards contract
Financial assets		8,829
Level 1 | Financial assets carried at fair value through profit or loss | Term deposits
Foreign currency forwards contract
Financial assets		€ 8,829
Level 2 | Financial assets carried at fair value through profit or loss
Foreign currency forwards contract
Financial assets			1,791
Level 2 | Financial assets carried at fair value through profit or loss | Foreign currency forwards
Foreign currency forwards contract
Financial assets			€ 1,791
Level 3 | Financial liabilities carried at fair value through profit or loss
Foreign currency forwards contract
Financial liabilities	9,876
Level 3 | Financial liabilities carried at fair value through profit or loss | Long-term financial debt - derivatives
Foreign currency forwards contract
Financial liabilities	€ 9,876

Accounting Principles - Foreign

Accounting Principles - Foreign currency transactions and Segment information (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Principles
Amount of expenses denominated in foreign currency	€ 15.9	€ 13.5	€ 2.5
Foreign currency expenses as a percentage of operating expenses	21%	21%	7%

Accounting Principles - Segment

Accounting Principles - Segment information (Details)	12 Months Ended
	Dec. 31, 2022
Accounting Principles
Number of operating segments	1

Accounting Principles - Going C

Accounting Principles - Going Concern (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Nov. 28, 2022 EUR (€)	May 16, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Accounting Principles
Cash and cash equivalents		€ 86,736			€ 86,553	€ 105,687	€ 35,840
Short-term deposits		1,000
Finance contract with EIB
Accounting Principles
Notional amount				€ 50,000
Finance contract with EIB, first tranche
Accounting Principles
Notional amount			€ 25,000
Finance contract with EIB, second tranche
Accounting Principles
Notional amount		€ 25,000
ATM | Top Of range
Accounting Principles
Sale of ordinary shares | $	$ 58.3

Accounting Principles - geograp

Accounting Principles - geographical split (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of geographical areas [line items]
Intangible assets	€ 568	€ 770	€ 935	€ 1,228
Property, plant and equipment	7,385	3,196	3,282	€ 3,721
Other non-current asset	1,668	2,442	1,706
Revenues	12,179	4,194	372
France
Disclosure of geographical areas [line items]
Intangible assets	568	770	935
Property, plant and equipment	6,324	3,096	3,282
Other non-current asset	1,603	2,442	1,706
Revenues	125	194	€ 372
USA
Disclosure of geographical areas [line items]
Property, plant and equipment	1,062	101
Other non-current asset	65
Revenues		€ 4,000
China
Disclosure of geographical areas [line items]
Revenues	€ 12,054

Intangible Assets (Details)

Intangible Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	€ 770	€ 935	€ 1,228
Increases	(202)	(165)	(293)
Decreases		1
Balance at the end	568	770	935
Depreciation expenses	200	200	200
Gross
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	3,717	3,674	3,674
Increases	15	53	1
Decreases		10
Balance at the end	3,732	3,717	3,674
Amortization
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	(2,947)	(2,739)	(2,446)
Increases	(217)	(217)	(293)
Decreases		(10)
Balance at the end	(3,164)	(2,947)	(2,739)
Library of compounds | Gross
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	2,142	2,142	2,142
Balance at the end	2,142	2,142	2,142
Library of compounds | Amortization
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	(1,487)	(1,322)	(1,157)
Increases	(165)	(165)	(165)
Balance at the end	(1,651)	(1,487)	(1,322)
Software licenses | Gross
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	1,575	1,533	1,532
Increases	15	53	1
Decreases		10
Balance at the end	1,590	1,575	1,533
Software licenses | Amortization
Reconciliation of changes in intangible assets other than goodwill
Balance at the beginning	(1,460)	(1,417)	(1,289)
Increases	(52)	(53)	(129)
Decreases		(10)
Balance at the end	€ (1,512)	€ (1,460)	€ (1,417)

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	€ 3,196	€ 3,282	€ 3,721
Increases	4,200	52	(424)
Decreases	(17)	0	0
Others	7	(274)	(16)
Balance at the end	7,385	3,196	3,282
Depreciation charges		700	700
Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	10,321	9,810	9,736
Increases	5,655	761	292
Decreases	(41)	(113)	0
Others	7	(137)	(218)
Balance at the end	15,941	10,321	9,810
Gross | IFRS 16
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning		9,810
Balance at the end			9,810
Depreciation and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(7,124)	(6,528)	(6,015)
Increases	(1,455)	(709)	(716)
Decreases	24	113	0
Others	0	(137)	202
Balance at the end	(8,555)	(7,124)	(6,528)
Land | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	172	172	172
Increases	0	0	0
Decreases		0	0
Others		0	0
Balance at the end	172	172	172
Buildings | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	3,407	3,407	3,407
Increases	86	0	0
Decreases	(23)	0	0
Others		0	0
Balance at the end	3,470	3,407	3,407
Buildings | Depreciation and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(1,931)	(1,737)	(1,542)
Increases	(196)	(194)	(196)
Decreases	23	0	0
Others		0	0
Balance at the end	(2,104)	(1,931)	(1,737)
Technical facilities, equipment and tooling
Reconciliation of changes in property, plant and equipment [abstract]
Acquisitions		300
Technical facilities, equipment and tooling | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	5,118	4,856	4,748
Increases	357	336	108
Decreases	(18)	(75)	0
Others		0	0
Balance at the end	5,457	5,118	4,856
Technical facilities, equipment and tooling | Depreciation and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(4,091)	(3,782)	(3,396)
Increases	(355)	(384)	(386)
Decreases	1	75	0
Others		0	0
Balance at the end	(4,446)	(4,091)	(3,782)
Other property, plant and equipment
Reconciliation of changes in property, plant and equipment [abstract]
Acquisitions		200
Other property, plant and equipment | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	1,422	1,203	1,157
Increases	97	223	46
Decreases		(4)	0
Others		0	0
Balance at the end	1,519	1,422	1,203
Other property, plant and equipment | Depreciation and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(1,087)	(976)	(874)
Increases	(128)	(116)	(102)
Decreases		4	0
Others		0	0
Balance at the end	(1,216)	(1,087)	(976)
Property, plant and equipment in progress | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	59	137	0
Increases	5	59	137
Decreases		0	0
Others		(137)	0
Balance at the end	65	59	137
Right of use | Gross
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	143	34	252
Increases	5,109	143	0
Decreases		(34)	0
Others	7	0	(218)
Balance at the end	5,259	143	34
Right of use | Depreciation and impairment
Reconciliation of changes in property, plant and equipment [abstract]
Balance at the beginning	(14)	(33)	(203)
Increases	(776)	(16)	(32)
Decreases		34	0
Others	0	0	202
Balance at the end	€ (790)	€ (14)	€ (33)

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Details) - 12 months ended Dec. 31, 2022 € in Millions, $ in Millions	EUR (€)	USD ($)
Property, Plant and Equipment
Increase in net value of property, plant and equipment	€ 4.2
Fibroscan machines
Property, Plant and Equipment
Additions to right-of-use assets	€ 5.1	$ 5.1

Other Non-Current Assets (Detai

Other Non-Current Assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Non-Current Assets
Advances to suppliers - non-current	€ 895	€ 689
Longterm deposit accounts	700	1,745	€ 1,698
Accrued income	65
Security deposits	8	8	8
Other noncurrent assets	€ 1,668	€ 2,442	€ 1,706

Other Non-Current Assets - Adva

Other Non-Current Assets - Advances to supplier - non-current (Details) € in Thousands, $ in Millions	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)
Other Non Current Assets
Advances to suppliers - non-current	€ 895		€ 689
Contract CRO with Pharmaceutical Research Associates B.V.
Other Non Current Assets
Advances to suppliers - non-current		$ 0.9	€ 700

Other Non-Current Assets - Long

Other Non-Current Assets - Long-term deposit accounts (Details) € in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2022 EUR (€) item	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€) item	Jan. 06, 2021 EUR (€) item	Feb. 01, 2019 EUR (€) item
Other Non Current Assets
Decrease in long-term deposit accounts		€ (1,000)
Number of pledges over cash | item			2
Cash pledged as security			€ 1,700
Pledge over cash, Abbott agreement
Other Non Current Assets
Number of pledges over cash | item	2				1
Cash pledged as security					€ 700
Amount of pledge as a percentage of sum not covered by the indemnity to be received					50%
Pledge over cash, tax authorities
Other Non Current Assets
Number of pledges over cash | item				1
Pledge over cash, tax authorities, fiscal year 2016
Other Non Current Assets
Decrease in financial assets pledged as collateral through release	€ 1,000
Pledge over cash, tax authorities, fiscal year 2017
Other Non Current Assets
Decrease in financial assets pledged as collateral through release	€ 700
Tax disputes with French tax authorities | Pledge over cash, tax authorities
Other Non Current Assets
Cash pledged as security				€ 1
Crdit Agricole bank [Member] | If dispute remains unresolved
Other Non Current Assets
Cash pledged as security				€ 1,700

Inventories (Details)

Inventories (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Inventory Disclosure [Line Items]
Inventories	€ 373	€ 392	€ 320
Laboratory inventories
Schedule of Inventory Disclosure [Line Items]
Inventories	406	425	353
Inventories write-down
Schedule of Inventory Disclosure [Line Items]
Inventories	€ (33)	€ (33)	€ (33)

Trade Receivables and Other C_3

Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	Jan. 31, 2022	Dec. 31, 2020
Trade Receivables and Other Current Assets and Receivables [Line Items]
Trade receivables	€ 4,000	€ 0		€ 48
Average payment period for trade receivables	30 days
AbbVie [Member]
Trade Receivables and Other Current Assets and Receivables [Line Items]
Milestone payments received	€ 4,000		€ 4,000
3 months or less
Trade Receivables and Other Current Assets and Receivables [Line Items]
Trade receivables	€ 4,000	€ 0		€ 48

Trade Receivables and Other C_4

Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Trade Receivables and Other Current Assets and Receivables
CIR	€ 5,994	€ 4,357	€ 9,012
Other	13	16	16
Tax receivables	6,007	4,373	9,028
Prepaid expenses	8,601	7,454	3,313
Short-term deposit accounts	1,048	8,829	7,336
Current accrued income	117	92	2,000
Foreign currency forwards	0		1,791
Liquidity agreement - Cash	282	762	1,029
VAT receivables	3,057	2,828	1,625
Other receivables	162	294	821
Other current assets	13,267	20,260	17,914
Other current assets and receivables	€ 19,274	€ 24,632	€ 26,942

Trade Receivables and Other C_5

Trade Receivables and Other Current Assets and Receivables - Additional Information (Details) € in Thousands, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2021 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	May 14, 2021 USD ($)	Dec. 31, 2020 USD ($)
Trade Receivables and Other Current Assets and Receivables [Line Items]
CIR and other research tax credits receivable		€ 6,000	€ 4,400
Increase in research and development expense			12,000
Research and development expenses		60,469	48,452	€ 23,717
Research tax credits receivable from current tax year			3,800
Decrease in CIR and other research tax credits through payments			4,200
Decrease in CIR and other research tax credits through corrective claims			3,800
Short-term deposit accounts		1,048	8,829	7,336
Decrease in current deposit accounts		(7,800)
Decrease in current accrued income through payments	€ 2,000
Increase in prepaid expense				1,100
Prepaid expenses		8,601	7,454	€ 3,313
Inventiva Inc.
Trade Receivables and Other Current Assets and Receivables [Line Items]
CIR and other research tax credits receivable			200
Research tax credits receivable from current tax year		€ 800
Inventiva Inc.
Trade Receivables and Other Current Assets and Receivables [Line Items]
Research tax credits receivable from current tax year			200
Foreign currency forwards
Trade Receivables and Other Current Assets and Receivables [Line Items]
Total amount of loan | $						$ 60	$ 60	$ 60
Societe Generale
Trade Receivables and Other Current Assets and Receivables [Line Items]
Decrease in current deposit accounts			€ (8,800)		$ (10)

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents
Other cash equivalents	€ 16,798	€ 42,900	€ 12,001
Cash at bank and at hand	69,939	43,653	93,686
Cash and cash equivalents	€ 86,736	€ 86,553	€ 105,687	€ 35,840

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 EUR (€)	Oct. 31, 2021 EUR (€)	Oct. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Cash and Cash Equivalents
Cash and cash equivalents	€ 86,736		€ 86,553			€ 105,687	€ 35,840
Increase in cash and cash equivalents	€ 100
Societe Generale
Cash and Cash Equivalents
Decrease in other cash equivalents through withdrawals | $		$ 31
Notional amount of deposit account				€ 30,900	$ 35

Shareholders' Equity (Details)

Shareholders' Equity (Details) - EUR (€)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 15, 2020
Shareholders' Equity
Share capital	€ 421,000	€ 409,000	€ 386,000	€ 383,930.11
Number of fully authorized, subscribed and paid up shares	42,134,169
Nominal value per share	€ 0.01

Shareholders' Equity - Changes

Shareholders' Equity - Changes in share capital (Details) € / shares in Units, $ in Millions														1 Months Ended			12 Months Ended
	Jun. 15, 2022 EUR (€) € / shares shares	Oct. 01, 2021 EUR (€) item € / shares shares	Sep. 27, 2021 EUR (€) item € / shares shares	Jun. 28, 2021 EUR (€) € / shares shares	Dec. 14, 2020 EUR (€) € / shares shares	Nov. 30, 2020 EUR (€) € / shares shares	Jul. 15, 2020 EUR (€) € / shares shares	Jul. 15, 2020 USD ($) shares	Jun. 28, 2020 EUR (€) € / shares shares	Apr. 18, 2020 EUR (€)	Apr. 17, 2020 EUR (€)	Feb. 07, 2020 EUR (€) € / shares shares	Jan. 26, 2020 EUR (€) € / shares shares	Jun. 30, 2022 EUR (€)	Jul. 31, 2020 USD ($)	Feb. 29, 2020 EUR (€)	Dec. 31, 2022 EUR (€) € / shares shares	Dec. 31, 2021 EUR (€) € / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2019 EUR (€) € / shares shares
Disclosure of classes of share capital [line items]
Shareholders' equity																	€ 45,476,000	€ 88,866,000		€ 111,211,000	€ 41,392,000
Number of shares outstanding | shares																	42,134,169
Nominal value per share | € / shares																	€ 0.01
Issue of ordinary shares															$ 107.7		€ 9,366,000	25,426,000		109,099,000
Transaction costs																	(539,000)			(7,397,000)
Capital increase in cash																€ 14,700,000
Gross proceeds from initial public offering | $								$ 107.7
Reclassification of debit retained earnings to premium related to share capital										€ 48,000,000
At Market Offering [Member]
Disclosure of classes of share capital [line items]
Issue of ordinary shares																	€ 9,400,000
Number of shares issued during the period | shares																	1,260,618
Gross proceeds from initial public offering														€ 9,400,000					$ 31.9
AGA 2019-1 [Member]
Disclosure of classes of share capital [line items]
Nominal value per share | € / shares				€ 0.01
Share capital
Disclosure of classes of share capital [line items]
Shareholders' equity																	€ 421,341	€ 408,735		€ 386,302	€ 268,461
Number of shares outstanding | shares																	42,134,169	40,873,551		38,630,261	26,846,112
Nominal value per share | € / shares						€ 0.01	€ 0.01					€ 0.01					€ 0.01	€ 0.01		€ 0.01	€ 0.01
Issue of ordinary shares						€ 100	€ 74,783					€ 37,783					€ 13,000	€ 22,000		€ 113,000
Increase (decrease) in number of shares outstanding | shares						10,000	7,478,261	7,478,261				3,778,338
Number of shares issued during the period | shares																		2,214,190	2,214,190	11,256,599
Share capital | At Market Offering [Member]
Disclosure of classes of share capital [line items]
Nominal value per share | € / shares	€ 0.01	€ 0.01	€ 0.01
Issue of ordinary shares	€ 12,606	€ 1,309	€ 20,833
Increase (decrease) in number of shares outstanding | shares	1,260,618	130,856	2,083,334
Capital increase in cash		€ 25,400,000	€ 25,400,000
Number of ATM emissions | item		2	2
Share capital | AGA Bonus Plans
Disclosure of classes of share capital [line items]
Nominal value per share | € / shares				€ 0.01	€ 0.01				€ 0.01				€ 0.01
Issue of ordinary shares				€ 291	€ 2,273				€ 2,270				€ 633
Increase (decrease) in number of shares outstanding | shares				29,100	227,250				227,000				63,300
Number of shares issued during the period | shares				29,100
Premiums related to share capital
Disclosure of classes of share capital [line items]
Shareholders' equity																	173,885,665	€ 165,071,566		€ 139,667,603	€ 86,011,893
Issue of ordinary shares						€ 66,650	€ 94,024,272					€ 14,962,218					9,354,000	€ 25,404,000		108,986,000
Transaction costs							€ (7,077,866)					€ (319,564)					€ (539,000)			(7,397,000)
Appropriation of the issue premium											€ (48,000,000)									€ (48,000,000)
Premiums related to share capital | At Market Offering [Member]
Disclosure of classes of share capital [line items]
Issue of ordinary shares	€ 9,353,504	€ 1,615,584	€ 25,556,803
Transaction costs	€ (539,404)
Premiums related to share capital | AGA Bonus Plans | At Market Offering [Member]
Disclosure of classes of share capital [line items]
Transaction costs		€ (1,768,424)

Shareholders' Equity - Liquidit

Shareholders' Equity - Liquidity agreement (Details)		12 Months Ended
	Jan. 19, 2018	Dec. 31, 2022
Shareholders' Equity
Liquidity Agreement Term	12 months	12 months

Shareholders' Equity - Share wa

Shareholders' Equity - Share warrants plans (Details) - € / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Directors | BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price					€ 0.53
Service Providers | BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price				€ 0.48
David Nikodem | BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price	€ 2.45		€ 0.18
David Nikodem | Bonus Share Award Plans [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Subscription price		€ 0.29

Shareholders' Equity - Characte

Shareholders' Equity - Characteristics of BSPCE share warrants plans (Details)			12 Months Ended
	Apr. 16, 2021 € / shares shares	Dec. 13, 2013 employee € / shares shares	Dec. 31, 2021 € / shares	Dec. 31, 2022 € / shares
BSPCE plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted			600,000
BSPCE 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares per warrant | shares	1
Number of bonus shares granted	600,000		600,000
Number of warrants granted | shares	600,000
Subscription price (€)	€ 0
BSPCE exercise price (€)	€ 11.74		€ 11.74	€ 11.74
Expected volatility	64%
Average life (years)	5 years
Risk-free rate	0.60%
BSPCE 2021 [Member] | Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value at grant date (€)	€ 5.4
BSPCE 2021 [Member] | Top Of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value at grant date (€)	€ 5.7
BSPCE 2013-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares per warrant | shares		100
Number of beneficiaries | employee		3
Number of bonus shares granted		9,027
Subscription price (€)		€ 58.50
BSPCE exercise price (€)		0.585
Fair value at grant date (€)		€ 19
Expected volatility		35%
Average life (years)		5 years
Risk-free rate		1.13%

Shareholders' Equity - Charac_2

Shareholders' Equity - Characteristics of BSA share warrant plans (Details)

12 Months Ended

Apr. 16, 2021 EUR (€) € / shares shares

Apr. 16, 2021 EUR (€) € / shares shares

Apr. 16, 2021 EUR (€) item € / shares shares

Apr. 16, 2021 EUR (€) Y € / shares shares

Mar. 09, 2020 EUR (€) Y item € / shares shares

Jun. 28, 2019 Y item € / shares shares

Dec. 14, 2018 EUR (€) item Y € / shares shares

May 29, 2017 EUR (€) item Y € / shares shares

Dec. 31, 2020 € / shares

Dec. 31, 2022 € / shares

Dec. 31, 2021 € / shares

Jun. 26, 2019 EUR (€)

BSA - 2017 plan

Disclosure of terms and conditions of share-based payment arrangement [line items]

Subscription premium price per share (€)

€ 0.534

Exercise price (in euros)

€ 6.67

€ 6.67

€ 6.67

BSA - 2017 plan | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

1 year

BSA - 2017 plan | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

2 years

BSA - 2017 plan | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

BSA - 2018 plan

Disclosure of terms and conditions of share-based payment arrangement [line items]

Exercise price (in euros)

€ 6.07

6.07

6.07

BSA 2018-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Issued | item

126,000

Number of shares per BSA | shares

1

Subscription premium price per share (€)

€ 0.48

Exercise price (in euros)

€ 6.067

Fair value per BSA at grant date (€) | €

€ 1.98

Expected volatility

40%

Average life (years) | Y

6

Risk free rate

0.30%

BSA 2018-1 | Top Of range

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

BSA 2018-1 | Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

1 year

BSA 2019

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

1 year

Issued | item

10,000

Number of shares per BSA | shares

1

Subscription premium price per share (€)

€ 0.18

Exercise price (in euros)

€ 2.20

Fair value per BSA at grant date (€) | €

€ 0.48

Expected volatility

40%

Average life (years) | Y

5.5

Risk free rate

0.33%

BSA 2019 bis

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

1 year

Issued

10,000

10,000

Number of shares per BSA | shares

1

Subscription premium price per share (€)

€ 0.29

Exercise price (in euros)

€ 3.68

€ 3.68

3.68

3.68

Fair value per BSA at grant date (€) | €

€ 0.90

Expected volatility

40%

Average life (years) | Y

6

Risk free rate

0%

BSA 2019 ter

Disclosure of terms and conditions of share-based payment arrangement [line items]

Issued

36,000

36,000

Number of shares per BSA | shares

1

Subscription premium price per share (€)

€ 0.29

Exercise price (in euros)

€ 3.68

€ 3.68

€ 3.68

€ 3.68

Fair value per BSA at grant date (€) | €

€ 0.90

Expected volatility

40%

Average life (years) | Y

6

Risk free rate

0%

BSA 2019 ter | Top Of range

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

BSA 2019 ter | Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

1 year

BSA 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Issued

50,000

50,000

Number of shares per BSA | shares

1

1

1

1

Subscription premium price per share (€)

€ 2.45

€ 2.45

€ 2.45

€ 2.45

Exercise price (in euros)

€ 11.74

€ 11.74

€ 11.74

€ 11.74

Expected volatility

64%

Average life (years) | Y

5

Risk free rate

0.60%

BSA 2021 [Member] | Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fair value per BSA at grant date (€) | €

€ 3

€ 3

€ 3

€ 3

BSA - 2017

Disclosure of terms and conditions of share-based payment arrangement [line items]

Issued | item

195,000

Number of shares per BSA | shares

1

Exercise price (in euros)

€ 6.675

Fair value per BSA at grant date (€) | €

€ 2.47

Expected volatility

40%

Average life (years) | Y

6

Risk free rate

0.22%

BSA - 2017 | Top Of range

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fair value per BSA at grant date (€) | €

€ 3.2

€ 3.2

€ 3.2

€ 3.2

Shareholders' Equity - Movement

Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details) € / shares in Units, € in Thousands			12 Months Ended
	Apr. 16, 2021 € / shares	Mar. 09, 2020 EquityInstruments item € / shares	Dec. 31, 2022 EUR (€) € / shares shares	Dec. 31, 2021 EUR (€) € / shares shares	Dec. 31, 2020 EUR (€) € / shares shares
BSA 2019 bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)		€ 3.68	€ 3.68	€ 3.68	€ 3.68
Outstanding, Beginning balance			10,000	10,000
Issued		10,000			10,000
Outstanding, Ending balance			10,000	10,000	10,000
Number of shares exercisable			10,000	10,000
Number of bonus shares granted | EquityInstruments		10,000
BSA 2019 bis | JPG Healthcare LLC
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted					10,000
BSA 2019 ter
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)		€ 3.68	€ 3.68	€ 3.68	€ 3.68
Outstanding, Beginning balance			36,000	36,000
Issued		36,000			36,000
Outstanding, Ending balance			36,000	36,000	36,000
Number of shares exercisable			24,000	12,000
Number of bonus shares granted | EquityInstruments		36,000
BSA 2019 ter | David Nikodem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted					36,000
BSPCE and BSA share warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance			930,800	310,800	274,800
Issued				650,000	46,000
Exercised/Vesting					(10,000)
Forfeited			(124,000)	(30,000)
Outstanding, Ending balance			806,800	930,800	310,800
Number of shares exercisable			298,800	286,800	226,134
Share based payment expense | €			€ 765	€ 859	€ 18
BSPCE plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance			608,800	8,800	8,800
Issued				600,000
Forfeited			(120,000)
Outstanding, Ending balance			488,800	608,800	8,800
Number of shares exercisable			8,800	8,800	8,800
Number of share warrants outstanding | shares			480,088	600,088	88
BSPCE - 2013 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)			€ 0.59	€ 0.59	€ 0.59
Outstanding, Beginning balance			8,800	8,800	8,800
Outstanding, Ending balance			8,800	8,800	8,800
Number of shares exercisable			8,800	8,800	8,800
BSPCE 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)	€ 11.74		€ 11.74	€ 11.74
Outstanding, Beginning balance			600,000
Issued	600,000			600,000
Forfeited			(120,000)
Outstanding, Ending balance			480,000	600,000
BSPCE 2021 [Member] | Frederic Cren and Pierre Broqua
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted				600,000
BSA plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance			322,000	302,000	266,000
Issued				50,000	46,000
Exercised/Vesting					(10,000)
Forfeited			(4,000)	(30,000)
Outstanding, Ending balance			318,000	322,000	302,000
Number of shares exercisable			290,000	278,000	217,334
BSA - 2017 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)			€ 6.67	€ 6.67	€ 6.67
Outstanding, Beginning balance			130,000	130,000	140,000
Exercised/Vesting					(10,000)
Outstanding, Ending balance			130,000	130,000	130,000
Number of shares exercisable			130,000	130,000	130,000
BSA - 2017 plan | Karen Aach (former administrator)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercised/Vesting					(10,000)
BSA - 2018 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)			€ 6.07	€ 6.07	€ 6.07
Outstanding, Beginning balance			116,000	116,000	116,000
Outstanding, Ending balance			116,000	116,000	116,000
Number of shares exercisable			116,000	116,000	77,334
BSA - 2019 plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)			€ 2.20	€ 2.20	€ 2.20
Outstanding, Beginning balance			10,000	10,000	10,000
Issued | EquityInstruments		46,000
Outstanding, Ending balance			10,000	10,000	10,000
Number of shares exercisable			10,000	10,000	10,000
BSA - Plan 2021-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (in euros)			€ 11.74	€ 11.74
Outstanding, Beginning balance			20,000
Issued				50,000
Forfeited			(4,000)	(30,000)
Outstanding, Ending balance			16,000	20,000
BSA - Plan 2021-1 | ISLS Consulting
Disclosure of terms and conditions of share-based payment arrangement [line items]
Forfeited				(30,000)
BSA - Plan 2021-1 | ISLS Consulting and David Nikadem
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of bonus shares granted				50,000

Shareholders' Equity - Bonus sh

Shareholders' Equity - Bonus share award plans (Details)				12 Months Ended
	Dec. 08, 2022 EUR (€) shares	Dec. 08, 2021 EUR (€) shares	Apr. 16, 2021 EUR (€) shares	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2022 plan
Bonus Share Award Plans [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of free share award plans | plan						2
Issued				373,000	589,000
AGA 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period			3 years
Issued		123,000	466,000
Number of shares per AGA | shares			1
Expected volatility			64%
Average life (years)			3 years
Risk-free rate			0.60%
AGA 2021 [Member] | Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value per AGA at grant date (€)			€ 9.8
AGA 2021 [Member] | Top Of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value per AGA at grant date (€)			€ 11.3
AGA 2021-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued					466,000
AGA 2021-bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period		3 years
Issued		123,000			123,000
Number of shares per AGA | shares		1
Expected volatility		64%
Average life (years)		2 years 3 months 18 days
Risk-free rate		0.60%
AGA 2021-bis | Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value per AGA at grant date (€)		€ 11.4
AGA 2021-bis | Top Of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value per AGA at grant date (€)		€ 12.2
AGA 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year
Holding period (year)	1 year
Issued	373,000			373,000
Number of shares per AGA | shares	1
Fair value per AGA at grant date (€)	€ 4.18

Shareholders' Equity - Bonus _2

Shareholders' Equity - Bonus share movements (in number of shares issuable upon exercise) (Details) € / shares in Units, € in Thousands											12 Months Ended
	Dec. 08, 2022 EquityInstruments	Dec. 08, 2021	Jun. 28, 2021	Apr. 16, 2021	Dec. 14, 2020 EquityInstruments	Jun. 28, 2020 EquityInstruments	Jan. 26, 2020 EquityInstruments	Jun. 28, 2019	Dec. 14, 2018	Jan. 26, 2018	Dec. 31, 2022 EUR (€) EquityInstruments € / shares shares	Dec. 31, 2021 EUR (€) € / shares shares	Dec. 31, 2020 EquityInstruments	Dec. 31, 2020	Dec. 31, 2020 EUR (€)	Dec. 31, 2020 € / shares
AGA [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued | EquityInstruments	373,000
Exercised/Vesting													(517,550)	(517,550)
Bonus Share Award Plans [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Beginning balance											571,000	29,100		556,050
Issued											373,000	589,000
Exercised/Vesting												(29,100)		(517,550)
Forfeited											(153,400)	(18,000)		(9,400)
Outstanding, Ending balance											790,600	571,000		29,100
Share based payment expense | €											€ 1,452	€ 1,231			€ 920
AGA 2018-2 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)																€ 5.76
Outstanding, Beginning balance														63,300
Exercised/Vesting							(63,300)			(63,300)				(63,300)
AGA 2018-3 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)																6.28
Outstanding, Beginning balance														227,250
Exercised/Vesting					(227,250)				(227,250)					(227,250)
AGA 2019-1 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)												€ 2				2
Outstanding, Beginning balance												29,100		37,500
Exercised/Vesting			(29,100)					(29,100)				(29,100)
Forfeited											(18,000)			(8,400)
Outstanding, Ending balance														29,100
Number of new shares issued upon vesting | shares												29,100
AGA 2019-2 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)																€ 2
Outstanding, Beginning balance														228,000
Exercised/Vesting						(227,000)		(227,000)						(227,000)
Forfeited														(1,000)
AGA 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued		123,000		466,000
AGA 2021 [Member] | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of total potential new shares | shares												589,000
AGA 2021-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)											€ 11.30	€ 11.30
Outstanding, Beginning balance											448,000
Issued												466,000
Forfeited											(107,200)	(18,000)
Outstanding, Ending balance											340,800	448,000
Number of shares forfeited due to departure of employees | shares											22,000
Number of shares forfeited due to recruitments conditions not reached | shares											85,200
AGA 2021-bis
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)											€ 12.20	€ 12.20
Outstanding, Beginning balance											123,000
Issued		123,000										123,000
Forfeited											(46,200)
Outstanding, Ending balance											76,800	123,000
Number of shares forfeited due to departure of employees | shares											27,000
Number of shares forfeited due to recruitments conditions not reached | shares											19,200
AGA 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Stock price at grant date (in euros)											€ 4.18
Issued	373,000										373,000
Outstanding, Ending balance											373,000
AGA 2022 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued | EquityInstruments											373,000

Financial debt - Changes in bor

Financial debt - Changes in borrowings (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial debt
Beginning balance	€ 10,119	€ 10,055	€ 114
Subscription of bank borrowings	15,400		9,979
New lease contracts	5,109	143
Repayment of bank borrowings	(1,033)	(13)	(61)
Repayment of lease liabilities	(735)	(15)	(26)
Early termination of lease contracts			(9)
Capitalized interests	(308)		59
Accrued interests		(51)	0
Subscription of state-guaranteed PGE loan	1,780
Subscription of PPR loan	3,560
Subscription of derivatives instruments	9,469
Change in fair value of derivatives instruments	(407)
Exchange rate change	6
Ending balance	€ 44,390	€ 10,119	€ 10,055

Financial debt - Guaranteed loa

Financial debt - Guaranteed loan and equity recovery loans (Details) € in Thousands	1 Months Ended					12 Months Ended
	Jun. 30, 2022 EUR (€) loan	May 31, 2020 EUR (€)	May 31, 2020 EUR (€)	May 31, 2020 EUR (€) loan	May 31, 2020 EUR (€) agreement	Dec. 31, 2022 EUR (€) loan	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)
Guarantee Details
Loan obtained						€ 30,209		€ 9,979
Repayments of borrowings						€ 1,033	€ 13	€ 61
Loan agreements with a syndicate of French banks
Guarantee Details
Number of loan agreements | loan	3
Total amount of loan	€ 5,300
Loan agreements with syndicate of French banks, under stimulus economic plan
Guarantee Details
Number of loan agreements | loan	2
Total amount of loan	€ 5,300
Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)
Guarantee Details
Percentage of loan guaranteed by French state	90%
Equity recovery loans
Guarantee Details
Number of loan agreements | loan						2
Financing period of loan	8 years
Repayment period for loan	4 years
Financing from a syndicate of French banks
Guarantee Details
Loan obtained			€ 10,000
Number of loans obtained guaranteed by the french state				3	3
Extension of term of debt		4 years						4 years
Number of loan agreements | loan	3
Total amount of loan		€ 10,000	€ 10,000	€ 10,000	€ 10,000
Repayments of borrowings						€ 1,000

Financial debt - Derivatives (D

Financial debt - Derivatives (Details) € / shares in Units, € in Thousands		12 Months Ended
	Nov. 28, 2022 EUR (€) D € / shares shares	Dec. 31, 2022 € / shares shares	Jul. 01, 2022 shares
BSA 2022
Disclosure of detailed information about borrowings [line items]
Number of bonus shares granted		2,266,023
Number of shares per BSA | shares		1
Subscription premium price per share (€)		€ 0.01
Exercise price (in euros)		€ 4.02
Number of BSA outstanding | shares	2,266,023	2,266,023
Stock price (€)	4.13	4.75
Maturity (years)	12 years	11 years 10 months 24 days
Volatility	68%	68%
Cap of the put option (m€)	25	25
Fair Value (k€)	€ 9,469	€ 9,876
Unit fair value (€)	0.0418	0.0436
Warrant agreement with the European Investment Bank
Disclosure of detailed information about borrowings [line items]
Percentage of Company's share capital outstanding, issued as warrants	5.40%
Exercise price of warrant	€ 4.0152
Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares	95%
Number of shares per BSA | shares			1
Warrant agreement with the European Investment Bank | Derivatives
Disclosure of detailed information about borrowings [line items]
Number of warrants issued | shares	2,266,023
Percentage of Company's share capital outstanding, issued as warrants	5.40%
Exercise price of warrant	€ 4.0152
Maximum potential gross proceeds from exercise of warrants | €	€ 9,100
Transactions costs | €	€ 56
Threshold trading days of warrants | D	90

Financial debt - Credit facilit

Financial debt - Credit facility agreement with Europian Investment Bank and Lease Liabilities (Details) € in Thousands, $ in Millions

1 Months Ended

8 Months Ended

12 Months Ended

Dec. 08, 2022 EUR (€)

Nov. 28, 2022 EUR (€) shares

Nov. 04, 2022 EUR (€)

Nov. 04, 2022 USD ($)

Jun. 15, 2022 EUR (€)

May 16, 2022 EUR (€) tranche

Jul. 15, 2020 USD ($)

Jun. 30, 2022 EUR (€)

Dec. 31, 2022 EUR (€)

Dec. 31, 2022 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 EUR (€)

Jul. 01, 2022 EUR (€)

Dec. 31, 2019 EUR (€)

Disclosure of detailed information about borrowings [line items]

Gross proceeds | $

$ 107.7

Proceeds from issuance of shares

[1]

€ 8,827

€ 25,475

€ 101,782

Lease liabilities

€ 4,510

4,510

130

2

Borrowings

44,390

44,390

€ 10,119

€ 10,055

€ 114

Fibroscan machines

Disclosure of detailed information about borrowings [line items]

Additions to right-of-use assets

€ 5,100

$ 5.1

Lease term

4 years

4 years

ATM

Disclosure of detailed information about borrowings [line items]

Gross proceeds

€ 9,400

$ 31.9

ATM | ADS

Disclosure of detailed information about borrowings [line items]

Gross proceeds

€ 9,400

Warrant agreement with the European Investment Bank | Derivatives

Disclosure of detailed information about borrowings [line items]

Number of warrants issued | shares

2,266,023

Licensing and collaboration agreement with CTTQ

Disclosure of detailed information about borrowings [line items]

Amount received attributable to withholding taxes

€ 1,300

$ 1.3

Finance contract with EIB

Disclosure of detailed information about borrowings [line items]

Notional amount

€ 50,000

Number of equal tranches | tranche

2

Notional amount per tranche

€ 25,000

Number of warrants issued | shares

2,266,023

Cancellation term for funds not dispersed after execution of finance contract

36 months

Finance contract with EIB | Warrant agreement with the European Investment Bank

Disclosure of detailed information about borrowings [line items]

Notional amount

€ 50,000

Finance contract with EIB, first tranche

Disclosure of detailed information about borrowings [line items]

Notional amount

€ 25,000

Notional amount per tranche

€ 25,000

Aggregate amount to be received either in exchange for new shares of the Company or through the receipt of upfront or milestone payments

€ 18,000

€ 18,000

Maturity term after the disbursement of the tranche

4 years

4 years

Interest rate

8%

8%

Finance contract with EIB, first tranche | Financial liabilities at amortized cost

Disclosure of detailed information about borrowings [line items]

Notional amount

€ 25,000

Borrowing costs

€ 100

Borrowings

€ 15,400

€ 15,400

Borrowings, effective interest rate

21.91%

21.91%

Finance contract with EIB, first tranche | ATM

Disclosure of detailed information about borrowings [line items]

Net proceeds from issuance of shares

€ 8,800

Proceeds from issuance of shares

9,400

Finance contract with EIB, first tranche | Warrant agreement with the European Investment Bank

Disclosure of detailed information about borrowings [line items]

Number of warrants issued | shares

2,022

Finance contract with EIB, first tranche | Licensing and collaboration agreement with CTTQ

Disclosure of detailed information about borrowings [line items]

Net amount received

11,400

Amount received attributable to withholding taxes

€ 1,300

Finance contract with EIB, second tranche

Disclosure of detailed information about borrowings [line items]

Notional amount

€ 25,000

€ 25,000

Aggregate amount to be received either in exchange for new shares of the Company or through the receipt of upfront or milestone payments

70,000

€ 70,000

Minimum upfront payments for out-licensing, partnership or royalty transaction

€ 10,000

€ 10,000

Maturity term after the disbursement of the tranche

3 years

Interest rate

7%

Lease liabilities | Maximum

Disclosure of detailed information about borrowings [line items]

Interest rate

5.18%

5.18%

Lease liabilities | Minimum

Disclosure of detailed information about borrowings [line items]

Interest rate

1.89%

1.89%

[1] Including subscriptions to BSA share warrants for €539 thousand, € 49 thousand, and € 13 thousand for the period ended December 31, 2022, December 31, 2021, and December 31, 2020 respectively.

Financial debt - Debt and borro

Financial debt - Debt and borrowings (Details) € in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2020 EUR (€) loan	Sep. 30, 2022	Dec. 31, 2022 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2019 EUR (€)
Disclosure of detailed information about borrowings [line items]
Bank borrowings			€ 29,689	€ 9,992	€ 9,984
Derivatives instruments			9,876
Other loans and similar borrowings			316	62	6
Lease liabilities			4,510	2	130
Total debt			44,390	10,055	€ 10,119	€ 114
Increase (Decrease) in borrowings				9,900
Loan obtained			€ 30,209	€ 9,979
Financing from a syndicate of French banks
Disclosure of detailed information about borrowings [line items]
Number of loans obtained | loan	3
Loan obtained	€ 10,000
Extension of term of debt	4 years			4 years
Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)
Disclosure of detailed information about borrowings [line items]
Amended reimbursement period		4 years
Societe Generale
Disclosure of detailed information about borrowings [line items]
Total debt				€ 13

Financial debt - Breakdown betw

Financial debt - Breakdown between long term and short term debt (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about borrowings [line items]
Bank borrowings	€ 29,689	€ 9,984	€ 9,992
Derivatives instruments	9,876
Other loans and similar borrowings	316	6	62
Lease liabilities	4,510	130	2
Total longterm debt	44,390	10,119	10,055	€ 114
Less than 1 year
Disclosure of detailed information about borrowings [line items]
Bank borrowings	4,474	1,244	13
Other loans and similar borrowings	100		3
Lease liabilities	1,277	38	2
Total longterm debt	5,851	1,282	18
Between 1 and 3 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	4,999	7,484	9,979
Other loans and similar borrowings	0	6	59
Lease liabilities	3,233	92	0
Total longterm debt	8,232	7,582	€ 10,037
Between 3 and 5 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	17,768	1,256
Derivatives instruments	9,876
Other loans and similar borrowings	216
Total longterm debt	27,860	€ 1,256
More than 5 years
Disclosure of detailed information about borrowings [line items]
Bank borrowings	2,448
Total longterm debt	€ 2,448

Provisions (Details)

Provisions (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Long term provisions
Beginning balance	€ 0	€ 2,377	€ 574
Additions			1,804
Reversals		(2,377)
Closing balance	0	0	2,377
Short term provisions
Beginning balance	180	130	1,264
Additions		51	90
Reversals	(180)		(1,224)
Closing balance		180	130
Total Provisions
Other provisions at beginning of period	180	2,507	1,837
Additions		51	1,894
Unused provision reversed, other provisions	(180)	(2,377)	(1,224)
Other provisions at end of period		180	2,507
Indemnification amount received		2,000
Provision for tax adjustment risk in respect of payroll taxes for the years ended December 31, 2016, 2017 and 2018
Short term provisions
Beginning balance		130	1,264
Additions			90
Reversals			(1,224)
Closing balance			130
Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member]
Long term provisions
Beginning balance		1,497	358
Additions			1,139
Reversals		(1,497)
Closing balance			1,497
Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 [Member]
Long term provisions
Beginning balance		880	216
Additions			665
Reversals		(880)
Closing balance			880
Provision for tax audit for the years ended December 31, 2016 - 2018
Short term provisions
Beginning balance	180	130
Additions		51
Reversals	€ (180)
Closing balance		€ 180	€ 130

Provisions for Retirement Ben_3

Provisions for Retirement Benefit Obligations - Principal actuarial assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Provisions for Retirement Benefit Obligations
Retirement age	65 years	65 years	65 years
Payroll taxes	41.41%	41.41%	41.41%
Salary growth rate	2%	2%	2%
Discount rate	3.70%	1%	0.35%
Threshold minimum maturity term for Eurozone AA rated corporate bonds	10 years

Provisions for Retirement Ben_4

Provisions for Retirement Benefit Obligations - Net provision (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Provisions for Retirement Benefit Obligations
Retirement benefit obligations	€ 1,234	€ 1,429	€ 1,385
Obligation	€ 1,234	€ 1,429	€ 1,385	€ 1,127
Increase in discount rate (as a percent)		2.70%
Increase in discount rate		€ 383,000

Provisions for Retirement Ben_5

Provisions for Retirement Benefit Obligations - Change in net provision (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Provisions for Retirement Benefit Obligations
At beginning of period	€ (1,429)	€ (1,385)	€ (1,127)
Other changes		(75)
Expense for the period	(230)	(200)	(209)
Actuarial gains or losses recognized in other comprehensive income	425	82	(49)
At end of period	€ (1,234)	€ (1,429)	€ (1,385)

Provisions for Retirement Ben_6

Provisions for Retirement Benefit Obligations - Breakdown of expense recognized for the period (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Provisions for Retirement Benefit Obligations
Service cost for the period	€ (237)	€ (224)	€ (202)
Interest cost for the period	(14)	(5)	(8)
Benefits for the period	21	29
Total	€ (230)	€ (200)	€ (209)

Provisions for Retirement Ben_7

Provisions for Retirement Benefit Obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Provisions for Retirement Benefit Obligations
Demographic changes	€ 42	€ (27)	€ 14
Changes in actuarial assumptions	383	109	(63)
Total	€ 425	€ 82	€ (49)
Discount rate	3.70%	1%	0.35%

Provisions for Retirement Ben_8

Provisions for Retirement Benefit Obligations - Sensitivity analysis (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit obligation at December 31	€ 1,234	€ 1,429	€ 1,385
Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Percentage of reasonably possible increase or decrease in actuarial assumption	0.25%
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption (as a percent)	2.30%	2.80%	3.40%
Discount rate at 0.10%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage			0.10%
Benefit obligation at December 31			€ 1,433
Discount rate at 0.35%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage			0.35%
Benefit obligation at December 31			€ 1,385
Discount rate at 0.60%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage			0.60%
Benefit obligation at December 31			€ 1,340
Discount rate at 0.75%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage		0.75%
Benefit obligation at December 31		€ 1,471
Discount rate at 1.00%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage		1%
Benefit obligation at December 31		€ 1,429
Discount rate at 1.25%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage		1.25%
Benefit obligation at December 31		€ 1,389
Discount rate at 3.45%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage	3.45%
Benefit obligation at December 31	€ 1,263
Discount rate at 3.70%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage	3.70%
Benefit obligation at December 31	€ 1,234
Discount rate at 3.95%
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Benefit Obligation Percentage	3.95%
Benefit obligation at December 31	€ 1,205

Trade Payables and Other Curr_3

Trade Payables and Other Current Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Trade Payables and Other Current Liabilities
Trade payables	€ 19,359	€ 14,602	€ 6,923
Other current liabilities	5,485	6,789	6,838
Trade payables and other current liabilities	24,844	21,391	13,761
Accrued expenses	€ 11,200	€ 6,800	€ 4,300

Trade Payables and Other Curr_4

Trade Payables and Other Current Liabilities - Summary of Trade Payables Break Down By Payment Date (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Trade Payable And Other Current Liabilities [Line Items]
Trade payables	€ 19,359	€ 14,602	€ 6,923
Due in 30 days
Trade Payable And Other Current Liabilities [Line Items]
Trade payables	19,156	14,445	6,834
Due in 30 60 days
Trade Payable And Other Current Liabilities [Line Items]
Trade payables	201	€ 158	€ 89
Due in more than 60 days
Trade Payable And Other Current Liabilities [Line Items]
Trade payables	€ 2

Trade Payables and Other Curr_5

Trade Payables and Other Current Liabilities - Summary of Other Current Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Trade Payables and Other Current Liabilities
Employee-related payables	€ 1,866	€ 1,518	€ 1,405
Accrued payroll and other employeerelated taxes	1,340	1,234	1,375
VAT payable	2,128	879	753
Other accrued taxes and employeerelated expenses	140	178	106
Other miscellaneous payables	12	2,979	3,198
Other current liabilities	€ 5,485	€ 6,789	€ 6,838

Trade Payables and Other Curr_6

Trade Payables and Other Current Liabilities - Additional information (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Oct. 30, 2020
Trade Payable And Other Current Liabilities [Line Items]
Increase in trade accounts payable	€ 4.8
Studies fees	41.1	€ 31.2
Increase in studies fees	9.8	€ 24.2
Decrease in other current liabilities	1.3
Decrease in other miscellaneous liabilities	3
Increase in VAT payable	1.2
Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member]
Trade Payable And Other Current Liabilities [Line Items]
Payroll taxes payable	€ 1.6
Provision For Tax Audit For The Years Ended December 31, 2016 And December 31, 2017 [Member]
Trade Payable And Other Current Liabilities [Line Items]
Payroll taxes payable			€ 1.2

Financial Assets and Liabilit_3

Financial Assets and Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 90,014	€ 102,972	€ 120,417
Financial liabilities	63,821	27,701	20,177
Financial assets, at fair value	90,014	102,972	120,417
Financial liabilities, at fair value	63,821	27,701	20,177
Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	53,945	27,701	20,177
Financial liabilities carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	9,876
Long-term debt
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	28,663	8,837	10,037
Financial liabilities, at fair value	28,663	8,837	10,037
Long-term debt | Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	28,663	8,837	10,037
Derivative instruments
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	9,876
Financial liabilities, at fair value	9,876
Derivative instruments | Financial liabilities carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	9,876
Short-term debt
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	5,851	1,282	18
Financial liabilities, at fair value	5,851	1,282	18
Short-term debt | Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	5,851	1,282	18
Long-term contract liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	55
Financial liabilities, at fair value	55
Long-term contract liabilities | Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	55
Short-term contract liabilities
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	6
Financial liabilities, at fair value	6
Short-term contract liabilities | Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	6
Trade payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	19,359	14,602	6,923
Financial liabilities, at fair value	19,359	14,602	6,923
Trade payables | Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	19,359	14,602	6,923
Other miscellaneous payables
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	12	2,979	3,198
Financial liabilities, at fair value	12	2,979	3,198
Other miscellaneous payables | Financial liabilities carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	12	2,979	3,198
Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	90,014	94,143	118,626
Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial assets		8,829	1,791
Long-term accrued income
Disclosure of detailed information about financial instruments [line items]
Financial assets	65
Financial assets, at fair value	65
Long-term accrued income | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	65
Long-term deposit accounts
Disclosure of detailed information about financial instruments [line items]
Financial assets	700	1,745	1,698
Financial assets, at fair value	700	1,745	1,698
Long-term deposit accounts | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	700	1,745	1,698
Long-term security deposits
Disclosure of detailed information about financial instruments [line items]
Financial assets	8	8	8
Financial assets, at fair value	8	8	8
Long-term security deposits | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	8	8	8
Advance payment
Disclosure of detailed information about financial instruments [line items]
Financial assets	895
Financial assets, at fair value	895
Advance payment | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	895
Advances to suppliers - non-current
Disclosure of detailed information about financial instruments [line items]
Financial assets		689
Financial assets, at fair value		689
Advances to suppliers - non-current | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets		689
Current accrued income
Disclosure of detailed information about financial instruments [line items]
Financial assets	117	92	2,000
Financial assets, at fair value	117	92	2,000
Current accrued income | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	117	92	2,000
Shortterm deposit accounts
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,048	8,829	7,336
Financial assets, at fair value	1,048	8,829	7,336
Shortterm deposit accounts | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,048		7,336
Shortterm deposit accounts | Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial assets		8,829
Trade receivables
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	4,000	48
Financial assets, at fair value	0	4,000	48
Trade receivables | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	0	4,000	48
Foreign currency forwards
Disclosure of detailed information about financial instruments [line items]
Financial assets			1,791
Financial assets, at fair value			1,791
Foreign currency forwards | Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Financial assets			1,791
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Financial assets	86,736	86,553	105,687
Financial assets, at fair value	86,736	86,553	105,687
Cash and cash equivalents | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	86,736	86,553	105,687
Other receivables
Disclosure of detailed information about financial instruments [line items]
Financial assets	444	1,055	1,849
Financial assets, at fair value	444	1,055	1,849
Other receivables | Financial assets carried at amortized cost
Disclosure of detailed information about financial instruments [line items]
Financial assets	€ 444	€ 1,055	€ 1,849

Revenues and Other Income (Deta

Revenues and Other Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues and Other Income
Sales	€ 12,179	€ 4,194	€ 372
Total revenues	12,179	4,194	372
CIR	5,863	4,069	4,791
Subsidies	10	8
Other	762	229	100
Total other income	6,635	4,307	4,891
Total revenues and other income	€ 18,814	€ 8,501	€ 5,263

Revenues and Other Income - Add

Revenues and Other Income - Additional information (Details) € in Thousands			12 Months Ended
	Sep. 28, 2022 EUR (€)	Sep. 22, 2022 USD ($) Milestone item	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Jan. 31, 2022 EUR (€)
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Sales | €				€ 12,179	€ 4,194	€ 372
Revenue From Research Partnerships [Member]
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Sales | €					4,200
AbbVie [Member]
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Milestone payments received | €					€ 4,000		€ 4,000
Licensing and collaboration agreement with CTTQ
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Upfront payment receivable		$ 12,000,000
Number of development and regulatory milestones | Milestone		6
Maximum additional amount receivable upon the achievement of certain development and regulatory milestones		$ 40,000,000	$ 40,000,000
Number of successive targets | item		6
Maximum additional amount receivable upon the achievement of certain commercial milestones		$ 250,000,000	250,000,000
Maximum potential Regulatory and Commercial Milestone payments receivable		290,000,000
Sales | €				12,100
Additional billing not included in contract | €	€ 600
Licensing and collaboration agreement with CTTQ | Upfront payment
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Upfront payment receivable		$ 12,000,000
Sales | €				€ 12,000
Licensing and collaboration agreement with CTTQ | Regulatory and Commercial Milestones Payments
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Sales			0
Licensing and collaboration agreement with CTTQ | Royalties on commercial sales
Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items
Sales			$ 0

Research and Development, Mar_3

Research and Development, Marketing - Business Development and General and Administrative Expenses (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Expenses by nature to their function
Disposables		€ (1,681)	€ (1,472)	€ (1,243)
Energy and liquids		(633)	(513)	(539)
Patents		(510)	(543)	(343)
Studies		(42,377)	(33,004)	(10,987)
Maintenance		(995)	(1,017)	(846)
Fees		(4,587)	(3,044)	(2,548)
IT Systems		(960)	(806)	(651)
Support costs (including taxes)		(1,971)	(782)	(722)
Personnel costs		(15,332)	(13,413)	(10,680)
Depreciation, amortization and provisions		(1,683)	(927)	(1,009)
Other		(5,234)	(4,450)	(3,209)
Total operating expenses		(75,965)	(59,971)	(32,779)
Withholding tax (as a percent)	10%
Withholding taxes	€ 1,300
Research and development expenses
Expenses by nature to their function
Disposables		(1,681)	(1,472)	(1,243)
Energy and liquids		(633)	(513)	(539)
Patents		(510)	(543)	(343)
Studies		(42,375)	(33,004)	(10,987)
Maintenance		(995)	(1,017)	(846)
Fees		(175)	(160)	(201)
IT Systems		(852)	(744)	(597)
Personnel costs		(11,149)	(9,645)	(7,518)
Depreciation, amortization and provisions		(1,462)	(751)	(832)
Other		(637)	(602)	(608)
Total operating expenses		(60,469)	(48,452)	(23,717)
Marketing - business development expenses
Expenses by nature to their function
Fees		(570)	(138)	(341)
IT Systems		(16)	(9)	(8)
Support costs (including taxes)		(1,280)
Personnel costs		(219)	(213)	(197)
Other		(499)	(4)	(16)
Total operating expenses		(2,583)	(364)	(563)
General and administrative expenses
Expenses by nature to their function
Studies		(2)
Fees		(3,843)	(2,746)	(2,005)
IT Systems		(92)	(52)	(46)
Support costs (including taxes)		(692)	(782)	(722)
Personnel costs		(3,964)	(3,556)	(2,964)
Depreciation, amortization and provisions		(220)	(176)	(177)
Other		(4,099)	(3,844)	(2,585)
Total operating expenses		€ (12,912)	€ (11,155)	€ (8,499)

Research and Development, Mar_4

Research and Development, Marketing - Business Development and General and Administrative Expenses - Personnel costs and headcount (Details) € in Thousands		12 Months Ended
	Jun. 30, 2022 EUR (€)	Dec. 31, 2022 EUR (€) employee	Dec. 31, 2021 EUR (€) employee	Dec. 31, 2020 EUR (€) employee
Expenses by nature to their function
Number of employees | employee		113	105	94
Wages, salaries and similar costs		€ (9,814)	€ (8,097)	€ (6,442)
Payroll taxes		(3,069)	(3,010)	(3,098)
Provisions for retirement benefit obligations		(231)	(216)	(202)
Share-based compensation expense		(2,218)	(2,089)	(938)
Total personnel costs		€ (15,332)	(13,413)	(10,680)
Reversal of share-based compensation expense	€ 800
Inventiva S.A
Expenses by nature to their function
Number of employees | employee		105
Inventiva Inc.
Expenses by nature to their function
Number of employees | employee		8
Research and development expenses
Expenses by nature to their function
Wages, salaries and similar costs		€ (7,382)	(6,031)	(4,590)
Payroll taxes		(2,213)	(2,173)	(2,180)
Provisions for retirement benefit obligations		(157)	(148)	(141)
Share-based compensation expense		(1,397)	(1,293)	(607)
Total personnel costs		(11,149)	(9,645)	(7,518)
Marketing - business development expenses
Expenses by nature to their function
Wages, salaries and similar costs		(190)	(199)	(183)
Payroll taxes		(16)	0	8
Provisions for retirement benefit obligations			0	0
Share-based compensation expense		(13)	(13)	(22)
Total personnel costs		(219)	(213)	(197)
General and administrative expenses
Expenses by nature to their function
Wages, salaries and similar costs		(2,242)	(1,867)	(1,669)
Payroll taxes		(841)	(838)	(926)
Provisions for retirement benefit obligations		(73)	(68)	(60)
Share-based compensation expense		(808)	(783)	(309)
Total personnel costs		€ (3,964)	€ (3,556)	€ (2,964)

Other Operating Income (expen_3

Other Operating Income (expenses) - (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)
Other Operating Income (expenses)
Corrective claims - CIR				€ 2,863
Proceeds - Disposals of fixed assets	€ 0	€ 9
Reversal of restructuring expenses				43
Reversal of impairment on the carry back receivable		333	$ 0.3
Total other operating income	294	2,720		2,905
Disposals of assets	(9)
Provision for risk on payroll taxes		51		90
Accrued expenses to be paid to the tax authorities	0	1,584
Late payment interest on CIR 2013-2015	123
Impairment of tax loss carry back				(333)
Waiver claim		640
CIR provision		(137)		(1,804)
Transaction costs	121	952		2,881
Total other operating expenses	254	3,364		5,108
Other operating income (expenses)	40	(644)		€ (2,202)
Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member]
Other Operating Income (expenses)
Reversal of provisions		1,497
CIR provision	(1,100)
Decrease in accrued expenses through offset against reversal of provisions		1,600
Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 [Member]
Other Operating Income (expenses)
Reversal of provisions		880
Waiver claim		€ 600
CIR provision	(700)
Tax litigation
Other Operating Income (expenses)
Reversal of provisions	180
AMR Penalties
Other Operating Income (expenses)
Reversal of provisions	€ 114

Other Operating Income (expen_4

Other Operating Income (expenses) - Additional Information (Details) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 EUR (€)	Oct. 30, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Other Operating Income (expenses)
Other operating income decreased	€ 2,400	€ 3,100
Reversal of provisions	0	0		€ 2,377		€ 574
Waiver claim		640
Reversal of impairment on the carry back receivable		333	$ 0.3
Insurance costs		800
Corrective claims - CIR				2,863
CIR provision		137		1,804
IPO
Other Operating Income (expenses)
Initial public offering transaction costs				2,800
Provision For Tax Audit For The Years Ended December 31, 2016 And December 31, 2017 [Member]
Other Operating Income (expenses)
Accrued expense					€ 1,200
Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 [Member]
Other Operating Income (expenses)
Reversal of provisions				880		216
Waiver claim		600
CIR provision	700
Initial provision	900
Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member]
Other Operating Income (expenses)
Reversal of provisions				€ 1,497		€ 358
Accrued expense	1,600
CIR provision	1,100
Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member] | Minimum
Other Operating Income (expenses)
Initial provision	400
Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member] | Maximum
Other Operating Income (expenses)
Initial provision	€ 1,500
Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 To 2019
Other Operating Income (expenses)
Corrective claims - CIR		€ 2,900

Financial Income and Expenses_2

Financial Income and Expenses (Details) - EUR (€) € in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial income and expenses
Income from cash and cash equivalents				€ 390	€ 57	€ 226
Foreign exchange gains				4,532	5,421	40
Fair value variation gains / losses						1,791
Total financial income				4,923	5,478	2,057
Interest cost				(584)	(138)	(66)
Foreign exchange losses				(1,068)	(1,842)	(5,884)
Losses on change in fair value				407	651
Other financial expenses				(47)	(5)	(8)
Total financial expenses				(2,107)	(2,635)	(5,959)
Financial income (loss)				2,816	2,842	(3,902)
Foreign exchange gain on shirt term deposits				2,400
Unwinding of short term deposits	€ 8,000	€ 15,000	€ 8,000
Short-term deposits	16,798			16,798	€ 42,900	€ 12,001
United States of America, Dollars
Financial income and expenses
Bank accounts	2,700			2,700
Short-term deposits	€ 2,800			€ 2,800

Income Tax (Details)

Income Tax (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax
Loss before tax	€ (54,294)	€ (49,271)	€ (33,619)
Theoretical tax rate	25%	26.50%	28%
Tax benefit at theoretical rate	€ 13,574	€ 13,057	€ 9,413
Tax credits	1,432	1,078	2,143
Permanent differences	(305)	85	1,641
Other differences	(428)	(582)	(471)
Tax rate differences	55	(80)
Non recognition of deferred tax assets related to tax losses and temporary differences	(14,309)	(13,921)	(12,726)
Actual income tax benefit	20	(364)
Current taxes	(34)	€ (364)
Deferred taxes	€ (54)
Effective tax rate	0.06%	0.74%
Deferred tax assets	€ 0	€ 0	€ 0

Commitments (Details)

Commitments (Details) € in Millions, $ in Millions

1 Months Ended

Apr. 30, 2021 EUR (€)

Mar. 31, 2021 EUR (€) Center country

Dec. 31, 2022 EUR (€) $ / €

Dec. 31, 2022 USD ($) $ / €

Apr. 12, 2022 EUR (€)

Mar. 23, 2022 EUR (€)

Feb. 01, 2022 EUR (€)

Feb. 01, 2022 USD ($)

Jan. 14, 2022 EUR (€)

Dec. 31, 2021 $ / €

Oct. 31, 2021 EUR (€)

Sep. 30, 2021 EUR (€)

Mar. 31, 2021 USD ($)

Commitments

Exchange rate | $ / €

1.0666

1.0666

1.1326

Contract CRO with Pharmaceutical Research Associates B.V.

Commitments

Term of contract

7 years

Amount committed to pay

€ 223.8

€ 7.9

Bonus or malus maximum amount

€ 3.4

Contractual capital commitments

€ 198.1

Contract CRO with Pharmaceutical Research Associates B.V. | Top Of range

Commitments

Amount committed to pay

€ 231.6

Contract CMO with Fisher Clinical Services

Commitments

Number of countries involved in Phase III studies | country

25

Number of clinical centers | Center

300

Term of contract

7 years

Amount committed to pay

€ 11.4

Contractual capital commitments

9.6

Contract CRO signed with United BioSource LLC

Commitments

Amount committed to pay

€ 2.9

Contractual capital commitments

2.5

Contract CRO signed with Synexus Clinical Research GmbH

Commitments

Amount committed to pay

€ 7.1

Contractual capital commitments

5.5

Contract CRO signed with Syneos Health Clinical Research Services, LLC

Commitments

Amount committed to pay | $

$ 7.4

Contractual capital commitments | $

$ 3.1

Contract CRO signed with Clinical Research Services Kiel GmbH

Commitments

Amount committed to pay

€ 2.3

Contractual capital commitments

2

Service Agreement With Summit Clinical Services LLC [member]

Commitments

Amount committed to pay

€ 4.1

$ 4.4

Contractual capital commitments

€ 3.6

$ 3.8

Exchange rate

0.01067

0.01067

CMO and CRO contracts

Commitments

Contractual capital commitments

€ 6.2

Commitments - Commitments Recei

Commitments - Commitments Received (Details) - EUR (€)	Apr. 01, 2022	Mar. 31, 2022	Nov. 01, 2021	Apr. 01, 2018	Jan. 01, 2017	Mar. 21, 2016	Oct. 13, 2015	Dec. 31, 2022
Agreement with Novolyze | Premises and facilities
Commitments
Rental period							36 months
Amount of monthly rent	€ 8,000		€ 6,200
Annual increase of rent in percentage	2%		2%
Total amount of commitment received								€ 103,500
Commitments relating to future payments								199,100
Agreement with Synthecob | Research equipment and services
Commitments
Rental period						2 years
Amount of monthly rent	€ 2,900	€ 2,700		€ 2,500	€ 2,400
Annual increase of rent in percentage	1%
Total amount of commitment received								58,600
Commitments relating to future payments								€ 69,600

Related-Party Transactions - Su

Related-Party Transactions - Summary of transactions with key management personnel (Details) - Executive and corporate officers - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related-Party Transactions
Short-term benefits	€ 1,897	€ 1,517	€ 1,669
Post-employment benefits	(14)	92	77
Share-based payment	1,077	907	259
Net total	€ 2,960	€ 2,516	€ 2,005

Basic and Diluted Loss Per Sh_3

Basic and Diluted Loss Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Basic and Diluted Loss Per Share
Net loss for the period	€ (54,274)	€ (49,635)	€ (33,619)
Weighted average number of outstanding shares used for computing basic loss per share	41,449,732	39,168,152	33,874,751
Weighted average number of outstanding shares used for computing diluted loss per share	41,449,732	39,168,152	33,874,751
Basic loss per share	€ (1.31)	€ (1.27)	€ (0.99)
Diluted loss per share	€ (1.31)	€ (1.27)	€ (0.99)

Financial Risk management - Exp

Financial Risk management - Exposure to foreign exchange risk (Details) € in Millions, $ in Millions		1 Months Ended		10 Months Ended	12 Months Ended
	Jul. 15, 2020 USD ($)	Jun. 30, 2022 EUR (€)	Sep. 30, 2020 contract	May 14, 2021 USD ($) contract	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Financial Risk Management
Gross proceeds from initial public offering	$ 107.7
Foreign currency forwards
Financial Risk Management
Number of foreign currency forward contracts | contract			2	3
Total amount of loan				$ 60	$ 60	$ 60
At-The-Market
Financial Risk Management
Gross proceeds from initial public offering		€ 9.4			$ 31.9

Financial Risk management - E_2

Financial Risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Risk Management
Fair value of financial assets	€ 90,014	€ 102,972	€ 120,417
Exposure to foreign exchange risk | USD
Financial Risk Management
Percentage of reasonably possible increase (decrease) in risk assumption	5%
Inflation Risk | Minimum
Financial Risk Management
Percentage of reasonably possible increase (decrease) in risk assumption	5%
Inflation Risk | Maximum
Financial Risk Management
Percentage of reasonably possible increase (decrease) in risk assumption	10%
Cash and cash equivalents
Financial Risk Management
Fair value of financial assets	€ 86,736	86,553	105,687
Cash and cash equivalents | Exposure to foreign exchange risk | USD
Financial Risk Management
Fair value of financial assets	33,310
Impact of a 5% change in fair value	(1,586)
Short-term deposit accounts
Financial Risk Management
Fair value of financial assets	€ 1,048	€ 8,829	€ 7,336

Events After the Reporting Da_2

Events After the Reporting Date (Details) - Service contract with Avant Sante - Service contract with Avant Sante € in Millions	Feb. 21, 2023 EUR (€) item site
Events After the Reporting Date
Number of subjects randomized | item	120
Number of sites randomized | site	10
Estimated amount payable | €	€ 14.7